

Enilze de Souza Nogueira Volpato

*Subsídios para construção de estratégia de busca
para revisões sistemáticas na base de dados
Medline via PubMed*

Botucatu

2013

Enilze de Souza Nogueira Volpato

**Subsídios para construção de estratégia de busca
para revisões sistemáticas na base de dados
MEDLINE via PubMed**

Dissertação apresentada à Faculdade de Medicina de Botucatu, Universidade Estadual Paulista, Campus de Botucatu, para obtenção do título de Mestre em Bases Gerais da Cirurgia.

Orientadora: Profa. Dra. Regina Paolucci El Dib

Botucatu

2013

FICHA CATALOGRÁFICA ELABORADA PELA SEÇÃO TÉC. AQUIS. TRATAMENTO DA INFORM.
DIVISÃO DE BIBLIOTECA E DOCUMENTAÇÃO - CAMPUS DE BOTUCATU – UNESP
BIBLIOTECÁRIA RESPONSÁVEL: *ROSEMEIRE APARECIDA VICENTE*

Volpato, Enilze de Souza Nogueira.

Subsídios para construção de estratégia de busca para revisões sistemáticas na base de dados Medline via Pubmed / Enilze de Souza Nogueira Volpato. - Botucatu, 2013

Dissertação (mestrado) - Universidade Estadual Paulista, Faculdade de Medicina de Botucatu

Orientador: Regina El Dib

Capes: 60702036

1. Organização da informação. 2. Banco de dados - Busca. 3. Recuperação da informação. 4. Medicina baseada em evidências.

Palavras-chave: Armazenamento e recuperação da informação ; Estratégias de busca; Medline; Pubmed; Revisões sistemáticas.



Dedicatória

Dedico este trabalho

aos meus pais e aos meus professores,
autênticos mestres, que me ensinaram a
gostar de ler e escrever, de estudar e aprender.



Agradecimento

Antes de tudo deveria agradecer à minha família e desculpar-me pelas horas roubadas do convívio para dedicá-las ao trabalho e ao estudo, mas não vou pedir desculpas por fazer o que gosto e que considero importante. No entanto agradeço **por** minha pequena família:

meus pais, Orlando de Souza Nogueira e Anaite Colaute Nogueira,

minha irmã, Edméa Nogueira Guzzo,

minha filha, Alana Nogueira Volpato, mãe do meu mais novo amor,

Raul Volpato Castanheira,

e os que vieram de outras famílias, para aumentar a minha:

meu esposo, José Carlos Volpato,

meu cunhado, Paulo Guzzo e

meu genro, Alexandre Lodeiro Castanheira.

Sou grata pela serenidade que sinto por ter a certeza de que conto sempre com seu apoio, mesmo quando não entendem as motivações ou razões dos meus projetos, planos ou decisões que, aliás, confesso, algumas vezes, nem eu mesma sei discernir.

Sou grata também **por** minha memória, que generosa, nos momentos importantes da minha vida - bons e ruins - traz-me à lembrança meu irmão, Orlando de Souza Nogueira Filho, com tanta clareza que quase sinto sua presença, mesmo ele não estando mais ao alcance do nosso abraço... Essa presença sentida é um agradável conforto.

Daqui para frente, não vou resistir à veia bibliotecária e estabelecerei um critério para ordenação de meus agradecimentos: ordem cronológica. Assim os agradecimentos serão feitos às pessoas de acordo com minha lembrança sobre o momento em que foram envolvidas e contribuíram para que esse trabalho fosse realizado. Agradeço então:

- à Marluci Betini, siamesa, bibliotecária como eu, minha colega de trabalho que me conclamou a fazer a pós-graduação e bateu em algumas portas por nós. Zelosa e organizada cuidou da "papelada", da burocracia, dos contatos, dos prazos aliviando meu trabalho. Mais do que uma boa parceira para todas as horas é uma amiga com quem posso contar sempre que precisar;

- ao professor doutor Antônio José Maria Cataneo, entusiasta de Medicina baseada em Evidência, comprometido com o ensino da metodologia de elaboração de revisões sistemáticas na Faculdade de Medicina de Botucatu e inseriu a biblioteca nesse contexto. Como coordenador do curso de Pós-graduação em Bases Gerais da Medicina, me encorajou a elaborar e submeter um projeto de pesquisa para galgar o Mestrado. Compôs as bancas examinadoras do exame geral de qualificação e da defesa do trabalho de dissertação, criticou e ensinou;

- à professora doutora Regina ElDib, minha orientadora, que elevou o nível de envolvimento da biblioteca no contexto de pesquisa na Faculdade de Medicina de Botucatu. Embrenhou-se na Biblioteconomia com a coragem e o empreendedorismo que lhe é peculiar. Arriscou-se a orientar duas bibliotecárias no curso de Bases Gerais da Cirurgia e o fez com diligência. Ensinou-me o “bê-a-bá” da Medicina baseada em evidências para que eu pudesse entender o contexto e desenvolver este trabalho. Ofereceu-me, porém, mais que ensino, orientação e oportunidade, ofereceu-me sua amizade e generosidade;

- aos meus superiores hierárquicos que me deram a oportunidade de estudar: professores doutores Luiz Carlos Vulcano, Professor Edivaldo Velini, presidentes do Grupo Administrativo do Campus de Botucatu, e à bibliotecária Sulamita Selma Clemente Colnago, diretora da Divisão Técnica de Biblioteca e Documentação;

- à equipe da Seção de Pós-graduação da Faculdade de Medicina de Botucatu pelo atendimento sempre competente, ágil e gentil;

- ao Juliano Contin Ventrella e à equipe da Seção de Recursos Humanos da Administração Geral do Campus de Botucatu e à Valéria Aparecida Angelo Catharini, assessora administrativa do Grupo Administrativo do Campus de Botucatu pelas orientações e mediações relativas ao processo de afastamento para realização do curso;

- aos Coordenadores do curso de Pós-graduação em Bases Gerais da Cirurgia da Faculdade de Medicina de Botucatu, professores doutores César Tadeu Spadella e Regina Helena Garcia Martins;

- aos professores do curso de Pós-graduação em Bases Gerais da Cirurgia da Faculdade de Medicina de Botucatu pela paciência, empenho e sabedoria imprescindíveis para ministrar aulas sobre temas tão específicos para classes tão heterogêneas e multidisciplinares;

- ao professor doutor José Eduardo Corrente, pela análise estatística e pela paciência com que me ensinou a interpretar os resultados dessa análise;

- a toda equipe da Divisão Técnica de Biblioteca e Documentação, verdadeiro time, que sempre compartilhou comigo o sonho de democratizar o livro e a leitura, o ideal de excelência dos serviços prestados, o compromisso com os usuários de promover o acesso e a produção do conhecimento científico e valores como o respeito à sociedade, à vida e à memória;

- às colegas que me auxiliaram com serviços bibliográficos ou de redação: Silene Fernandes França Toledo, Diva Aparecida L. G. Rodrigues, Aparecida Regina Denadai da Silva, Marlene Seraphim, Nivaldete Costa Fernandes Cruz, Maria Luiza Deléu da Silva, Luzia de B. Belver Fernandes, Tais de Almeida Firmino Pereira, Rosemary Cristina da Silva, Luciana Pizzani, Rosemeire Aparecida Vicente;

- aos professores doutores que participaram das bancas examinadoras de exame geral de qualificação e de defesa da dissertação: Erica Nishida Hasimoto, Olavo Ribeiro Rodrigues, Altair Silva Costa Junior, Regina Stella Spagnuolo e Ricardo Augusto Monteiro de Barros;

- à FAPESP pelo auxílio pesquisa concedido (Processo FAPESP nº 2011/13988-9).



Epígrafe

Por que pois buscar sistemas vãos de vãs
filosofias, religiões, seitas [voz de pensadores],
se o erro é condição da nossa vida, a única
certeza da existência?

Assim cheguei a isto: tudo é erro, da verdade
há apenas uma ideia à qual não corresponde
realidade.

Este perpétuo analisar de tudo, este buscar de
uma nudez suprema raciocinada
coerentemente é que tira a inocência funda de
si, do mundo ...

Fernando Pessoa. *O horror de conhecer.*



Sumário

1 INTRODUÇÃO	29
1.1 Revisão sistemática	31
1.2 Estratégia de busca	32
1.3 MEDLINE	37
2 OBJETIVO	43
2.1 Objetivos específicos	44
2.2 Hipótese nula	44
2.3 Hipótese alternativa	45
3 MÉTODO	46
3.1 Local do estudo	47
3.2 Desenho do estudo	47
3.3 Critérios de inclusão.....	47
3.4 Definição dos eventos a serem mensurados	48
3.4.1 Parênteses ou aspas para indicar frase	48
3.4.2 Truncagem	50
3.4.3 Etapas da pesquisa	51
3.5 Cálculo do tamanho da amostra	55
3.6 Coleta e tabulação dos dados	55
4 RESULTADO	58
5 DISCUSSÃO	62
5.1 Parênteses e aspas para indicar frase	65
5.2 Truncagem	67
5.3 Única etapa ou uso do histórico de pesquisa	69
6 CONCLUSÃO	70
REFERÊNCIAS	72
Apêndice	79
Apêndice A – Estratégias de busca submetidas ao PubMed	80
Apêndice B – Número de registros recuperados em cada estratégia	163
Apêndice C – Estratégias de busca feitas com e sem uso de truncagem interpretadas pela interface PubMed	168
Anexo	175
Anexo A – Parecer do Comitê de Ética em Pesquisa.....	176



Lista de Figuras

Figura 1 - Representação gráfica de expressões booleanas com operadores AND e OR	34
Figura 2 - Caixa de pesquisa da PubMed com única sentença	52
Figura 3 - Caixa de pesquisa da PubMed com primeira etapa de pesquisa.....	52
Figura 4 - Caixa de pesquisa da PubMed com segunda etapa de pesquisa	53
Figura 5 - Caixa de pesquisa da PubMed com terceira etapa de pesquisa	53
Figura 6 - Histórico de pesquisa da PubMed com resultados das três etapas parciais da pesquisa	54
Figura 7 - Etapa final de combinação dos conjuntos anteriores	54
Figura 8 - Comparação do total de estratégias de busca com número de resultados igual, menor ou maior que a estratégia padrão	61
Figura 9 - Mensagem de aviso para termo submetido com truncagem na interface PubMed	68



Lista de Tabelas

Tabela 1 - Comparação de número de registros recuperados em 120 estratégias de busca mediante uso ou não, de parênteses e aspas para indicar frase, truncagem e combinação de resultados do histórico de pesquisa na base de dados MEDLINE via PubMed	59
--	----



Lista de Quadros

Quadro 1 -	Indicações para uso do operador booleano OR	34
Quadro 2 -	Uso de parênteses para indicar prioridade das operações	35
Quadro 3 -	Uso de parênteses ou aspas para indicar uma unidade (frase, expressão ou termo composto)	36
Quadro 4 -	Uso de asterisco (*) ou cifrão (\$) para indicar o radical	36
Quadro 5 -	Interpretação das estratégias de busca submetidas sem parênteses e sem aspas, com parênteses e com aspas na interface PubMed	66



Lista de Abreviaturas

Ajax	–	Asynchronous Javascript and XML
Amed	–	Allied Health and Complementary Medicine
BVS	–	Biblioteca Virtual de Saúde
CEP	–	Comitê de Ética na Pesquisa
CINAHL	-	Cumulative Index to Nurse and Allied Health Literature
COS	–	Commity of Science
DeCS	–	Descritores em Ciências da Saúde ou Descriptores en Ciencias de la Salud
DOM	–	Document Object Model
Embase	–	Excerpta Medica Database
FMB	–	Faculdade de Medicina de Botucatu
Infotrieve	–	Information Search and Retrieval Services
MBE	–	Medicina baseada em evidências
MEDLINE	–	Medical Literature Analysis and Retrieval System Online
MeSH	–	Medical Subject Headings
NLM	–	National Library of Medicine
PHP	–	PHP: Hypertext Preprocessor, originalmente Personal Home Page
RS	–	revisão sistemática
RSs	-	revisões sistemáticas



Resumo

Volpato ESN. Subsídios para construção de estratégia de busca para revisões sistemáticas na base de dados MEDLINE via PubMed. 2013. Dissertação (Mestrado) - Faculdade de Medicina de Botucatu, Universidade Estadual Paulista, Botucatu, 2013.

Introdução: A qualidade da pesquisa em fontes eletrônicas é essencial para assegurar a precisão e a abrangência na recuperação de artigos para elaboração de uma revisão sistemática. Para isso os pesquisadores devem conhecer o vocabulário controlado e as ferramentas disponíveis em cada base de dados para ajustar seus resultados de pesquisa de acordo com as suas necessidades de especificidade ou exaustividade na recuperação da informação. **Objetivo:** Foi analisada amostra disponível de estratégias de busca para identificar o melhor método para a pesquisa na base de dados MEDLINE via PubMed, considerando o uso ou não de parênteses, aspas duplas, truncagem e uso de busca em uma única etapa ou utilizando o histórico de pesquisa. Trabalhamos com a hipótese de que haveria uma diferença entre o número de registros recuperados mediante estratégia de busca com ou sem utilização de parênteses, de aspas e de truncagem ou com uma sentença em etapa única ou com combinação de resultados parciais do histórico de pesquisa, reduzindo assim as incertezas que ainda existem no campo da biblioteconomia médica. **Método:** Neste estudo transversal foram selecionadas e analisadas as estratégias de busca referentes às pesquisas bibliográficas realizados durante as aulas de Medicina baseada em evidências e em revisões sistemáticas realizadas pela nossa unidade na Faculdade de Medicina de Botucatu, UNESP, São Paulo, Brasil. **Resultado:** Foram analisadas 120 estratégias de busca. Não houve diferença entre os resultados obtidos com e sem parênteses em 100% das amostras analisadas ($p = 1,0$). Nas estratégias em que foram usadas aspas ou truncagem, o número de registros recuperados foi menor em comparação com a estratégia padrão ($p = 0,04$ e $p = 0,08$, respectivamente). O número de resultados obtidos mediante submissão de estratégias de busca em uma única etapa foi idêntico ao recuperado em pesquisas submetidas em várias etapas com a combinação dos resultados parciais do histórico de pesquisa ($p = 1,0$). **Conclusão:** Nas estratégias

de busca na base de dados MEDLINE via PubMed, o pesquisador deve usar aspas para indicar frase, ou seja, quando desejar recuperar os registros que tragam os termos exatamente como foram submetidos (mesmos termos e mesma ordem). Os parênteses não cumprem essa função e são desprezados pelo sistema. Não recomendamos o uso de truncagem em estratégias de busca para revisões sistemáticas na base de dados MEDLINE via PubMed para encontrar estudos de intervenção no campo da saúde, pois registros importantes podem não ser recuperados. Embora os resultados obtidos mediante pesquisa feita com uma única sentença ou combinando os resultados parciais do histórico de pesquisa sejam idênticos, recomendamos usar o último que proporciona maior flexibilidade na avaliação dos resultados parciais.

Palavras-chave: PubMed; MEDLINE; Armazenamento e recuperação da informação; Revisão sistemática; Medicina baseada em evidências.



Abstract

Volpato ESN. Testing search strategies for systematic reviews in the MEDLINE literature database through PubMed. 2013. Thesis (Masters) - Botucatu Medical School, UNESP – Univ Estadual Paulista, Botucatu, 2013.

Background: A high-quality electronic search is essential insuring accuracy and completeness in retrieved records for the conducting of a systematic review. To achieve such a search, the researchers must know the controlled retrieval languages and available tools of each database to adjust their search results according to their needs for specificity or exhaustiveness in information retrieval.

Objective: We analyzed the available sample of search strategies to identify the best method for searching in MEDLINE through PubMed, considering the use or not of parentheses, double quotation marks, truncation and use of a simple search or search history. We hypothesized that there would be a difference in the results retrieved by using a search strategy with parentheses and double quotations marks compared to searching without them, thereby reducing the uncertainties that still exist in the medical librarianship field. **Method:** In our cross-sectional study of search strategies, we selected and analyzed the available searches performed during Evidence-Based Medicine classes and in systematic reviews conducted by our unit at the Botucatu Medical School, UNESP, São Paulo, Brazil.

Result: We analyzed 120 search strategies. With regard to the use of phrase searches with parentheses, there was no difference between the results with and without parentheses in 100% of the sample analyzed ($p = 1.0$). The number of results retrieved by the searches analyzed was smaller using double quotations marks and using truncation, compared to the standard strategy ($p = 0.04$ and $p = 0.08$, respectively). The number of results retrieved by the search strategies was exactly the same when comparing simple searches or search history tools ($p = 1.0$). **Conclusion:** There is no need to use phrase searching parentheses to retrieve studies; however, we recommend the use of double quotation marks when an investigator attempts to retrieve articles in which a term appears to be exactly the same as what was proposed in the search form. Furthermore, we do not recommend the use of truncation in search strategies for systematic reviews in the MEDLINE literature database through PubMed to find interventional studies in the

health field. Although the results of simple searches or search history tools were the same, we recommend using the latter, as it provided us with greater flexibility in manipulating the partial results.

Keywords: PubMed; MEDLINE; Information storage and retrieval; Systematic reviews; evidence-based Medicine.



1 Introdução

A elaboração de estratégia de busca é um importante passo na busca de evidências. Deve representar a pergunta de um pesquisador que buscará respostas em um banco de informações ou em uma base de dados. Para a formulação da estratégia de busca existem recursos universais como os operadores booleanos e outros peculiares a cada base de dados e, também, a cada interface de pesquisa. Em virtude dessa diversidade uma mesma estratégia de busca pode ser adequada em uma base de dados ou interface de pesquisa e inadequada em outra base de dados ou interface.

Para obter o resultado de pesquisa desejado é importante que o pesquisador conheça bem a base de dados, como por exemplo, como o sistema opera, quais as ferramentas disponíveis e qual o tipo de organização do vocabulário (controlado ou livre).

Este trabalho foca quatro possibilidades de formulação da estratégia de busca: a utilização ou não de parênteses ou de aspas para indicar frase, o uso ou não de truncagem e a submissão da estratégia de busca em uma única expressão ou com submissões parciais com combinação posterior dos resultados anteriores.

A base de dados escolhida para o estudo foi MEDLINE por ser uma base com ampla cobertura da área médica e reportada como uma das bases de dados mais utilizadas no mundo todo (Younger & Boddy, 2008). A interface escolhida para o estudo foi PubMed que é a interface da própria *National Library of Medicine* – NLM (produtora da MEDLINE) e propicia o acesso aberto à MEDLINE, ou seja, pode ser consultada livremente por qualquer pessoa em qualquer lugar do mundo, sem restrições e sem pagamento de taxas ou assinaturas.

A atenção para a importância da elaboração de estratégias de busca cresceu com a Medicina baseada em evidências (MBE) e que tem como fonte de pesquisa trabalhos primários identificados, selecionados e analisados criteriosamente por meio de revisões sistemáticas e metanálises, de modo que, a qualidade na recuperação desses trabalhos é fundamental para a qualidade dos estudos a serem desenvolvidos (McGowan et al., 2010).

1.1 Revisão sistemática

Medicina baseada em evidências (MBE) foi definida como o uso consciencioso, explícito e judicioso das melhores evidências para a tomada de decisão sobre o cuidado de um paciente, integrando a experiência clínica individual com as evidências resultantes de pesquisas sistemáticas que podem avaliar desde acurácia e precisão de testes diagnósticos e poder dos marcadores de prognóstico, até a eficácia e segurança de intervenções de terapia, reabilitação e prevenção (Sacket et al., 1996). Uma revisão sistemática (RS) é o melhor instrumento para reunir e sintetizar as melhores evidências sobre a efetividade de determinada intervenção clínica (Linde & Willich, 2003) e tem sido cada vez mais utilizada para tomada de decisão na prática profissional como também na definição de políticas de saúde (Cook et al., 1997).

Uma revisão sistemática é diferente de uma revisão narrativa que por ser mais subjetiva, menos abrangente, sem critérios para seleção e sem protocolo para confecção está sujeita a vieses de seleção e suscetível à percepção subjetiva do pesquisador (Bernardo et al., 2004; Cordeiro et al., 2007). Outra característica importante da revisão sistemática é o interesse em recuperar um grande número de artigos para assegurar que o resultado das buscas nas fontes seja abrangente e completo (Brettell & Long, 2001; Younger & Boddy, 2009). Uma revisão sistemática tem como objetivo responder a uma determinada pergunta específica enquanto que uma revisão narrativa oferece uma visão panorâmica sobre determinado assunto (Petticrew, 2003; Justo et al., 2005).

Resumindo, a revisão sistemática tem como objetivo, responder uma questão clínica específica, utiliza toda gama de fontes de pesquisa disponíveis buscando ampla abrangência na obtenção dos documentos primários que serão avaliados e explicita a estratégia de busca e as fontes utilizadas na pesquisa bibliográfica. Os critérios de seleção relativos ao delineamento e à metodologia para inclusão dos trabalhos avaliados e exclusão daqueles que podem incluir algum tipo de viés são claramente definidos e rigorosamente aplicados. Em geral, é baseada em resultados de pesquisas clínicas. Podem, ainda, incluir uma análise estatística do conjunto de dados avaliados, ou seja, uma metanálise (Cook & Mulrow, 1997; Rother, 2007).

Segundo El Dib & Atallah (2006) uma revisão sistemática compreende as seguintes etapas: formulação de uma questão clínica; recuperação dos artigos que apresentam algum impacto na resposta da pergunta; busca nas bases de dados; avaliação dos títulos e resumos dos artigos em potencial; avaliação da qualidade metodológica considerando a relevância de erros sistemáticos para não comprometer a investigação e o resultado do tema estudado e, avaliação da aplicabilidade dos resultados na prática clínica.

Para Sampaio & Mancini (2007) os cinco passos da revisão sistemática são: definição da pergunta; busca da evidência; revisão e seleção dos estudos; análise da qualidade metodológica dos estudos e apresentação dos resultados. Os autores destacam que a busca da evidência compreende a definição das palavras-chave, elaboração da estratégia de busca e escolha das bases de dados eletrônicas a serem pesquisadas. Consideram que essa etapa é fundamental e deve ser efetuada de modo que o pesquisador tenha a segurança de que todos os documentos relevantes ou de impacto sobre o assunto sejam identificados.

Segundo Sampson et al. (2009) a qualidade da estratégia de busca é essencial para a condução de uma revisão sistemática já que a qualidade da revisão sistemática, estudo secundário, depende da recuperação exaustiva dos estudos primários identificados nas bases de dados da área da saúde.

1.2 Estratégia de busca

Lopes (2002) considera que para assegurar a qualidade na recuperação da informação é necessário planejar e adaptar cada estratégia de busca para cada base de dados a ser consultada. O autor definiu estratégia de busca como uma técnica que permite o “encontro entre uma pergunta formulada e a informação armazenada”.

Na prática bibliotecária, podemos dizer que estratégia de busca é uma fórmula composta por palavras, que geralmente inclui operadores booleanos e pode incluir sinais e filtros. Consiste em uma linguagem escrita que tem a habilidade de ser interpretada por um sistema de armazenamento e recuperação

de informação. Tem valor semântico e representa uma pergunta que será feita a uma base de dados.

Em 1990, Bates distinguiu duas etapas no processo de recuperação de informação em bases de dados eletrônicas. Uma desenvolvida pelo indivíduo e outra, pelo sistema de informação, que inclui a linguagem de busca do sistema e a estrutura de informação da base de dados.

Para que um pesquisador encontre, num arquivo ou banco de dados, os estudos em potencial que respondem a determinada pergunta, ele deve conhecer o vocabulário controlado (por exemplo, o MeSH – *Medical Subject Headings*) e as ferramentas disponíveis em cada base de dados para obter resultados que atendam suas necessidades quanto à exaustividade e à relevância desejadas (Aleixandre-Benavent et al., 2011).


Em indexação, técnica da documentação que se ocupa da identificação de assuntos tratados num documento e da tradução desses termos de acordo com a linguagem da indexação (Fujita, 2003), existem dois aspectos a serem considerados em relação a recuperação de registros mediante uma busca em uma base de dados que dizem respeito à abrangência ou relevância dos resultados.

Exaustividade ou sensibilidade refere-se à cobertura, abrangência e amplitude ou extensão dos resultados recuperados. Relevância refere-se à especificidade ou pertinência dos resultados obtidos (Pinto & Lancaster, 1999). Uma pesquisa que prioriza a exaustividade propiciará a recuperação de muitos resultados, porém a proporção de resultados precisos (que estão bem relacionados à consulta) na totalidade dos resultados obtidos será menor que a proporção de resultados precisos obtidos mediante a pesquisa na qual se prioriza a relevância.

Para ajustar os resultados à sua necessidade, o pesquisador deve usar os operadores booleanos **OR** para exaustividade e **AND** para relevância ou especificidade dos resultados (figura 1). O operador **OR** expande os resultados e deve ser utilizado para sinônimos, acrônimos, siglas, abreviaturas, variantes, diferentes grafias ou termos relacionados (quadro 1). O operador booleano **AND** é usado para restringir a pesquisa, fazendo a intersecção dos conjuntos de

trabalhos que possuem os termos combinados, ou seja, recupera apenas documentos que contenham, simultaneamente, todos os termos conectados por esse operador (Volpato, 2000).

Figura 1: Representação gráfica de expressões booleanas com operadores **AND** e **OR**.



Quadro 1: Indicações para uso do operador booleano **OR**.

Problema de linguagem	Estratégia de busca indicada
Sinônimos	hipertensão OR pressão arterial alta OR pressão sanguínea alta
Acrônimos, siglas ou abreviações	acidente vascular cerebral OR AVC
Variantes ou diferenças de grafia	ultrassonografia OR ultrason OR ultrassom OR ultra-son
Termos relacionados	doenças cardiovasculares OR arritmias cardíacas OR isquemias

A formulação de estratégias de busca também pode incluir outros recursos como parênteses, aspas e truncagem.

Os parênteses são utilizados, para indicar a ordem de precedência dos conectivos lógicos, ou seja, a prioridade desejada nas operações (quadro 2). Os termos combinados dentro dos parênteses são considerados uma unidade que

deve ser executada antes das combinações dos termos fora dos parênteses. Quando os parênteses não são intencionalmente indicados pelo usuário, o sistema fará automaticamente uma interpretação da expressão apresentada e assumirá algum parênteses para submeter determinada busca proposta.

Os sistemas de armazenagem e recuperação de informação têm dois critérios diferentes de estabelecimento de precedência de operação. Um dos critérios é o tipo de operador, de modo que NOT tem prioridade sobre operador AND que tem prioridade sobre operador OR, com precedência da esquerda para direita para operadores do mesmo tipo. Outro critério é a ordem de aparecimento dos operadores na expressão, ou seja, a precedência é da esquerda para direita independente do tipo de operador. Desse modo, a expressão sem parênteses A OR B AND C poderá ser interpretada, no primeiro caso como, A OR (B AND C) e no segundo caso como, (A OR B) AND C, gerando resultados diferentes. Sendo assim é importante que o usuário faça a inserção dos parênteses de precedência de operações corretamente para obter a resposta adequada à sua busca (Korfhage, 1997).

Quadro 2: Uso de parênteses para indicar prioridade das operações.

Para a estratégia de busca	Precedência dos conectivos lógicos
(papiloma or papilomatose) and (bucal or boca)	<p>Primeiro: conjunto 1 - (papiloma or papilomatose)</p> <p>Segundo: conjunto 2 - (bucal or boca)</p> <p>Terceiro: resultado do conjunto 1 and resultado do conjunto 2</p>

Os parênteses também podem ser utilizados para indicar termos compostos que segundo, Bernardo (2004), sempre devem ser indicados entre parênteses. No entanto, importantes fontes eletrônicas de informação utilizam aspas para indicação de termos compostos. No buscador Google (2012), por exemplo, as aspas são indicadas para essa função chamada de pesquisa exata, ou seja, “procura pela ocorrência exata (com as palavras agrupadas)” na mesma ordem em que foi indicada (Quadro 3).

Quadro 3: Uso de parênteses ou aspas para indicar uma unidade (frase, expressão ou termo composto).

Para pesquisar	Usando ()	Usando “ ”
doenças cardiovasculares	(doenças cardiovasculares)	“doenças cardiovasculares”
acidente vascular cerebral	(acidente vascular cerebral)	“acidente vascular cerebral”

A truncagem é uma ferramenta utilizada para fazer um corte num radical invariável de uma palavra, portanto seu uso é recomendado para formas derivadas e plurais (Volpato, 2000). Geralmente, o símbolo utilizado para indicar truncagem nas bases de dados é o asterisco (*) como, por exemplo, a PubMed. No entanto, algumas bases utilizam o cifrão (\$), como, por exemplo, a LILACS (quadro 4).

Quadro 4: Uso de asterisco (*) ou cifrão (\$) para indicar o radical.

Para pesquisar	Usando *	Usando \$
psicologia, psicológico, psicológicos, psicológica, psicológicas	psicol*	psicol\$
Efeito, efeitos	efeito*	efeito\$

Younger & Boddy (2009) constataram que uma mesma pesquisa em uma base de dados disponibilizada em diferentes interfaces recupera diferentes resultados e que, provavelmente, registros relevantes podem ser perdidos. Embora as bases de dados ofereçam diversas ferramentas para buscas eletrônicas, encontrar as informações pode ser complexo, portanto o domínio do conhecimento sobre as bases de dados e das múltiplas interfaces nas quais as bases podem ser disponibilizadas é importante para a formulação da melhor estratégia possível que permita a recuperação ideal de resultados (Castro et al., 1997; Lopes, 2002; Gehanno et al., 2009).

1.3 MEDLINE

A base de dados MEDLINE (*Medical Literature Analysis and Retrieval System Online*) foi criada em 1966 (Henner, 2000), considerada a principal base de dados bibliográfica da NLM (*U. S. National Library of Medicine*) contém 18 milhões de registros referentes a artigos de 5.516 periódicos do mundo todo em ciências da vida com uma concentração em biomedicina.

O período coberto é, em geral, a partir de 1946 até o presente, abrange 39 idiomas, atualmente. Embora tenha sido criada pela NLM, conta com parcerias internacionais de diversas organizações colaboradoras. Uma característica da base de dados MEDLINE é a indexação de acordo com um vocabulário controlado, o MeSH (*Medical Subject Headings*) que originou o vocabulário DeCS (*Descritores em Ciências da Saúde e Descriptores en Ciencias de la Salud*), com versões para o espanhol e português desenvolvido pelo Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde (Pinillo León & Cañedo Andalia, 2005; BIREME, 2011; NLM, 2011).

Segundo Pinillo León & Cañedo Andalia (2005) uma das grandes vantagens do uso do MeSH é a facilidade para identificar termos equivalentes, pois quando se introduz o termo desejado na caixa de pesquisa o próprio sistema apresenta os termos similares que poderão compor a estratégia de busca para que todos os termos relacionados e de interesse sejam utilizados.

Em 26 de junho de 1997, foi oficialmente anunciado, que por meio da interface PubMed, criada pela própria NLM, MEDLINE teria acesso aberto (NLM, 2006), ou seja, poderia ser consultada livremente por qualquer pessoa em qualquer lugar do mundo sem nenhum pagamento.

Segundo Harms (2009) MEDLINE, continuação da publicação impressa, Index Medicus, é a mais abrangente base de dados com informações em ciências da vida e biomédicas, sendo considerada a principal base de dados bibliográfica online do mundo. Younger & Boddy (2009) consideram a MEDLINE a base de dados mais popular do mundo na área médica.

Eveillard & Hannedouche (2007) consideram que MEDLINE é uma base de dados de referência para os clínicos e tem grande número de usuários, recebendo cerca de dez milhões de acessos por dia. Caro-Rojas & Eslava-Schmalbach (2005) afirmam que MEDLINE é uma das fontes de informação mais usada atualmente, fornecendo, aos médicos, informações para auxiliar na tomada de decisão.

Segundo Suarez-Almazor et al., (2000), embora, na Europa, a base de dados Embase (Excerpta Medica Database) seja frequentemente utilizada, a MEDLINE é a base de dados mais amplamente acessada na América do Norte. Díaz-Castorena (1998) considera que, indubitavelmente, MEDLINE é o melhor banco de dados nas áreas biomédicas e destaca que a base cobre também, as áreas de Enfermagem e Odontologia.

Desde sua criação vários fornecedores de publicações ou serviços de informação criaram interfaces para pesquisa no MEDLINE (Henner, 2000; Vanhecke et al., 2007), como por exemplo BVS, OVID, BioMedSearch, Medscape, Gateway, Infotrieve.

Segundo Dornelles (2004), interface é o conjunto de elementos que fazem a mediação do usuário com a informática, compreendendo equipamento (tela do monitor) e programa, ou seja, plataforma visual do sistema operacional do computador ou servidor.

Ao longo dos anos, enquanto as mídias ou suportes de informações eletrônicas mudavam passando pelo CD-ROM até o avanço tecnológico que permitiu o acesso à Internet com qualidade e rapidez, essas interfaces receberam inovações para se tornarem, cada vez mais amigáveis e ricas em ferramentas agregando valor e, sobretudo, facilitando seu uso. Na literatura encontram-se trabalhos que avaliam as possibilidades de consulta e recuperação de informação em diferentes mídias e interfaces de MEDLINE, alguns, apresentados a seguir.

As inovações da tecnologia facilitam o trabalho dos pesquisadores. Delwiche (2008), por exemplo, descreveu recursos disponíveis na interface PubMed, com ênfase no item MyNCBI que possibilita a atualização e envio automático de pesquisas salvas. Giglia (2009) em estudo sobre semântica para agrupamento de pesquisas e Muin et al. (2006), com trabalho sobre uso de

protocolos e modelos linguagem (PHP, DOM e Ajax) mostraram como recursos aplicáveis à WEB, agregam funcionalidades que propiciam facilidades ao usuário final de MEDLINE via PubMed.

Caro-Rojas & Eslava-Schmalbach (2005) compararam resultados de 175 estratégias de busca submetidas na base MEDLINE-CD (em cd-rom) e interfaces na Internet, PubMed, BioMedNet, Medscape e Gateway. Encontraram baixos índices de coincidências entre os resultados obtidos nos dois diferentes suportes (CD-ROM e Internet) e nas quatro diferentes interfaces avaliadas. Concluíram que isso afeta a reprodutibilidade das estratégias de busca.

De Groot (2000) comparou telas de pesquisa, apresentação de resultados, recursos especiais e explorou vantagens e desvantagens de três interfaces de MEDLINE: PubMed, InternetGratefulMed e OVID. Concluiu que todas as interfaces são construídas tendo como foco os usuários finais (pesquisadores) e apresentam vantagens e desvantagens. Os usuários devem conhecer os recursos de cada interface para realizar pesquisas eficazes e considera que a maioria dos usuários precisa ser treinada ou ler os manuais de instruções disponíveis online em cada interface.

Henner (2000), interessado em estudar o impacto da implantação do acesso aberto à MEDLINE, avaliou a percepção de bibliotecários em relação à interface PubMed. Concluiu que conveniência, acesso e familiaridade com as interfaces, são fatores que influenciam as escolhas dos bibliotecários, além de preferências pessoais.

Pérez & Picasso (1999) compararam três interfaces de acesso aberto, ou seja, gratuitos do banco de dados MEDLINE, PubMed, Infotrieve e COS. Avaliaram dados sobre instituição responsável por cada interface, atualização, desenho, acesso e porcentagem de registros recuperados. Concluíram que PubMed oferece o melhor serviço de livre acesso à base MEDLINE.

Jacobs et al. (1998) avaliaram várias características como campos dos registros e operadores estabelecidos como padrão para a pesquisa, formas de acesso ao MeSH e aos subcabeçalhos e uso de truncagem em seis interfaces de MEDLINE (Avicenna, America Online, HealthGate, PubMed, Medscape e Physicians'Online) e formularam uma lista de verificação para avaliação de

interfaces. Consideram que, em virtude de constantes inovações, os bibliotecários devem continuamente desenvolver estudos de avaliação das interfaces disponíveis.

Schoonbaert (1996), mediante a disponibilização da base de dados MEDLINE em CD-ROM, comparou o desempenho de três interfaces (SPIRS, WinSPIRS e OVID), concluindo que nenhuma delas era perfeita, mas que ofereciam recursos complementares.

Com a introdução e disseminação da MBE, surgiram trabalhos avaliando a cobertura, abrangência e limitações da MEDLINE. Conforme trabalhos apresentados a seguir, pode-se inferir que a base de dados MEDLINE é relevante e indispensável em Medicina e nas Ciências da Saúde, embora, isoladamente, seja insuficiente para recuperação de informações na abrangência necessária para a realização de revisões sistemáticas consistentes.

Bay et al. (2007) consideram a MEDLINE insuficiente pois, muitos ensaios clínicos, não publicados no idioma inglês, não são encontrados na base. Os autores basearam-se no estudo de Türp et al. (2002) que compararam resultados de uma pesquisa busca manual em periódicos alemães com uma busca na base de dados eletrônica MEDLINE. Constataram que, aproximadamente, metade dos ensaios randomizados controlados em Odontologia, publicados em alemão, não foram recuperados na bases.

Brazier & Begley (1996) compararam resultados de pesquisa na área de Enfermagem em versões em CD-ROM das bases MEDLINE e CINAHL (*Cumulative Index to Nurse and Allied Health Literature*) produzida por CINAHL Information Systems of California que indexa diversos tipos de documentos além de periódicos (livros, audiovisual, panfletos, programas, trabalhos acadêmicos como teses e dissertações). Compararam números de trabalhos recuperados, relevância e facilidade de obtenção dos trabalhos originais. Recomendaram que MEDLINE seja a primeira escolha entre as bases de dados para qualquer tema de Enfermagem, com exceção de trabalhos sobre organização.

Burnham & Shearer (1993) também pesquisaram temas em Enfermagem e fizeram pesquisa nas bases CINAHL, Embase e MEDLINE e constataram que a qualidade de resultados das bases depende do assunto pesquisado e que, em

virtude da natureza e distribuição da literatura de Enfermagem, a escolha da base de dados a ser consultada depende do foco de interesse do pesquisador.

Outra contribuição da MBE para o melhor uso de fontes de informação, por exemplo, MEDLINE, foram os estudos sobre formulação de estratégias de busca específicas para determinados assuntos ou tipos de estudos.

Fraser et al. (2006) avaliaram a sensibilidade, precisão e especificidade de resultados obtidos com uso de filtros aplicados nas bases de dados MEDLINE e Embase para recuperação de artigos sobre intervenções cirúrgicas, concluindo que os filtros sugeridos contribuíram para buscas bibliográficas eficientes.

Laranjeira et al. (2000) propuseram estratégia de busca para identificar pesquisas originais sobre álcool e drogas em MEDLINE, publicadas em oito periódicos de Psiquiatria indexados na base.

Winchester & Bavry (2010) avaliaram a precisão dos limites de busca “humano” e “ensaios clínicos” na Interface PubMed e constataram que esses filtros podem eliminar, incorretamente, artigos cuja indexação não tenha sido concluída (16,1%) ou esteja incorreta (0,8%).

Leclercq et al. (2011) em comentário sobre o trabalho de Winchester & Bavry (2010), sugerem uma outra estratégia para recuperação de artigos sobre humanos formulada na seguinte expressão: “(NOT (Animals [MeSH] NOT Humans [MeSH]))”. Os autores dos dois trabalhos recomendam que os pesquisadores busquem a assessoria de bibliotecários para elaborarem suas estratégias de busca.

Younger & Boddy (2009) desenvolveram estudo para avaliar e comparar resultados de diferentes interfaces da base de dados Amed (*Allied Health and Complementary Medicine*). Amed é produzida por *Health Care Information Service* da *British Library* (2011) e indexa periódicos, a partir de 1985, sobre Medicina complementar, Fisioterapia, Terapia ocupacional, Reabilitação, Podologia, Cuidados paliativos e Fonoaudiologia. Os autores constataram que a mesma busca, em período idêntico e com igual atualização, processadas nas diferentes interfaces de Amed, podiam apresentar resultados diferentes. Concluíram que diferentes interfaces requerem diferentes estratégias de busca e consideram que

é função dos bibliotecários da área médica avaliar sistematicamente diferentes interfaces de bases de dados e assim orientar seus usuários para que possam obter, em cada interface, resultados relevantes, precisos e apropriados ou para capacitarem os pesquisadores a recuperarem o maior número possível de registros independentemente da interface utilizada.

Desta forma, considerando a importância da estratégia de busca no contexto da MBE e do aumento do interesse na realização de revisões sistemáticas, é proposta uma maneira mais efetiva na construção de estratégias de busca.

2 Objetivo

Identificar subsídios para a construção da estratégia de busca ideal para revisões sistemáticas na base de dados MEDLINE via PubMed avaliando a aplicabilidade de parênteses, aspas, truncagem e uso do histórico de pesquisa, ou seja, combinação final dos resultados das submissões parciais registrados no histórico de pesquisa para compor a estratégia de busca completa.

2.1 Objetivos específicos

- a) Avaliar se a base de dados MEDLINE via PubMed recupera o mesmo número de resultados com ou sem a utilização de parênteses para indicar frase;
- b) Avaliar se a base de dados MEDLINE via PubMed recupera o mesmo número de resultados com ou sem a utilização de aspas para indicar frase;
- c) Avaliar se a base de dados MEDLINE via PubMed recupera o mesmo número de resultados com uso de truncagem ou com registro de todas palavras com o mesmo radical na íntegra;
- d) Avaliar se a base de dados MEDLINE via PubMed recupera o mesmo número de resultados comparando a busca submetida em uma única etapa e a busca formulada com combinação de resultados de diversas etapas parciais, isto é, usando o histórico de pesquisa.

2.2 Hipótese nula

- a) O número de resultados obtidos na base de dados MEDLINE via PubMed em estratégias de busca que utilizam parênteses para indicar frase é igual ao número obtido nas estratégias que não os utilizam;
 - b) O número de resultados obtidos na base de dados MEDLINE via PubMed em estratégias de busca que utilizam aspas para indicar frase é igual ao número obtido nas estratégias que não as utilizam;
 - c) O número de resultados obtidos na base de dados MEDLINE via PubMed em estratégias de busca que utilizam truncagem é igual ao número obtido nas estratégias que não a utilizam, ou seja, em que todas as palavras com mesmo radical são registradas na íntegra;
-

d) O número de resultados obtidos na base de dados MEDLINE via PubMed em estratégias de busca submetidas em uma única etapa é igual ao número obtido com a combinação final dos resultados das submissões parciais registrados no histórico de pesquisa.

2.3 Hipótese alternativa

a) O número de resultados obtidos na base de dados MEDLINE via PubMed em estratégias de busca que utilizam parênteses para indicar frase é menor que o número obtido nas estratégias que não os utilizam;

b) O número de resultados obtidos na base de dados MEDLINE via PubMed em estratégias de busca que utilizam aspas para indicar frase é maior que o número obtido nas estratégias que não as utilizam;

c) O número de resultados obtidos na base de dados MEDLINE via PubMed em estratégias de busca que utilizam truncagem é menor que o número obtido nas estratégias que não a utilizam, ou seja, em que todas as palavras com mesmo radical são registradas na íntegra;

d) O número de resultados obtidos na base de dados MEDLINE via PubMed em estratégias de busca submetidas em uma única etapa é menor que o número obtido com a combinação final dos resultados das submissões parciais registrados no histórico de pesquisa.

3 Método

O projeto foi submetido ao CEP (Comitê de Ética na Pesquisa) da FMB (Faculdade de Medicina de Botucatu) e dispensado da obtenção de parecer ético, por não envolver, direta ou indiretamente, seres humanos (Anexo 1).

3.1 Local do estudo

O estudo foi realizado na Divisão Técnica de Biblioteca e Documentação do Campus de Botucatu e junto ao Grupo de Medicina baseada em evidências da Faculdade de Medicina de Botucatu (FMB) – UNESP.

3.2 Desenho do estudo

Estudo transversal de estratégias de busca referentes às pesquisas em andamento no Grupo de Medicina baseada em evidências da Faculdade de Medicina de Botucatu, de usuários que procuraram o serviço de orientação na elaboração de pesquisas em fontes eletrônicas na Divisão Técnica de Biblioteca e Documentação da UNESP, Campus de Botucatu e de alunos de pós-graduação em aulas sobre uso de fontes de informação que fizeram buscas relativas aos seus projetos de pesquisa.

3.3 Critérios de inclusão

Os critérios de inclusão de estratégia de busca foram relativos aos requisitos mínimos que permitissem aplicar as modificações necessárias para viabilizar a realização de todos os testes propostos, de modo que todas as estratégias deveriam apresentar, pelo menos:

a) um descritor (ou palavra-chave) composto, ou seja, formado por duas ou mais palavras, para permitir o teste de comparação entre uso ou não de parênteses e aspas;

b) duas palavras com mesmo radical conectadas com operador OR para permitir o teste de comparação do uso ou não de truncagem;

c) um operador AND para permitir o teste de comparação entre a submissão da expressão completa em apenas uma vez ou com várias submissões parciais com posterior combinação dos resultados das etapas anteriores para o resultado final.

3.4. Definição dos eventos a serem mensurados

O modelo padrão de estratégia de busca com a composição necessária para receber as variações referentes aos recursos que foram testados e permitir a comparação entre os resultados teve configuração conforme exemplo:

(obstructive sleep apnoeas OR obstructive sleep apnoea OR obstructive breathing disorders OR snoring) AND (adenotonsillectomy OR tonsillotomy OR intracapsular partial tonsillectomy OR uvulopharyngoplasty OR uvulopalatopharyngoplasty) AND (high blood pressure OR high blood pressures OR hypertension OR cardiac events)

Conforme exemplo acima, na estratégia padrão foram usados parênteses para indicação de precedência dos conectivos lógicos; as palavras foram registradas sem uso de truncagem, ou seja, todas redigidas na íntegra, mesmo quando apresentavam radicais comuns e foi submetida em uma única vez.

3.4.1 Parênteses ou aspas para indicar frase

O uso de parênteses para indicar precedência de operações foi sempre mantido e foi avaliada apenas a função de indicação de frase.

3.4.1.1 Uso de parênteses para indicar frase

Consideramos a utilização dos parênteses para indicar frase aqueles em que palavras compostas foram registradas entre parênteses, como no exemplo a seguir:

((obstructive sleep apnoeas) OR (obstructive sleep apnoea) OR (obstructive breathing disorders) OR snoring) AND (adenotonsillectomy OR tonsillotomy OR (intracapsular partial tonsillectomy) OR uvulopharyngoplasty OR uvulopalatopharyngoplasty) AND (high blood pressure) OR (high blood pressures) OR hypertension OR (cardiac events))

3.4.1.2 Sem uso de parênteses para indicar frase (modelo padrão)

Consideramos a não utilização dos parênteses de indicação de frase a retirada dos mesmos ao indicar frase, desta forma, mantivemos os parênteses externos usados para indicar a ordem de execução das operações, como no exemplo seguir:

(obstructive sleep apnoeas OR obstructive sleep apnoea OR obstructive breathing disorders OR snoring) AND (adenotonsillectomy OR tonsillotomy OR intracapsular partial tonsillectomy OR uvulopharyngoplasty OR uvulopalatopharyngoplasty) AND (high blood pressure OR high blood pressures OR hypertension OR cardiac events)

3.4.1.3 Uso de aspas para indicar frase

Consideramos a utilização de aspas para indicar frase aquelas estratégias em que as palavras compostas foram registradas entre aspas, como no exemplo a seguir:

(“obstructive sleep apneas” OR “obstructive sleep apnoea” OR “obstructive breathing disorders” OR snoring) AND (adenotonsillectomy OR tonsillotomy OR “intracapsular partial tonsillectomy” OR uvulopharyngoplasty OR uvulopalatopharyngoplasty) AND (“high blood pressure” OR “high blood pressures” OR hypertension OR “cardiac events”)

3.4.1.4 Sem uso de aspas para indicar frase (modelo padrão)

Consideramos a não utilização de aspas para indicar frase a retirada dos mesmos, como no exemplo seguir:

(obstructive sleep apnoeas OR obstructive sleep apnoea OR obstructive breathing disorders OR snoring) AND (adenotonsillectomy OR tonsillotomy OR intracapsular partial tonsillectomy OR uvulopharyngoplasty OR uvulopalatopharyngoplasty) AND (high blood pressure OR high blood pressures OR hypertension OR cardiac events)

3.4.2 Truncagem

3.4.2.1 Com uso de truncagem

Consideramos a utilização de truncagem quando palavras com radicais comuns existentes no conteúdo das estratégias submetidas ao teste foram redigidas apenas com os dígitos comuns e a partir daí inseriu-se o símbolo asterisco (*), indicador de truncagem na interface PubMed como, por exemplo, a estratégia de busca a seguir:

(obstructive sleep apnoea OR obstructive breathing disorders OR snoring) AND (adenotonsillectomy OR tonsillotomy OR intracapsular partial tonsillectomy OR uvulopharyngoplasty OR uvulopalatopharyngoplasty) AND (high blood pressure* OR hypertension OR cardiac events)*

3.4.2.2 Sem uso de truncagem (modelo padrão)

Consideramos a não utilização de truncagem quando as palavras com radicais comuns existentes no conteúdo das estratégias submetidas ao estudo foram redigidas na íntegra, como no exemplo a seguir:


(obstructive sleep apnoeas OR obstructive sleep apnoea OR obstructive breathing disorders OR snoring) AND (adenotonsillectomy OR tonsillotomy OR intracapsular partial tonsillectomy OR uvulopharyngoplasty OR uvulopalatopharyngoplasty) AND (high blood pressure OR high blood pressures OR hypertension OR cardiac events)

3.4.3 Etapas de pesquisa

3.4.3.1 Em etapa única (modelo padrão)

Consideramos pesquisa com etapa única aquela em que a estratégia de busca com configuração padrão (como no exemplo indicado a seguir) foi integralmente submetida em uma única etapa na caixa de busca da interface (Figura 2).

(obstructive sleep apnoeas OR obstructive sleep apnoea OR obstructive breathing disorders OR snoring) AND (adenotonsillectomy OR tonsillotomy OR intracapsular partial tonsillectomy OR uvulopharyngoplasty OR uvulopalatopharyngoplasty) AND (high blood pressure OR high blood pressures OR hypertension OR cardiac events)

Figura 2: Caixa de pesquisa da PubMed com única sentença.


3.4.3.2 Submissões parciais com combinação dos resultados do histórico de pesquisa

Consideramos pesquisa em várias etapas aquela em que cada subconjunto da estratégia, ou seja, cada grupo de termos inseridos entre parênteses e conectados pelo operador booleano OR foi submetido individualmente na caixa de pesquisa da interface e ao final os resultados desses conjuntos parciais foram combinados com o operador AND para completar a estratégia de busca.

A seguir apresentamos exemplo da sequência de operações executadas para realização da pesquisa em cinco etapas:

- **etapa 1:** submissão do primeiro subconjunto da estratégia de busca (Figura 3);


(obstructive sleep apnoeas OR obstructive sleep apnoea OR obstructive breathing disorders OR snoring)

Figura 3: Caixa de pesquisa da PubMed com primeira etapa de pesquisa.

- **etapa 2:** submissão do segundo subconjunto da estratégia de busca (Figura 4);

(adenotonsillectomy OR tonsillotomy OR intracapsular partial tonsillectomy OR uvulopharyngoplasty OR uvulopalatopharyngoplasty)


Figura 4: Caixa de pesquisa da PubMed com segunda etapa de pesquisa.



- **etapa 3:** submissão do terceiro subconjunto da estratégia de busca (Figura 5);

(high blood pressure OR high blood pressures OR hypertension OR cardiac events)

Figura 5: Caixa de pesquisa da PubMed com terceira etapa de pesquisa.



- **etapa 4:** exibição do histórico de pesquisa (Figura 6);

Figura 6: Histórico de pesquisa da PubMed com resultados das três etapas parciais da pesquisa.

History				Clear history
Search	Add to builder	Query	Items found	Time
#4	Add	Search high blood pressure OR high blood pressures OR hypertension OR cardiac events	470464	15:22:00
#3	Add	Search adenotonsillectomy OR tonsillotomy OR intracapsular partial tonsillectomy OR uvulopharyngoplasty OR uvulopalatopharyngoplasty	2082	15:19:32
#2	Add	Search obstructive sleep apnoeas OR obstructive sleep apnoea OR obstructive breathing disorders OR snoring	25031	15:15:09

- **última etapa:** combinação dos resultados das pesquisas parciais anteriores para formulação final (Figura 7).

Figura 7: Etapa final de combinação dos conjuntos anteriores.

NCBI Resources How To Sign in to NCBI

PubMed Home More Resources Help

PubMed Advanced Search Builder YouTube Tutorial

#2 and #3 and #4

Edit Clear

3.5 Cálculo do tamanho da amostra

Empiricamente assumiu-se um erro de 3%, sendo que 95% das operações realizadas com o modelo padrão e com as variações referentes aos recursos avaliados recuperariam o mesmo número de registros; dessa forma, seria preciso avaliar cerca de 84 estratégias de busca com um intervalo de confiança de 95%, de acordo com a fórmula abaixo para calcular o tamanho de amostra:

$$\varepsilon = Z_{\alpha} \sqrt{pq/n}, \text{ sendo:}$$

ε = erro amostral (0,03);

z_{α} = quantil 95% da distribuição normal padrão (1,96);

α = nível de significância (5%);

p = proporção de resultados obtidos na base de dados MEDLINE via PubMed das estratégias de buscas que apresentam o mesmo número com a utilização de parênteses para indicar prioridade das operações daqueles obtidos nas estratégias que não os utilizam (0,97);

q = complementar de p ($1 - p$);

n = tamanho da amostra.

3.6 Coleta e tabulação dos dados

As estratégias de busca utilizadas neste estudo foram obtidas nas revisões sistemáticas em andamento no Grupo de Medicina baseada em evidências da Faculdade de Medicina de Botucatu, das demandas de usuários que procuraram o serviço de orientação na elaboração de pesquisas em fontes eletrônicas na Divisão Técnica de Biblioteca e Documentação da UNESP, Campus de Botucatu e de pesquisas de alunos de pós-graduação em aulas sobre uso de fontes de informação que fizeram buscas relativas aos seus projetos de pesquisa. As construções originais receberam modificações demandadas para o desenvolvimento dos testes de acordo com cada quesito a ser avaliado.

Todas as estratégias foram digitadas previamente com uso de programa editor de texto e identificadas mediante numeração progressiva 1 a 120 e subitens de .1 a .5 (anexo 1) sendo:

- 1 identificou a construção elaborada para testar uso de parênteses para indicar frase;
- 2 identificou a construção elaborada para testar uso de aspas para indicar frase;
- 3 identificou a construção elaborada para testar ausência de sinais para indicar frase;
- 4 identificou a construção elaborada para testar uso de truncagem;
- 5 identificou a construção elaborada para testar submissão em várias etapas.

A redação das cinco formulações diferentes para cada estratégia de busca seguiu uma sequência de procedimentos com objetivo de evitar erros, sobretudo, de digitação e manter similaridade entre os elementos que não poderiam ser alterados nas diferentes formulações, de modo que:

- a estratégia .1 foi digitada e depois copiada e colada para a construção da estratégia .2 que teve os parênteses de termos compostos substituídos por aspas;
 - a estratégia .2 foi copiada e colada para a construção da estratégia .3 que teve as aspas excluídas de modo que os termos compostos ficaram sem sinalização específica;
 - a estratégia .3 foi copiada e colada para a construção da estratégia .4 que recebeu truncagem nos termos com radicais comuns;
 - a estratégia .3 foi copiada e colada para a construção da estratégia .5 que foi dividida em número de etapas igual ao número de operadores AND para teste de pesquisas com submissões parciais.
-

As cinco formulações referentes às variações de uma mesma estratégia de busca, foram submetidas no mesmo dia, sequencialmente, no período compreendido entre os meses de junho a agosto de 2012. Todas as estratégias foram submetidas para busca no formulário avançado de pesquisa (*PubMed Advanced Search Builder*) da interface e foi mantida a configuração padrão, automaticamente assumida pelo sistema, para definição dos campos de pesquisa, ou seja, todos os campos (*all fields*).

Os números absolutos correspondentes ao número de registros recuperados em cada submissão foram transcritos em uma tabela de Excell, organizados conforme objetivos específicos descritos (anexo 2). Para análise estatística foi utilizado o teste *Kruskal–Wallis one-way analysis of variance by ranks* e o programa SAS.

Dois investigadores (ESNV e MB) afiliados ao Grupo de MBE da FMB/UNESP avaliaram independentemente as estratégias de busca quanto aos desfechos e contexto descritos anteriormente.

4 Resultado

Os números absolutos correspondentes ao número de registros obtidos em cada formulação das 120 estratégias de busca pesquisadas estão registrados em arquivo Excell (apêndice B). A tabela 1 sumariza os resultados obtidos.

Tabela 1 - Comparação de número de registros recuperados em 120 estratégias de busca mediante uso ou não, de parênteses e aspas para indicar frase, truncagem e combinação de resultados do histórico de pesquisa na base de dados MEDLINE via PubMed.

Sinal/ recurso avaliado	Número de registros recupe- rados igual	Número de registros recupe- rados menor	Número de registros recupe- rados maior	Com ou sem	Number	P value	Mean	Median	Range	SD
Parênteses para indicar frase	120	N/A	N/A	com	38997,5	1.0	2521,2	374,0	28664	5198,1
				sem	38997,5		2521,2	374,0	28664	5198,1
Aspas para indicar frase	10	106	4	com	31370,0	0.04	1696,1	181,5	20638	3939.2
				sem	38997,5		2521,2	374,0	28664	5198,1
Truncagem	17	96	7	com	31940,0	0.08	1774,9	149,0	27702	4351.8
				sem	38997,5		2521,2	374,0	28664	5198,1
Histórico de pesquisa	120	0	0	com	38997,5	1.0	2521,2	374,0	28664	5198,1
				sem	38997,5		2521,2	374,0	28664	5198,1

Os resultados obtidos mediante as buscas com ou sem parênteses com a função de indicar frase foram idênticos, ou seja, as 120 estratégias submetidas nos dois formatos recuperaram os mesmos números de resultados.


Mediante as estratégias submetidas com ou sem aspas com a função de indicar frase, em apenas dez foram obtidos resultados idênticos. Em 106 estratégias com aspas o número de resultados foi menor e somente quatro estratégias com aspas recuperaram mais registros do que sem sua utilização.

Nas estratégias submetidas com uso de truncagem ou com registro integral das palavras com o mesmo radical, 17 recuperaram idêntico número de resultados. Em 96 estratégias o número de registros recuperados foi maior quando as palavras foram indicadas na forma integral e em apenas sete estratégias com uso de truncagem foi recuperado número maior de registros do que aquelas em que as palavras foram redigidas na íntegra.

Os resultados obtidos mediante busca submetida em uma única etapa e a busca formulada com combinação de resultados de diversas etapas parciais, isto é, usando o histórico de pesquisa, foram idênticos em todas as estratégias (120).

O gráfico apresentado a seguir permite a visualização do número de estratégias que recuperaram número de resultados iguais, maiores ou menores para cada recurso avaliado, ou seja, com parênteses, com aspas, com truncagem e em várias etapas usando histórico de pesquisa, comparado com o número de estratégias em que os recursos não foram aplicados.

Figura 8: Comparação do total de estratégias de busca com número de resultados igual, menor ou maior que a estratégia padrão.



5 Discussão

Em nossa investigação comparamos o número de registros recuperados mediante cinco diferentes formas de construção da mesma estratégia de busca, ou seja, os mesmos termos com os mesmos operadores booleanos foram usados com parênteses ou aspas para indicar frase, com asteriscos para indicar truncagem e uma única formulação na caixa de pesquisa ou em varias etapas, combinando os resultados apresentados no histórico de pesquisa, na base de dados MEDLINE via PubMed com objetivo de identificar a melhor forma de elaborar estratégias nessa interface para pesquisas.

Usamos como desfecho desejado o maior número de resultados recuperados e não a relevância dos registros encontrados. Para avaliar a relevância, o estudo deveria ter outro delineamento, com a participação de dois ou mais pesquisadores especialistas avaliadores para cada estratégia analisada, aplicação de questionários, elaboração de escores e índices e tudo isso exigiria um tempo muito maior para execução e implicaria em diminuição do número de estratégias de busca a serem submetidas. Para exemplificar a necessidade da restrição para estudos que avaliam relevância, consideramos o trabalho de Brazier & Begley (1996) que compararam tanto número como a relevância de resultados obtidos nas bases MEDLINE e CINAHL em algumas áreas da Enfermagem. Selecionaram mediante randomização, entre 168 estratégias referentes a projetos em andamento, apenas seis, que foram restringidas mediante determinação do período de publicação (de um a quatro anos no máximo), campo de busca (apenas título de artigo) e em idioma Inglês. Tal restrição favoreceu a avaliação da relevância dos resultados obtidos.

Opostamente, em nosso estudo, cada estratégia de busca foi submetida quatro vezes de modo que obtivemos 460 resultados de pesquisa. A pesquisa foi abrangente, ou seja, a busca foi feita em todos os campos, sem limitação de idioma, período, tipo de estudo ou uso de qualquer outro filtro que pudesse limitar os resultados.

Quanto à escolha da base de dados e da interface a serem avaliadas, o critério foi a amplitude da cobertura temática, ou seja, uma base de dados bem abrangente quanto aos assuntos incluídos e a extensão do número de acessos. Acreditamos que os resultados da pesquisa devem ser de interesse do maior

número possível de pesquisadores. Desta forma consideramos que a escolha da base de dados MEDLINE atendeu ao requisito de cobertura temática e a interface PubMed, atendeu ao requisito de extensão do número de acessos, já que a interface permite o acesso aberto ou livre a qualquer interessado em qualquer lugar do mundo, ou seja, não há nenhum custo de assinatura, diferente do que ocorre com outras interfaces ou fornecedores que exigem assinaturas para oferecerem os serviços (OVID, SCOPUS, EMBASE etc). Esses fornecedores oferecem a mesma base de dados MEDLINE, apresentam interfaces de pesquisas amigáveis e contam com outras ferramentas não disponíveis na interface PubMed, no entanto, os resultados dos estudos feitos nessas bases teriam interesse restrito aos usuários de instituições assinantes desses fornecedores.

Sobre a formulação da estratégia de busca é preciso considerar que uma pergunta pode ser traduzida por diferentes formulações de estratégia de busca que deve ser moldada para necessidade e objetivo específico do pesquisador no momento da busca. Neste estudo elaboramos um modelo simples de estratégia de busca a ser aplicado na caixa de pesquisa do formulário avançado em todos os campos, sem uso de filtros. Não foi preocupação deste trabalho avaliar a precisão da estratégia em relação à pergunta ou ao PICO, ou seja, não tivemos como objetivo avaliar o número de registros obtidos em relação à qualidade semântica da estratégia e sim o uso de sinais e seus efeitos na recuperação de registros.

As estratégias utilizadas neste estudo, em sua maioria, correspondiam a interesses dos usuários, ou seja, foram coletadas no mundo real, não havendo critérios de seleção temática. Outras foram formuladas durante aulas e os alunos elaboraram estratégias para testar a aprendizagem ou sondar possibilidades de pesquisas de modo que a quantidade e abrangência dos termos constantes das estratégias formuladas não foram limitadas. As padronizações propostas foram apenas aquelas que viabilizavam a aplicação do uso dos recursos a serem avaliados descritos no tópico critérios de inclusão da seção Método.

O número de resultados obtidos em resposta às 120 estratégias utilizadas neste estudo foi bem variável, sendo o menor igual a zero e o maior igual 28.664,

com desvio padrão de 5.198,1 e 3.939,2, independente do recurso avaliado. Essa diversidade pode ser atribuída à baixa padronização bem como à diversidade na origem e objetivos das estratégias utilizadas. A média de registros recuperados também é alta, sendo 2.521 nos resultados dos testes de uso ou não de parênteses para indicar frase e o mesmo valor nos testes do número de etapas. Nos testes de uso de aspas para indicar frase, a média foi de 1.696 e, nos testes de uso de truncagem, foi de 1.774. Mesmo para revisões sistemáticas essas médias podem ser altas. O número máximo encontrado (28.664) é muito alto, provavelmente, em virtude do tipo de pesquisa, ou seja, sem utilização de filtros na submissão das buscas, uso do formato *default* da interface PubMed que inclui varredura em todos os campos dos registros e abrangência dos termos utilizados. Para pesquisas de demanda real, seria necessário utilizar mecanismos de restrição para viabilizar a elaboração de uma revisão sistemática.

Foram testados dois sinais para indicar frase: parênteses e aspas. Sobre esse aspecto estudado é importante esclarecer que o manual disponível na interface PubMed (NLM, 2012) orienta que devem ser usadas aspas para indicação de frases. No entanto, havia uma prática baseada na experiência trazida por alguns usuários e ensinada em outras instituições, na qual os parênteses eram utilizados para essa função. Por esse motivo resolvemos incluir neste estudo os testes dos dois sinais (parênteses e aspas) a fim de podermos comparar os resultados para embasarmos nossa prática bibliotecária e o ensino que oferecemos aos usuários em resultados científicos.

5.1 Parênteses e aspas para indicar frase

Nas 120 estratégias formuladas para comparar o uso ou não de parênteses para indicar frase obtivemos os mesmos números de registros recuperados em 100% das pesquisas. Ocorre que o motor de busca da interface PubMed despreza os parênteses utilizados com essa função. Por outro lado quando comparamos estratégias sem aspas e com utilização de aspas, apenas dez tiveram número de resultados coincidentes e 106 estratégias recuperaram menos artigos com uso de aspas com diferença estatisticamente significativa (p value = 0,045080).

Para explicar esses resultados é interessante observar como as estratégias introduzidas pelo usuário na caixa de pesquisa da interface PubMed são interpretadas pelo motor de busca do sistema de informação. Essas interpretações são descritas na caixa intitulada “search details” que mostra como a estratégia é “traduzida”, o seja, o formato final em que é realmente submetida ao sistema para a busca dos registros. As estratégias introduzidas pelo usuário com e sem a utilização de parênteses são interpretadas de forma idêntica pelo sistema. Ao contrário, as estratégias elaboradas e submetidas com ou sem aspas recebem “traduções” diferentes. O quadro 5 mostra como as estratégias foram interpretadas na interface.

Quadro 5 - Interpretação das estratégias de busca submetidas sem parênteses e sem aspas, com parênteses e com aspas na interface PubMed.

Estratégia de busca inserida na caixa de pesquisa pelo usuário	Estratégia interpretada e submetida pelo sistema conforme descrição na caixa “search details” após a realização da pesquisa	Número de resultados obtidos
mediastinal neoplasms	<i>"mediastinal neoplasms"[MeSH Terms] OR ("mediastinal"[All Fields] AND "neoplasms"[All Fields]) OR "mediastinal neoplasms"[All Fields]</i>	25.904
(mediastinal neoplasms)	<i>"mediastinal neoplasms"[MeSH Terms] OR ("mediastinal"[All Fields] AND "neoplasms"[All Fields]) OR "mediastinal neoplasms"[All Fields]</i>	25.904
"mediastinal neoplasms"	<i>"mediastinal neoplasms"[All Fields]</i>	11.572

Nota: Registros recuperados em 4 de julho de 2012 mediante pesquisa feita no formulário Advanced usando *default*.

Podemos verificar que, quando a estratégia de busca é inserida na caixa de pesquisa com parênteses para indicar frase, o motor de busca, descarta esses parênteses e executa uma busca idêntica àquela em que não se utilizam os parênteses. Formula várias sintaxes a partir da estratégia original, ou seja, além de fazer a busca no campo MESH (*"mediastinal neoplasms"[MeSH Terms]*), também pesquisa em todos os demais campos do registro (*"mediastinal neoplasms"[All Fields]*) e ainda faz uma busca ampla que corresponde à combinação dos termos conectados com operador AND varrendo todos os campos dos registros da base (*("mediastinal"[All Fields] AND "neoplasms"[All Fields])*), ampliando as possibilidades de recuperação.

Por outro lado, a estratégia inserida com aspas recebe interpretação fiel à original e coincide com uma das sintaxes feitas pelo próprio sistema na estratégia sem uso de aspas ("*mediastinal neoplasms*"[All Fields]), ou seja, é um subconjunto contido no conjunto maior representado na estratégia que não utiliza o sinal. Por isso os resultados obtidos com uso de aspas serão sempre iguais ou menores do que os que não incluem esse sinal.

Carvalho et al. (2010) em estudo sobre mecanismos e estratégias de busca no Google, testaram estratégias com ou sem uso de aspas para indicar frase e também recuperaram menos registros com o uso de aspas porém consideraram o resultado mais relevante.

Recomendamos, portanto, o uso de aspas naquelas buscas em que o pesquisador requer alto índice de relevância dos resultados obtidos, evitando descarte manual de resultados falsos positivos.


5.2 Truncagem

Um dos problemas relatados na literatura sobre o uso da truncagem é que ela amplia as possibilidades de busca e podem ser recuperados termos não desejados, sobretudo quando a truncagem é usada com radicais curtos, que podem ter muitas variações não correspondentes aos termos de interesse do pesquisador (Marshall, 1980), ou seja, a truncagem torna a estratégia de busca mais sensível. No entanto, neste trabalho, ou seja, na interface PubMed da base MEDLINE, ocorreu o oposto.

Avaliando os números de resultados obtidos nas 120 estratégias com uso de truncagem, verificamos que em 96 o número de registros recuperados foram menores e, em apenas 17 foram iguais àquelas em que não foi usado o recurso. Embora, mediante análise estatística tal diferença não seja significativa (p value = 0,086127), não podemos negligenciar que em 80% das estratégias submetidas foram recuperados menos resultados com uso do que quando o recurso não foi aplicado. Tal resultado parece ser surpreendente, pois supostamente, o uso da truncagem em um termo deveria ampliar a abrangência já que todas as formas de

grafias complementares da raiz dos termos usados com truncagem deveriam ser recuperadas. Ocorre que na interface PubMed existe uma limitação no uso de truncagem de modo que, quando um termo truncado produz mais que 600 variações uma mensagem de aviso é apresentada na tela de resultado alertando sobre isso e sugerindo que a raiz utilizada seja ampliada (NLM, 2012). A Figura 9 é um exemplo desse tipo de mensagem obtida para a indicação do termo câncer com truncagem (*cancer**) submetido à pesquisa:

Figura 9 – Mensagem de aviso para termo submetido com truncagem na interface PubMed.



Para melhor compreensão sobre como essas variações podem ocorrer copiamos as traduções da caixa “search details” feitas pela interface PubMed para o termo *cancer* submetido para pesquisa com e sem truncagem. Quando o termo *cancer* é usado com truncagem há uma varredura buscando várias combinações do termo com outros até que atinge o limite de 600 combinações e aí interrompe a busca, mesmo havendo outras. Em virtude do tamanho da estratégia produzida pela interface PubMed para o termo com truncagem as interpretações estão no Anexo A.

Desta forma, para termos que apresentam mais de 600 variações dentro da base MEDLINE, existe um índice de perdas correspondente a todas as possíveis outras variações do termo e não sabemos qual o tamanho da perda de registros.

Em buscas bibliográficas, sobretudo, para elaboração de revisões sistemáticas, qualquer perda pode ser prejudicial à qualidade do trabalho a ser desenvolvido e, como o uso de truncagem pode restringir a pesquisa por não recuperar todos os termos desejados, não recomendamos o uso desse recurso na interface PubMed.

A truncagem tem como objetivo facilitar o trabalho do pesquisador, tanto na digitação dos termos com mesma raiz como também na identificação de variáveis possíveis. No entanto, na interface PubMed da base de dados MEDLINE, em virtude de características do motor de busca, o uso do recurso pode diminuir o número de resultados obtidos. Portanto, na interface PubMed, recomendamos que todas as variações da raiz de determinada palavra sejam indicadas e não se recorra ao uso da truncagem ou do asterisco, que indica essa operação.

5.3 Única etapa ou uso do histórico de pesquisa

Quando comparamos os resultados das estratégias submetidas em uma única etapa ou em várias etapas combinando os resultados do histórico de pesquisa, podemos verificar que os resultados foram idênticos em 100% das pesquisas. Como nas revisões sistemáticas podem requerer estratégias muito extensas, consideramos que a pesquisa em várias etapas possa ser preferível e talvez mais segura.

Cada etapa da estratégia deve representar uma das partes do PICO. Quando cada parte da estratégia é submetida separadamente o pesquisador pode fazer uma comparação entre o número de resultados obtidos em cada etapa e sua expectativa e, mediante sua avaliação, refazer a formulação parcial inicial, evitando erros, não perceptíveis quando a estratégia é elaborada em uma etapa apenas.

Além disso, quando realizada por etapas, as estratégias relativas a cada parte do pico são menores, facilitando ao pesquisador sua visualização na caixa de busca e, conseqüentemente, a detecção de erros de digitação, grafia, sinais, uso de operadores e outros.

O papel dos bibliotecários é orientar os usuários na utilização das fontes de informação e elaboração de estratégias de busca eficazes sendo assim consideramos que o método de várias etapas utilizando o recurso de combinar resultados apresentados no histórico de pesquisa é a forma mais didática a ser usada pela biblioteca para instrução de usuários e a prática que propicia maior controle do processo de busca.

6 Conclusão

- a) A base de dados MEDLINE via PubMed recupera o mesmo número de resultados com ou sem utilização de parênteses para indicar frase;
 - b) A base de dados MEDLINE via PubMed recupera um número menor de resultados com a utilização de aspas para indicar frase;
 - c) A base de dados MEDLINE via PubMed recupera um número menor de resultados com uso de truncagem do que com registro de todas palavras com o mesmo radical na íntegra;
 - d) A base de dados MEDLINE via PubMed recupera o mesmo número de resultados comparando a busca submetida em uma única etapa e a busca formulada com combinação de resultados de diversas etapas parciais, isto é, usando o histórico de pesquisa.
-



Referências

Aleixandre-Benavent R, González Alcaide G, González De Dios J, Alonso-Arroyo A. Sources of bibliographic information. Rationale for conducting a literature search. *Acta Pediatr Espan*. 2011;69:131-6.

Bay Y, Gao J, Li Z. Is MEDLINE alone enough for a meta-analysis? *Aliment Pharmacol Ther*. 2007;26:126-6.

Bates M J. Where should the person stop and the information search interface start? *Inf Process Manag* 1990;26:575-91.

Bernardo WM, Nobre MRC, Jatene FB. A prática clínica baseada em evidências. Parte 2: buscando as evidências em fontes de informação. *Rev Assoc Med Bras*. 2004;50:104-8.

BIREME. DeCS: descritores em ciências da saúde. [Internet]. São Paulo: BIREME; 2011. [cited 2011 Ago 1]. Available from: <http://decs.bvs.br/P/decsweb2011.htm>.

Brazier H, Begley CM. Selecting a database for literature searches in nursing: MEDLINE or CINAHL? *J Adv Nurs*. 1996;24: 868–75. doi: 10.1046/j.1365-2648.1996.26426.x.

Brettle AJ, Long AF. Comparison of bibliographic databases for information on the rehabilitation of people with severe mental illness. *Bull Med Libr Assoc*. 2001; 89: 353-62.

British Library. AMED: Allied and Complementary Medicine Database. [Internet]. Ipswich (MA): EBSCO; 2011. [cited 2011 Jun 28]. Available from: <http://www.bl.uk/reshelp/findhelpsubject/scitctenv/medicinehealth/amed/amed.html>.

International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journal: sample references [Internet]. Bethesda: U. S. National Library of Medicine; 2009 [update 2009 May 12; cited 2009 Set 10]. Available from: http://www.nlm.nih.gov/bsd.uniform_requirements.html

Burnham J, Shearer B. Comparison of CINAHL, Embase, and MEDLINE databases for nurse researcher. *Med Ref Serv Q.* 1993;12:45-57.

Caro-Rojas RA, Eslava-Schmalbach JH. Agreement between MEDLINE searches using the MEDLINE –CD-ROM and Internet PubMed, BioMedNet, Medscape and Gateway search engines. *Rev Salud Publica.* 2005;7:214-226.

Daniele Carvalho D, Belmino L, Cavalcante M. Mecanismos e estratégias de busca na WEB. In: *Anais Eletrônicos do 33º. Encontro Nacional de Estudantes de Biblioteconomia, Documentação, Gestão, e Ciência da Informação Encontro Nacional de Estudantes de Biblioteconomia, Documentação, Gestão, e Ciência da Informação*; 18-24 jul 2010; João Pessoa, PB. João Pessoa: ENEBED; 2010.

Castro AA, Clark OAC, Atallah AN. Optimal search strategy for clinical trials in the Latin American Caribbean Health Science Literature databases (LILACS). *São Paulo Med J.* 1997;115:1423-6.

Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. *Ann Intern Med.* 1997;126:376-80.

Cordeiro AM, Oliveira GM, Rentería JM, Guimarães CA. Revisão sistemática: uma revisão narrativa. *Rev Col Bras Cir.* 2007;34:428-31.

De Groote SL. PubMed, InternetGratefulMed, and Ovid: a comparison of three MEDLINE Internet interfaces. *Med Ref Serv Q.* 2000;19:1-13.

Delwich FA. Searching MEDLINE via PubMed. *Clin Lab Med.* 2008;21:35-41.

Diaz Castorena JC. MEDLINE: principal fuente de información biomédica. *Rev Fac Med UNAM.* 1998;41:7-11.

Dornelles J. Antropologia e Internet: quando o "campo" é a cidade e o computador é a "rede". *Horiz Antropol.* [Internet]. 2004;10:241-71. [cited 2011 Ago 01] Available from: <http://www.scielo.br/pdf/ha/v10n21/20627.pdf>.

El Dib RP, Atallah AN. Fonoaudiologia baseada em evidências e o centro Cochrane do Brasil. *Diagn Trat.* 2006;11:103-6

Eveillard P, Hannedouche T. Recherche bibliographique médicale avec MEDLINE–PubMed: une approche pratique basée sur l'exemple. *Néphrol Thér.* 2007;3:475–85.

Fraser C, Murray A, Burr J. Identifying observational studies of surgical interventions in MEDLINE and Embase. *BMC Med Res Method.* 2006;6:41.

Fujita MSL. A identificação de conceitos no processo de análise de assunto para indexação. *Rev Digit Bibliotecon Ciênc Inf.* 2003;1:60-90.

Gehanno JF, Rollin L, Jean TL, Louvel A, Darmori S, Shaw W. Precision and recall of search strategies for identifying studies on return-to-work in MEDLINE. *J Occup Rehabil.* 2009;19:223–30. doi 10.1007/s10926-009-9177-0.

Giglia E. MEDLINE/PubMed revisited: new, semantic tools to explore the biomedical literature. *Eur J Phys Rehabil Med.* 2009; 45: 293-7.

Google search. [Internet]. Cupertino (CA): Apple; 2010. [cited 2012 Mar 05]. Available from: http://pt.wikipedia.org/wiki/Google_Search.

Harms M. MEDLINE [editorial]. *Physiotherapy.* 2009;95:149–50.

Henner TA. Free MEDLINE and implications for library operations. *Med Ref Serv Q.* 2000;19:71-9.

Jacobs M, Edwards A, Graves RS, Johson ED. Criteria for evaluating alternative MEDLINE search engines. *Med Ref Serv Q.* 1998;17: 1-12.

Justo LP, Soares BGO, Calil HM. Revisão sistemática, metanálise e Medicina baseada em evidências: considerações conceituais. *J Bras Psiquiatr.* 2005;54:242-7.

Korfhage RR. Information storage and retrieval. New York: Wiley; 1997.

Laranjeira R, Dunn J, Daher Junior E. O desenvolvimento de uma estratégia para fazer pesquisa bibliográfica pela MEDLINE na área de álcool e drogas. J Bras Psiquiatr. 2000; 49:29-33.

Leclercq E, Kramer B, Schats, W. Limitations of the MEDLINE database in constructing meta-analyses. [letter]. Ann Intern Med. 2011;154:371-2.

Linde K, Willich SN. How objective are systematic reviews? Differences between reviews on complementary medicine. J R Soc Med 2003;96:17–22.

Lopes IL. Estratégia de busca na recuperação da informação: revisão da literatura. Cienc. Inf. 2002;31:60-71.

Marshall DB. To improve searching check search results. Online. 1980;4:32-47.

McGowan J, Sampson M, Lefebvre C. An evidence based checklist for the peer review of electronic search strategies (PRESS EBC). Evid Based Libr Inf Pract. 2010; 5:149-54.

Muin M, Fontelo P, Ackerman M. PubMed Interact: an interact search application for MEDLINE/PubMed. AMIA Annu Symp Proc. 2006:1039.

National Library of Medicine. MEDLINE. [Internet]. Bethesda: U.S. National Library of Medicine; 2011. [updated 2011 Jan 26; cited 2011 Jun 27]. Available from: <http://www.nlm.nih.gov/pubs/factsheets/MEDLINE.html>.

National Library of Medicine. PubMed celebrates its 10th anniversary! NLM Tech Bull. [Internet]. 2006 [posted 2006 Oct 5; cited 2011 Jun28]. (352): e5. Available from: http://www.nlm.nih.gov/pubs/techbull/so06/so06_pm_10.html.

National Library of Medicine. [Internet]. Bethesda: U.S. National Library of Medicine; 2012. PubMed help. [updated 2012 Ago 8; cited 2012 oct 28]. Available from:

http://www.ncbi.nlm.nih.gov/books/NBK3827/#PubMedhelp.PubMed_Quick_Start

Pérez M, Picasso G. Free MEDLINE in Internet: análisis comparative de Infotrieve, PubMed Y Cos. Rev Hosp Matern Ramon Sarda. 1999;18:51-6.

Petticrew M. Why certain systematic reviews reach uncertain conclusions. BMJ. 2003; 326 (7329): 756-8.

Pinillo León AL, Cañedo Andalia R. EL MeSH: una herramienta clave para la búsqueda de información en la base de datos MEDLINE. ACIMED. [Internet] 2005 abr [cited 2011 Ago 1]; 13(2):15p. Available from: http://bvs.sld.cu/revistas/aci/vol13_2_05/aci06205.htm.

Pinto M, Lancaster FW. Abstracts and abstracting in knowledge discovery. Libr Trends. 1999;48:234-48.

Rother ET. Revisão sistemática x revisão narrativa [editorial]. Acta Paul Enferm. 2007;20: v-vi.

Sackett DL, Rosenberg WMC, Gray JAM, Richardson WS. Evidence based medicine: what it is and what it isn't. [editorial] BMJ. 1996;312:71-2.

Sampaio RP, Mancini MC. Estudos de revisão sistemática: um guia para síntese criteriosa da evidência científica. Rev Bras Fisioter. 2007;11:83-9.

Sampson M, McGowan J, Cogo E, Grimshaw J, Moher D, Lefebvre C. An evidence-based practice guideline for the peer review of electronic search strategies. J Clin Epidemiol. 2009;62:944-52.

Schoonbaert D. SPIRS, WinSPIRS, and Ovid: a comparison of three MEDLINE on CD-ROM interfaces. Bull Med Libr Assoc. 1996;84:63-70.

Suarez-Almazor ME, Belseck E, Homik J, Dorgan M, Ramus-Remus C. Identifying clinical trials in the medical literature with electronic databases: MEDLINE alone is not enough. *Control Clin Trials*. 2000;21:476–87.

Türp JC, Schulte JM, Antes G. Nearly half of dental RCTs published in German are not included in MEDLINE. *Eur J Oral Sci*. 2002;110:405–11.

Vanhecke TE, Barnes MA, Zimmermman J, Shoichet S. PubMed vs. HighWire Press: Ahead-to-head comparison of two medical literature search engines. *Comput Biol Med*. 2007;37:1252-8.

Volpato ESN. Pesquisa bibliográfica em ciências biomédicas. *J Pneumol*. 2000;26:77-9.

Winchester DE, Bavry AA. Limitations of the MEDLINE database in constructing meta-analyses [letter]. *Ann Intern Med*. 2010;153:347-8.

Younger P, Boddy K. When is a search not a search? A comparison of searching the AME complementary health database via EBSCOhost, OVID and DIALOG. *Health Inf Libr J*. 2009;26:126-35.



Apêndice

Apêndice A - Estratégias de busca submetidas ao PubMed

1.1

((mediastinal neoplasms) OR (mediastinal neoplasm) OR (mediastinum neoplasms) OR (mediastinum neoplasm) OR (cancer of mediastinum) OR (mediastinum cancers) OR (mediastinal cancer) OR (cancer of the mediastinum)) AND (complications OR (associated disease) OR (coexistent conditions) OR sequels OR (concomitant conditions) OR (concomitant disease) OR (associated conditions) OR (coexistent disease)) AND (therapy OR (operative therapy) OR (operative procedures) OR (invasive procedures) OR operations OR preoperative OR procedures OR (perioperative procedures) OR (preoperative procedures) OR (intraoperative procedures))

1.2

("mediastinal neoplasms" OR "mediastinal neoplasm" OR "mediastinum neoplasms" OR "mediastinum neoplasm" OR "cancer of mediastinum" OR "mediastinum cancers" OR "mediastinal cancer" OR "cancer of the mediastinum") AND (complications OR "associated disease" OR "coexistent conditions" OR sequels OR "concomitant conditions" OR "concomitant disease" OR "associated conditions" OR "coexistent disease") AND (therapy OR "operative therapy" OR "operative procedures" OR "invasive procedures" OR operations OR preoperative OR procedures OR "perioperative procedures" OR "preoperative procedures" OR "intraoperative procedures")

1.3

(mediastinal neoplasms OR mediastinal neoplasm OR mediastinum neoplasms OR mediastinum neoplasm OR cancer of mediastinum OR mediastinum cancers OR mediastinal cancer OR cancer of the mediastinum) AND (complications OR associated disease OR coexistent conditions OR sequels OR concomitant conditions OR concomitant disease OR associated conditions OR coexistent disease) AND (therapy OR operative therapy OR operative procedures OR invasive procedures OR operations OR preoperative OR procedures OR perioperative procedures OR preoperative procedures OR intraoperative procedures)

1.4

(mediastinal neoplasm* OR mediastinum neoplasm* OR cancer of mediastinum OR mediastin* cancer* OR cancer of the mediastinum) AND (complications OR associated disease OR coexistent conditions OR sequels OR concomitant conditions OR concomitant disease OR associated conditions OR coexistent disease) AND (therapy OR operative therapy OR operative procedures OR invasive procedures OR operations OR preoperative OR procedures OR perioperative procedures OR preoperative procedures OR intraoperative procedures)

1.5

mediastinal neoplasms OR mediastinal neoplasm OR mediastinum neoplasms OR mediastinum neoplasm OR cancer of mediastinum OR mediastinum cancers OR mediastinal cancer OR cancer of the mediastinum

AND

complications OR associated disease OR coexistent conditions OR sequels OR concomitant conditions OR concomitant disease OR associated conditions OR coexistent disease

AND

therapy OR operative therapy OR operative procedures OR invasive procedures OR operations OR preoperative OR procedures OR perioperative procedures OR preoperative procedures OR intraoperative procedures

2.1

((prostatic neoplasms) OR (prostate neoplasms) OR (prostate neoplasm) OR (prostatic neoplasm) OR (prostate cancer) OR (prostate cancers) OR (cancer of the prostate) OR (prostatic cancer) OR (cancer of prostate)) AND (prognosis OR prognoses)

2.2

("prostatic neoplasms" OR "prostate neoplasms" OR "prostate neoplasm" OR "prostatic neoplasm" OR "prostate cancer" OR "prostate cancers" OR "cancer of the prostate" OR "prostatic cancer" OR "cancer of prostate") AND (prognosis OR prognoses)

2.3

(prostatic neoplasms OR prostate neoplasms OR prostate neoplasm OR prostatic neoplasm OR prostate câncer OR prostate cancers OR cancer of the prostate OR prostatic cancer OR cancer of prostate) AND (prognosis OR prognoses)

2.4

(prostat* neoplasm* OR prostat* cancer* OR cancer of the prostate OR cancer of prostate) AND (prognosis OR prognoses)

2.5

prostatic neoplasms OR prostate neoplasms OR prostate neoplasm OR prostatic neoplasm OR prostate cancer OR prostate cancers OR cancer of the prostate OR prostatic cancer OR cancer of prostate

AND prognosis OR prognoses

3.1

((breast neoplasm) OR (breast neoplasms) OR (breast tumors) OR (breast tumor) OR (human mammary carcinoma) OR (human mammary carcinomas) OR (human mammary neoplasm) OR (human mammary neoplasms) OR (breast cancer) OR (cancer of the breast) OR (cancer of breast) OR (carcinoma of the breast) OR (breast carcinomas) OR (breast carcinoma) OR (breast adenocarcinoma) OR (breast adenocarcinomas) OR (adenocarcinoma of the breast)) AND (tykerb OR (lapatinib ditosylate) OR (N-(3-chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amine)methyl) -2-furyl)-4-quinazolinamine) OR (GW 282974X OR GW282974X) OR (GW-282974X OR GW572016) OR (GW-572016 OR GW 572016)) AND ((overall survival))

3.2

("breast neoplasm" OR "breast neoplasms" OR "breast tumors" OR "breast tumor" OR "human mammary carcinoma" OR "human mammary carcinomas" OR "human mammary neoplasm" OR "human mammary neoplasms" OR "breast cancer" OR "cancer of the breast" OR "cancer of breast" OR "carcinoma of the breast OR breast carcinomas" OR "breast carcinoma" OR "breast adenocarcinoma" OR "breast adenocarcinomas" OR "adenocarcinoma of the breast") AND (tykerb OR "lapatinib ditosylate" OR N-(3-chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amine)methyl) -2-furyl)-4-quinazolinamine OR GW 282974X OR GW282974X OR GW-282974X OR GW572016 OR GW-572016 OR GW 572016) AND "overall survival"

3.3

(breast neoplasm OR breast neoplasms OR breast tumors OR breast tumor OR human mammary carcinoma OR human mammary carcinomas OR human mammary neoplasm OR human mammary neoplasms OR breast cancer OR cancer of the breast OR cancer of breast OR carcinoma of the breast OR breast carcinomas OR breast carcinoma OR breast adenocarcinoma OR breast adenocarcinomas OR adenocarcinoma of the breast) AND (tykerb OR lapatinib ditosylate OR N-(3-chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amine)methyl) -2-furyl)-4-quinazolinamine OR GW 282974X OR GW282974X OR GW-282974X OR GW572016 OR GW-572016 OR GW 572016) AND overall survival

3.4

(breast neoplasm* OR breast tumor* OR human mammary carcinoma* OR human mammary neoplasm* OR breast cancer OR cancer of the breast OR cancer of breast OR carcinoma of the breast OR breast carcinoma* OR breast adenocarcinoma* OR adenocarcinoma of the breast) AND (tykerb OR lapatinib ditosylate OR N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-((2-methylsulfonyl)ethyl)amine)methyl)-2-furyl)-4-quinazolinamine OR GW 282974X OR GW282974X OR GW-282974X OR GW572016 OR GW-572016 OR GW 572016) AND overall survival

3.5

breast neoplasm OR breast neoplasms OR breast tumors OR breast tumor OR human mammary carcinoma OR human mammary carcinomas OR human mammary neoplasm OR human mammary neoplasms OR breast cancer OR cancer of the breast OR cancer of breast OR carcinoma of the breast OR breast carcinomas OR breast carcinoma OR breast adenocarcinoma OR breast adenocarcinomas OR adenocarcinoma of the breast AND tykerb OR lapatinib ditosylate OR N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-((2-methylsulfonyl)ethyl)amine)methyl)-2-furyl)-4-quinazolinamine OR GW 282974X OR GW282974X OR GW-282974X OR GW572016 OR GW-572016 OR GW 572016 AND overall survival

4.1

((prostatic hypertrophy) OR (prostatic adenomas) OR (prostatic adenoma) OR (benign prostatic hyperplasia) OR (benign prostatic hypertrophy)) AND (therapy OR treatment) AND clinical

4.2

("prostatic hypertrophy" OR "prostatic adenomas" OR "prostatic adenoma" OR "benign prostatic hyperplasia" OR "benign prostatic hypertrophy") AND (therapy OR treatment) AND clinical

4.3

(prostatic hypertrophy OR prostatic adenomas OR prostatic adenoma OR benign prostatic hyperplasia OR benign prostatic hypertrophy) AND (therapy OR treatment) AND clinical

4.4

(prostatic hypertrophy OR prostatic adenoma* OR benign prostatic hyperplasia OR benign prostatic hypertrophy) AND (therapy OR treatment) AND clinical

4.5

prostatic hypertrophy OR prostatic adenomas OR prostatic adenoma OR benign prostatic hyperplasia OR benign prostatic hypertrophy AND therapy OR treatment AND clinical

5.1

((urinary bladder neoplasm) OR (bladder tumors) OR (bladder tumor) OR (bladder neoplasms) OR (bladder neoplasm) OR (urinary bladder cancer) OR (cancer of bladder) OR (cancer of the bladder) OR (bladder cancer) OR (bladder cancers)) AND ((squamous cell carcinomas) OR (squamous cell carcinoma) OR (squamous carcinoma) OR (squamous carcinomas) OR (epidermoid carcinoma) OR (epidermoid carcinomas) OR (planocellular carcinoma) OR (planocellular carcinomas)) AND (risk factor)

5.2

("urinary bladder neoplasm" OR "bladder tumors" OR "bladder tumor" OR "bladder neoplasms" OR "bladder neoplasm" OR "urinary bladder cancer" OR "cancer of bladder" OR "cancer of the bladder" OR "bladder cancer" OR "bladder cancers") AND ("squamous cell carcinomas" OR "squamous cell carcinoma" OR "squamous carcinoma" OR "squamous carcinomas" OR "epidermoid carcinoma"

OR “epidermoid carcinomas” OR “planocellular carcinoma” OR “planocellular carcinomas”) AND risk factor

5.3

(urinary bladder neoplasm OR bladder tumors OR bladder tumor OR bladder neoplasms OR bladder neoplasm OR urinary bladder cancer OR cancer of bladder OR cancer of the bladder OR bladder cancer OR bladder cancers) AND (squamous cell carcinomas OR squamous cell carcinoma OR squamous carcinoma OR squamous carcinomas OR epidermoid carcinoma OR epidermoid carcinomas OR planocellular carcinoma OR planocellular carcinomas) AND risk factor

5.4

(urinary bladder neoplasm OR bladder tumor* OR bladder neoplasm* OR urinary bladder cancer OR cancer of bladder OR cancer of the bladder OR bladder cancer*) AND (squamous cell carcinoma* OR squamous carcinoma* OR epidermoid carcinoma* OR planocellular carcinoma OR planocellular carcinomas) AND risk factor

5.5

urinary bladder neoplasm OR bladder tumors OR bladder tumor OR bladder neoplasms OR bladder neoplasm OR urinary bladder cancer OR cancer of bladder OR cancer of the bladder OR bladder cancer OR bladder cancers AND squamous cell carcinomas OR squamous cell carcinoma OR squamous carcinoma OR squamous carcinomas OR epidermoid carcinoma OR epidermoid carcinomas OR planocellular carcinoma OR planocellular carcinomas AND risk factor

6.1

(pneumothorax) AND (complications OR (associated disease) OR (coexistent conditions) OR sequels OR (concomitant conditions) OR (concomitant disease) OR sequelae OR (associated conditions) OR (coexistent disease)) AND (diagnosis OR symptoms OR screening OR signs OR differential diagnosis OR findings)

6.2

pneumothorax AND (complications OR “associated disease” OR “coexistent conditions” OR sequels OR “concomitant conditions” OR “concomitant disease” OR sequelae OR “associated conditions” OR “coexistent disease”) AND (diagnosis OR symptoms OR screening OR signs OR “differential diagnosis” OR findings) pneumothorax AND (complications OR “associated disease” OR “coexistent conditions” OR sequels OR “concomitant conditions” OR “concomitant disease” OR sequelae OR “associated conditions” OR “coexistent disease”) AND (diagnosis OR symptoms OR screening OR signs OR “differential diagnosis” OR findings)

6.3

pneumothorax AND (complications OR associated disease OR coexistent conditions OR sequels OR concomitant conditions OR concomitant disease OR sequelae OR associated conditions OR coexistent disease) AND (diagnosis OR symptoms OR screening OR signs OR differential diagnosis OR findings) pneumothorax AND (complications OR associated disease OR coexistent conditions OR sequels OR concomitant conditions OR concomitant disease OR sequelae OR associated conditions OR coexistent disease) AND (diagnosis OR symptoms OR screening OR signs OR differential diagnosis OR findings)

6.4

pneumothorax AND (complications OR associated disease OR coexistent conditions OR sequel*OR concomitant conditions OR concomitant disease OR associated conditions OR coexistent disease) AND (diagnosis OR symptoms OR screening OR signs OR differential diagnosis OR findings)

6.5

Pneumothorax AND complications OR associated disease OR coexistent conditions OR sequels OR concomitant conditions OR concomitant disease OR sequelae OR associated conditions OR coexistent disease AND diagnosis OR symptoms OR screening OR signs OR differential diagnosis OR findings

7.1

((surface antigens) OR (cell surface antigen) OR (immunologic surface markers) OR (immunological surface markers) OR (surface antigen) OR (cell surface antigens)) AND ((erythrocytes OR erythrocyte OR (red blood corpuscle) OR (red blood corpuscles) OR (red blood cell) OR (red blood cells)) AND ((erythrocyte membrane) OR (erythrocyte membranes))

7.2

("surface antigens" OR "cell surface antigen" OR "immunologic surface markers" OR "immunological surface markers" OR "surface antigen" OR "cell surface antigens") AND (erythrocytes OR erythrocyte OR "red blood corpuscle" OR "red blood corpuscles" OR "red blood cell" OR "red blood cells") AND ("erythrocyte membrane" OR "erythrocyte membranes")

7.3

(surface antigens OR cell surface antigen OR immunologic surface markers OR immunological surface markers OR surface antigen OR cell surface antigens) AND (erythrocytes OR erythrocyte OR red blood corpuscle OR red blood corpuscles OR red blood cell OR red blood cells) AND (erythrocyte membrane OR erythrocyte membranes)

7.4

(surface antigen* OR cell surface antigen* OR immunologic* surface markers) AND (erythrocyte* OR red blood corpuscle* OR red blood cell*) AND (erythrocyte membrane*)

7.5

surface antigens OR cell surface antigen OR immunologic surface markers OR immunological surface markers OR surface antigen OR cell surface antigens AND erythrocytes OR erythrocyte OR red blood corpuscle OR red blood corpuscles OR red blood cell OR red blood cells AND erythrocyte membrane OR erythrocyte membranes

8.1

((prostatic neoplasms) OR (prostatic neoplasm) OR (prostate neoplasm) OR (prostate neoplasms) OR (prostatic cancers) OR (prostate cancer) OR (prostate cancers) OR (cancer of prostate) OR (cancer of the prostate)) AND epidemiology AND therapy AND (treatment outcome)

8.2

("prostatic neoplasms" OR "prostatic neoplasm" OR "prostate neoplasm" OR "prostate neoplasms" OR "prostatic cancers" OR "prostate cancer" OR "prostate cancers" OR "cancer of prostate" OR "cancer of the prostate") AND epidemiology AND therapy AND "treatment outcome"

8.3

(prostatic neoplasms OR prostatic neoplasm OR prostate neoplasm OR prostate neoplasms OR prostatic cancers OR prostate cancer OR prostate cancers OR cancer of prostate OR cancer of the prostate) AND epidemiology AND therapy AND treatment outcome

8.4

(prostat* neoplasm * OR prostat* cancer* OR cancer of prostate OR cancer of the prostate) AND epidemiology AND therapy AND treatment outcome

8.5

prostatic neoplasms OR prostatic neoplasm OR prostate neoplasm OR prostate neoplasms OR prostatic cancers OR prostate cancer OR prostate cancers OR cancer of prostate OR cancer of the prostate AND epidemiology AND therapy AND treatment outcome

9.1

((breast neoplasms) OR (breast neoplasm) OR (breast tumors) OR (breast tumor) OR (human mammary carcinomas) OR (human mammary carcinoma) OR (human mammary neoplasm) OR (human mammary neoplasms) OR (breast cancer) OR (cancer of the breast) OR (cancer of breast)) AND (therapy OR treatment OR (disease management)) AND (complications OR sequels OR sequelae OR (associated disease) OR (associated conditions) OR (concomitant disease))

9.2

("breast neoplasms" OR "breast neoplasm" OR "breast tumors" OR "breast tumor" OR "human mammary carcinomas" OR "human mammary carcinoma" OR "human mammary neoplasm" OR "human mammary neoplasms" OR "breast cancer" OR "cancer of the breast" OR "cancer of breast") AND (therapy OR treatment OR "disease management") AND (complications OR sequels OR sequelae OR "associated disease" OR "associated conditions" OR "concomitant disease")

9.3

(breast neoplasms OR breast neoplasm OR breast tumors OR breast tumor OR human mammary carcinomas OR human mammary carcinoma OR human mammary neoplasm OR human mammary neoplasms OR breast cancer OR cancer of the breast OR cancer of breast) AND (therapy OR treatment OR disease management) AND (complications OR sequels OR sequelae OR associated disease OR associated conditions OR concomitant disease)

9.4

(breast neoplasm* OR breast tumor* OR human mammary carcinoma* OR human mammary neoplasm* OR breast cancer OR cancer of the breast OR cancer of breast) AND (therapy OR treatment OR disease management) AND (complications OR sequel* OR associated disease OR associated conditions OR concomitant disease)

9.5

breast neoplasms OR breast neoplasm OR breast tumORS OR breast tumOR OR human mammary carcinomas OR human mammary carcinoma OR human mammary neoplasm OR human mammary neoplasms OR breast cancer OR cancer of the breast OR cancer of breast AND therapy OR treatment OR disease management AND complications OR sequels OR sequelae OR associated disease OR associated conditions OR concomitant disease

10.1

((small intestine) OR (small intestines)) AND ((neuroendocrine carcinoma) OR (neuroendocrine carcinomas) OR (carcinoid tumors) OR (carcinoid tumor) OR carcinoid OR carcinoids OR (neuroendocrine tumors) OR (neuroendocrine tumor))

10.2

("small intestine" OR "small intestines") AND ("neuroendocrine carcinoma" OR "neuroendocrine carcinomas" OR "carcinoid tumors" OR "carcinoid tumor" OR carcinoid OR carcinoids OR neuroendocrine tumors OR "neuroendocrine tumor")

10.3

(small intestine OR small intestines) AND (neuroendocrine carcinoma OR neuroendocrine carcinomas OR carcinoid tumors OR carcinoid tumor OR carcinoid OR carcinoids OR neuroendocrine tumors OR neuroendocrine tumor)

10.4

small intestine* AND (neuroendocrine carcinoma* OR carcinoid tumOR* OR carcinoid* OR neuroendocrine tumor*)

10-5

small intestine OR small intestines AND neuroendocrine carcinoma OR neuroendocrine carcinomas OR carcinoid tumORs OR carcinoid tumOR OR carcinoid OR carcinoids OR neuroendocrine tumORs OR neuroendocrine tumOR

11.1

((prostatic hypertrophy) OR (benign prostatic hyperplasia) OR (benign prostatic hypertrophy) OR (benign prostatic hyperplasias)) AND ((phytotherapy OR (herb therapy) OR (herbal therapy))) AND (recurrence OR recurrences OR relapse OR relapses)

11.2

("prostatic hypertrophy" OR "benign prostatic hyperplasia" OR "benign prostatic hypertrophy" OR "benign prostatic hyperplasias") AND (phytotherapy OR "herb therapy" OR "herbal therapy") AND (recurrence OR recurrences OR relapse OR relapses)

11.3

(prostatic hypertrophy OR benign prostatic hyperplasia OR benign prostatic hypertrophy OR benign prostatic hyperplasias) AND (phytotherapy OR herb therapy OR herbal therapy) AND (recurrence OR recurrences OR relapse OR relapses)

11.4

(prostatic hypertrophy OR benign prostatic hyperplasia* OR benign prostatic hypertrophy) AND (phytotherapy OR herb* therapy) AND (recurrence*OR relapse*)

11.5

prostatic hypertrophy OR benign prostatic hyperplasia OR benign prostatic hypertrophy OR benign prostatic hyperplasias AND phytotherapy OR herb therapy OR herbal therapy AND recurrence OR recurrences OR relapse OR relapses

12.1

((thoracotomy OR (thoracic surgery) OR (thorax surgery) OR (thoracic surgical procedures) OR (surgical procedure operative) OR (surgical procedures operatives)) AND ((intercostal suture) OR (intercostal sutures) OR (intracostal suture) OR (intracostal sutures) OR (muscle flap) OR (thoracic nerve) OR (thoracic nerves) OR (intercostal nerve) OR (intercostal nerves) OR (spinal nerve) OR (spinal nerves) OR (peripheral nerve) OR (peripheral nerves)))

12.2

(thoracotomy OR "thoracic surgery" OR "thorax surgery" OR "thoracic surgical procedures" OR "surgical procedure operative" OR "surgical procedures operatives") AND ("intercostal suture" OR "intercostal sutures" OR "intracostal suture" OR "intracostal sutures" OR "muscle flap" OR "thoracic nerve" OR "thoracic nerves" OR "intercostal nerve" OR "intercostal nerves" OR "spinal nerve" OR "spinal nerves" OR "peripheral nerve" OR "peripheral nerves")

12.3

(thoracotomy OR thoracic surgery OR thorax surgery OR thoracic surgical procedures OR surgical procedure operative OR surgical procedures operatives) AND (intercostal suture OR intercostal sutures OR intracostal suture OR intracostal sutures OR muscle flap OR thoracic nerve OR thoracic nerves OR intercostal nerve OR intercostal nerves OR spinal nerve OR spinal nerves OR peripheral nerve OR peripheral nerves)

12.4

(thoracotomy OR thora* surgery OR thoracic surgical procedures OR surgical procedure operative*) AND (intercostal suture* OR intracostal suture* OR muscle flap OR thoracic nerve* OR intercostal nerve* OR spinal nerve* OR peripheral nerve*)

12.5

thoracotomy OR thoracic surgery OR thorax surgery OR thoracic surgical procedures OR surgical procedure operative OR surgical procedures operatives AND intercostal suture OR intercostal sutures OR intracostal suture OR intracostal sutures OR muscle flap OR thoracic nerve OR thoracic nerves OR intercostal nerve OR intercostal nerves OR spinal nerve OR spinal nerves OR peripheral nerve OR peripheral nerves

13.1

(neoplasms OR neoplasm OR tumors OR tumor OR cancer OR cancers OR (benign neoplasms) OR (benign neoplasm)) AND ((germ cells) OR (germ cell) OR (germ line cells) OR (germ line cell) OR (germ line) OR (germ lines) OR gametes) AND (child OR children)

13.2

(neoplasms OR neoplasm OR tumors OR tumor OR cancer OR cancers OR "benign neoplasms" OR "benign neoplasm") AND ("germ cells" OR "germ cell" OR "germ line cells" OR "germ line cell" OR "germ line" OR "germ lines" OR gametes) AND (child OR children)

13.3

(neoplasms OR neoplasm OR tumors OR tumor OR cancer OR cancers OR benign neoplasms OR benign neoplasm) AND (germ cells OR germ cell OR germ line cells OR germ line cell OR germ line OR germ lines OR gametes) AND (child OR children)

13.4

(neoplasm* OR tumOR* OR cancer* OR benign neoplasm*) AND (germ cell* OR germ line cell* OR germ line* OR gametes) AND child*

13.5

neoplasms OR neoplasm OR tumORs OR tumOR OR cancer OR cancers OR benign neoplasms OR benign neoplasm
AND germ cells OR germ cell OR germ line cells OR germ line cell OR germ line OR germ lines OR gametes AND child OR children

14.1

(gleevec OR glivec OR (novartis brand of imatinib mesylate) OR (genpharm brand of imatinib mesylate) OR (ST 1571) OR ST1571 OR STI571 OR STI-571 OR (STI 571) OR (CPG 57148) OR CPG57148B OR CPG-57148 OR (imatinib mesylate)) AND ((gastrointestinal stromal tumor) OR (gastrointestinal stromal tumors) OR (gastrointestinal stromal sarcoma) OR (gastrointestinal stromal neoplasms) OR (gastrointestinal stromal neoplasm))

14.2

(gleevec OR glivec OR "novartis brand of imatinib mesylate" OR "genpharm brand of imatinib mesylate" OR "ST 1571" OR ST1571 OR STI571 OR STI-571 OR "STI 571" OR "CPG 57148" OR CPG57148B OR CPG-57148 OR "imatinib mesylate") AND ("gastrointestinal stromal tumor" OR "gastrointestinal stromal tumors" OR "gastrointestinal stromal sarcoma" OR "gastrointestinal stromal neoplasms" OR "gastrointestinal stromal neoplasm")

14.3

(gleevec OR glivec OR novartis brand of imatinib mesylate OR genpharm brand of imatinib mesylate OR ST 1571 OR ST1571 OR STI571 OR STI-571 OR STI 571 OR CPG 57148 OR CPG57148B OR CPG-57148 OR imatinib mesylate) AND (gastrointestinal stromal tumor OR gastrointestinal stromal tumors OR gastrointestinal stromal sarcoma OR gastrointestinal stromal neoplasms OR gastrointestinal stromal neoplasm)

14.4

(gleevec OR glivec OR novartis brand of imatinib mesylate OR genpharm brand of imatinib mesylate OR ST 1571 OR ST1571 OR STI571 OR STI-571 OR STI 571 OR CPG 57148 OR CPG57148B OR CPG-57148 OR imatinib mesylate) AND (gastrointestinal stromal tumor* OR gastrointestinal stromal sarcoma OR gastrointestinal stromal neoplasm*)

14.5

gleevec OR glivec OR novartis brand of imatinib mesylate OR genpharm brand of imatinib mesylate OR ST 1571 OR ST1571 OR STI571 OR STI-571 OR STI 571 OR CPG 57148 OR CPG57148B OR CPG-57148 OR imatinib mesylate
AND gastrointestinal stromal tumor OR gastrointestinal stromal tumors OR gastrointestinal stromal sarcoma OR gastrointestinal stromal neoplasms OR gastrointestinal stromal neoplasm

15.1

((speech pathology) OR (speech pathologies) OR (speech therapy) OR (speech therapies) OR (voice training) OR (voice trainings) OR (voice therapy) OR (voice therapies) OR (vocal treatment) OR (vocal treatments) OR (voice treatment) OR (voice treatments) OR (vocal rehabilitation) OR (vocal rehabilitations) OR (voice rehabilitation) OR (voice rehabilitations) OR (speech language pathology) OR (speech-language pathology) OR (speech language pathologies) OR (speech-language pathologies) OR (speech language therapy) OR (speech-language therapy) OR (speech-language therapies) OR (speech language therapies) AND ((vocal fold nodules) OR (vocal fold nodule) OR (vocal folds nodule) OR (vocal folds nodules) OR (vocal nodules) OR (vocal nodule) OR (vocal cord nodule) OR (vocal cord nodules) OR (vocal cords nodules) OR (vocal cords nodule) OR (vocal cords disorder) OR (vocal cords disorders) OR (vocal fold disorder) OR (vocal fold disorders) OR (vocal folds disorder) OR (vocal folds disorders) OR (vocal cord disorder) OR (vocal cord disorders))

15.2

("speech pathology" OR "speech pathologies" OR "speech therapy" OR "speech therapies" OR "voice training" OR "voice trainings" OR "voice therapy" OR "voice therapies" OR "vocal treatment" OR "vocal treatments" OR "voice treatment" OR "voice treatments" OR "vocal rehabilitation" OR

“vocal rehabilitations” OR “voice rehabilitation” OR “voice rehabilitations” OR “speech language pathology” OR “speech-language pathology” OR “speech language pathologies” OR “speech-language pathologies” OR “speech language therapy” OR “speech-language therapy” OR “speech-language therapies” OR “speech language therapies”) AND (“vocal fold nodules” OR “vocal fold nodule” OR “vocal folds nodule” OR “vocal folds nodules” OR “vocal nodules” OR “vocal nodule” OR “vocal cord nodule” OR “vocal cord nodules” OR “vocal cords nodules” OR “vocal cords nodule” OR “vocal cords disorder” OR “vocal cords disorders” OR “vocal fold disorder” OR “vocal fold disorders” OR “vocal folds disorder” OR “vocal folds disorders” OR “vocal cord disorder” OR “vocal cord disorders”)

15.3

(speech pathology OR speech pathologies OR speech therapy OR speech therapies OR voice training OR voice trainings OR voice therapy OR voice therapies OR vocal treatment OR vocal treatments OR voice treatment OR voice treatments OR vocal rehabilitation OR vocal rehabilitations OR voice rehabilitation OR voice rehabilitations OR speech language pathology OR speech-language pathology OR speech language pathologies OR speech-language pathologies OR speech language therapy OR speech-language therapy OR speech-language therapies OR speech language therapies) AND (vocal fold nodules OR vocal fold nodule OR vocal folds nodule OR vocal folds nodules OR vocal nodules OR vocal nodule OR vocal cord nodule OR vocal cord nodules OR vocal cords nodules OR vocal cords nodule OR vocal cords disorder OR vocal cords disorders OR vocal fold disorder OR vocal fold disorders OR vocal folds disorder OR vocal folds disorders OR vocal cord disorder OR vocal cord disorders)

15.4

(speech patholog* OR speech therap* OR voice training* OR voice therap* OR vocal treatment* OR voice treatment* OR vocal rehabilitation* OR voice rehabilitation* OR speech language patholog* OR speech-language patholog* OR speech language therap* OR speech-language therap*) AND (vocal fold* nodule* OR vocal nodule* OR vocal cord* nodule* OR vocal cords disorder* OR vocal fold* disorder* OR vocal cord* disorder*)

15.5

speech pathology OR speech pathologies OR speech therapy OR speech therapies OR voice training OR voice trainings OR voice therapy OR voice therapies OR vocal treatment OR vocal treatments OR voice treatment OR voice treatments OR vocal rehabilitation OR vocal rehabilitations OR voice rehabilitation OR voice rehabilitations OR speech language pathology OR speech-language pathology OR speech language pathologies OR speech-language pathologies OR speech language therapy OR speech-language therapy OR speech-language therapies OR speech language therapies
AND vocal fold nodules OR vocal fold nodule OR vocal folds nodule OR vocal folds nodules OR vocal nodules OR vocal nodule OR vocal cord nodule OR vocal cord nodules OR vocal cords nodules OR vocal cords nodule OR vocal cords disorder OR vocal cords disorders OR vocal fold disorder OR vocal fold disorders OR vocal folds disorder OR vocal folds disorders OR vocal cord disorder OR vocal cord disorders

16.1

((abdominal subcutaneous fats) OR (abdominal subcutaneous fat) OR (abdominal subcutaneous adipose tissue) OR (subcutaneous fat) OR (subcutaneous fats) OR (abdominal obesities) OR (abdominal obesity) OR (central obesity) OR (central obesities) OR (visceral obesities) OR (visceral obesity) OR (intra abdominal fat) OR (intra abdominal fats) OR (intra abdominal adipose tissue) OR (retroperitoneal fat) OR (retroperitoneal fats) OR (retroperitoneal adipose tissue) OR (visceral fat) OR (visceral fats) OR (visceral adipose tissue) OR (abdominal visceral fat) OR (abdominal visceral fats)) AND ((impaired glucose tolerance) OR (glucose intolerances) OR

(glucose intolerance) OR (ketosis resistant diabetes mellitus) OR (maturity onset diabetes mellitus) OR (non insulin dependent diabetes mellitus) OR (type 2 diabetes mellitus) OR (slow onset diabetes mellitus) OR (stable diabetes mellitus) OR (type II diabetes mellitus) OR (maturity onset diabetes mellitus) OR MODY OR NIDDM OR (adult onset diabetes mellitus) OR (noninsulin dependent diabetes mellitus) OR (metabolic syndrome)) AND ((incidence OR follow up studies) OR (follow up study) OR prognosis OR prognoses OR episode OR cohort OR (cohort studies) OR (cohort study) OR (controlled trial) OR (controlled trials))

16.2

("abdominal subcutaneous fats" OR "abdominal subcutaneous fat" OR "abdominal subcutaneous adipose tissue" OR "subcutaneous fat" OR "subcutaneous fats" OR "abdominal obesities" OR "abdominal obesity" OR "central obesity" OR "central obesities" OR "visceral obesities" OR "visceral obesity" OR "intra abdominal fat" OR "intra abdominal fats" OR "intra abdominal adipose tissue" OR "retroperitoneal fat" OR "retroperitoneal fats" OR "retroperitoneal adipose tissue" OR "visceral fat" OR "visceral fats" OR "visceral adipose tissue" OR "abdominal visceral fat" OR "abdominal visceral fats") AND ("impaired glucose tolerance" OR "glucose intolerances" OR "glucose intolerance" OR "ketosis resistant diabetes mellitus" OR "maturity onset diabetes mellitus" OR "non insulin dependent diabetes mellitus" OR "type 2 diabetes mellitus" OR "slow onset diabetes mellitus" OR "stable diabetes mellitus" OR "type II diabetes mellitus" OR "maturity onset diabetes mellitus" OR MODY OR NIDDM OR "adult onset diabetes mellitus" OR "noninsulin dependent diabetes mellitus" OR "metabolic syndrome") AND (incidence OR "follow up studies" OR "follow up study" OR prognosis OR prognoses OR episode OR cohort OR "cohort studies" OR "cohort study" OR "controlled trial" OR "controlled trials")

16.3

(abdominal subcutaneous fats OR abdominal subcutaneous fat OR abdominal subcutaneous adipose tissue OR subcutaneous fat OR subcutaneous fats OR abdominal obesities OR abdominal obesity OR central obesity OR central obesities OR visceral obesities OR visceral obesity OR intra abdominal fat OR intra abdominal fats OR intra abdominal adipose tissue OR retroperitoneal fat OR retroperitoneal fats OR retroperitoneal adipose tissue OR visceral fat OR visceral fats OR visceral adipose tissue OR abdominal visceral fat OR abdominal visceral fats) AND (impaired glucose tolerance OR glucose intolerances OR glucose intolerance OR ketosis resistant diabetes mellitus OR maturity onset diabetes mellitus OR non insulin dependent diabetes mellitus OR type 2 diabetes mellitus OR slow onset diabetes mellitus OR stable diabetes mellitus OR type II diabetes mellitus OR maturity onset diabetes mellitus OR MODY OR NIDDM OR adult onset diabetes mellitus OR noninsulin dependent diabetes mellitus OR metabolic syndrome) AND (incidence OR follow up studies OR follow up study OR prognosis OR prognoses OR episode OR cohort OR cohort studies OR cohort study OR controlled trial OR controlled trials)

16.4

(abdominal subcutaneous fat* OR abdominal subcutaneous adipose tissue OR subcutaneous fat* OR abdominal obesity* OR central obesity* OR visceral obesity* OR intra abdominal fat* OR intra abdominal adipose tissue OR retroperitoneal fat* OR retroperitoneal adipose tissue OR visceral fat* OR visceral adipose tissue OR abdominal visceral fat*) AND (impaired glucose tolerance OR glucose intolerance* OR ketosis resistant diabetes mellitus OR maturity onset diabetes mellitus OR non insulin dependent diabetes mellitus OR type 2 diabetes mellitus OR slow onset diabetes mellitus OR stable diabetes mellitus OR type II diabetes mellitus OR maturity onset diabetes mellitus OR MODY OR NIDDM OR adult onset diabetes mellitus OR noninsulin dependent diabetes mellitus OR metabolic syndrome) AND (incidence OR follow up stud* OR prognos* OR episode OR cohort OR cohort stud* OR controlled trial*)

16.5

abdominal subcutaneous fats OR abdominal subcutaneous fat OR abdominal subcutaneous adipose tissue OR subcutaneous fat OR subcutaneous fats OR abdominal obesities OR abdominal obesity OR central obesity OR central obesities OR visceral obesities OR visceral obesity OR intra abdominal fat OR intra abdominal fats OR intra abdominal adipose tissue OR retroperitoneal fat OR retroperitoneal fats OR retroperitoneal adipose tissue OR visceral fat OR visceral fats OR visceral adipose tissue OR abdominal visceral fat OR abdominal visceral fats

AND impaired glucose tolerance OR glucose intolerances OR glucose intolerance OR ketosis resistant diabetes mellitus OR maturity onset diabetes mellitus OR non insulin dependent diabetes mellitus OR type 2 diabetes mellitus OR slow onset diabetes mellitus OR stable diabetes mellitus OR (type II diabetes mellitus) OR maturity onset diabetes mellitus OR MODY OR NIDDM OR adult onset diabetes mellitus OR noninsulin dependent diabetes mellitus OR metabolic syndrome

AND

incidence OR follow up studies OR follow up study OR prognosis OR prognoses OR episode OR cohort OR cohort studies OR cohort study OR controlled trial OR controlled trials

17.1

((bariatric surgery) OR (bariatric surgeries)) AND ((postoperative complications) OR (postoperative complication))

17.2

("bariatric surgery" OR "bariatric surgeries") AND ("postoperative complications" OR "postoperative complication")

17.3

(bariatric surgery OR bariatric surgeries) AND (postoperative complications OR postoperative complication)

17.4

bariatric surger* AND postoperative complication*

17.5

Bariatric surgery OR bariatric surgeries AND postoperative complications OR postoperative complication

18.1

((prematurity retinopathies) OR (prematurity retinopathy) OR (retrolental fibroplasia) OR (retrolental fibroplasias)) AND ((angiogenesis inhibitors) OR (angiogenic inhibitors) OR (neovascularization inhibitors) OR (angiogenetic inhibitors) OR (angiogenic antagonists) OR (angiostatic agents) OR (anti-angiogenic drugs) OR (neovascularization inhibitors) OR (angiogenetic antagonists) OR (anti-angiogenetic agents) OR (anti angiogenetic agents) OR (antiangiogenic agents) OR (angiogenesis factor inhibitors) OR bevacizumab OR anti-VEGF OR avastin)

18.2

("prematurity retinopathies" OR "prematurity retinopathy" OR "retrolental fibroplasias" OR "retrolental fibroplasias") AND ("angiogenesis inhibitors" OR "angiogenic inhibitors" OR "neovascularization inhibitors" OR "angiogenetic inhibitors" OR "angiogenic antagonists" OR "angiostatic agents" OR "anti-angiogenic drugs" OR "neovascularization inhibitors" OR "angiogenetic antagonists" OR "anti-angiogenetic agents" OR "anti angiogenetic agents" OR "antiangiogenic agents" OR "angiogenesis factor inhibitors" OR bevacizumab OR anti-VEGF OR avastin)

18.3

(prematurity retinopathies OR prematurity retinopathy OR retrolental fibroplasia OR retrolental fibroplasias) AND (angiogenesis inhibitors OR angiogenic inhibitors OR neovascularization inhibitors OR angiogenetic inhibitors OR angiogenic antagonists OR angiostatic agents OR anti-angiogenic drugs OR neovascularization inhibitors OR angiogenetic antagonists OR anti-angiogenetic agents OR anti angiogenetic agents OR antiangiogenic agents OR angiogenesis factor inhibitors OR bevacizumab OR anti-VEGF OR avastin)

(prematurity retinopathies OR prematurity retinopathy OR retrolental fibroplasia OR retrolental fibroplasias) AND (angiogenesis inhibitors OR angiogenic inhibitors OR neovascularization inhibitors OR angiogenetic inhibitors OR angiogenic antagonists OR angiostatic agents OR anti-angiogenic drugs OR neovascularization inhibitors OR angiogenetic antagonists OR anti-angiogenetic agents OR anti angiogenetic agents OR antiangiogenic agents OR angiogenesis factor inhibitors OR bevacizumab OR anti-VEGF OR avastin)

18.4

(prematurity retinopath* OR retrolental fibroplasia*) AND (angiogenesis inhibitors OR angiogen* inhibitors OR neovascularization inhibitors OR angiogen* antagonists OR angiostatic agents OR anti-angiogenic drugs OR neovascularization inhibitors OR anti-angiogenetic agents OR anti angiogenetic agents OR antiangiogenic agents OR angiogenesis factor inhibitors OR bevacizumab OR anti-VEGF OR avastin)

18.5

prematurity retinopathies OR prematurity retinopathy OR retrolental fibroplasia OR retrolental fibroplasias AND angiogenesis inhibitors OR angiogenic inhibitors OR neovascularization inhibitors OR angiogenetic inhibitors OR angiogenic antagonists OR angiostatic agents OR anti-angiogenic drugs OR neovascularization inhibitors OR angiogenetic antagonists OR anti-angiogenetic agents OR anti angiogenetic agents OR antiangiogenic agents OR angiogenesis factor inhibitors OR bevacizumab OR anti-VEGF OR avastin

19.1

((reference counter-reference system) OR (reference counter reference system) OR (reference counter-reference systems) OR (reference counter reference systems) OR (reference counter-reference model) OR (reference counter reference model) OR (health service gatekeepers) OR (health service gatekeeper) OR (hospital referral) OR (hospital referrals)) AND ((health manager) OR (health managers) OR (professional health) OR (professionals health))

19.2

("reference counter-reference system" OR "reference counter reference system" OR "reference counter-reference systems" OR "reference counter reference systems" OR "reference counter-reference model" OR "reference counter reference model" OR "health service gatekeepers" OR "health service gatekeeper" OR "hospital referral" OR "hospital referrals") AND ("health manager" OR "health managers" OR "professional health" OR "professionals health")

19.3

(reference counter-reference system OR reference counter reference system OR reference counter-reference systems OR reference counter reference systems OR reference counter-reference model OR reference counter reference model OR health service gatekeepers OR health service gatekeeper OR hospital referral OR hospital referrals) AND (health manager OR health managers OR professional health OR professionals health)

19.4

(reference counter-reference system* OR reference counter reference system* OR reference counter-reference model OR reference counter reference model OR health service gatekeeper* OR hospital referral*) AND (health manager* OR professional* health)

19.5

reference counter-reference system OR reference counter reference system OR reference counter-reference systems OR reference counter reference systems OR reference counter-reference model OR reference counter reference model OR health service gatekeepers OR health service gatekeeper OR hospital referral OR hospital referrals
AND health manager OR health managers OR professional health OR professionals health

20.1

(hyperhidrosis OR (axillary hyperhidrosis) OR (hyperhidrosis of axillae) OR (hyperhidrosis of axilla) OR (hyperhidrosis of the axillae) OR (hyperhidrosis of the axilla)) AND ((randomized controlled trial) OR (controlled study) OR randomization or (double blind procedure) OR (single blind procedure) OR (clinical trial) OR (clinical trials) OR double OR single OR triple OR (blind OR mask) OR placebo OR random OR (methodology latin square) OR crossover OR (cross over) OR (crossover procedure) OR (drug comparison) OR (comparative study) OR (comparative trial) OR (comparative trials) OR (control OR controls OR prospective OR volunteer OR volunteers) OR (evaluation and follow up) OR (prospective study))

20.2

(hyperhidrosis OR "axillary hyperhidrosis" OR "hyperhidrosis of axillae" OR "hyperhidrosis of axilla" OR "hyperhidrosis of the axillae" OR "hyperhidrosis of the axilla") AND ("randomized controlled trial" OR "controlled study" OR "randomization or double blind procedure" OR "single blind procedure" OR "clinical trial" OR "clinical trials" OR double OR single OR triple OR blind OR mask OR placebo OR random OR "methodology latin square" OR crossover OR "cross over" OR "crossover procedure" OR "drug comparison" OR "comparative study" OR "comparative trial" OR "comparative trials" OR control OR controls OR prospective OR volunteer OR volunteers OR "evaluation and follow up" OR "prospective study")

20.3

(hyperhidrosis OR axillary hyperhidrosis OR hyperhidrosis of axillae OR hyperhidrosis of axilla OR hyperhidrosis of the axillae OR hyperhidrosis of the axilla) AND (randomized controlled trial OR controlled study OR randomization or double blind procedure OR single blind procedure OR clinical trial OR clinical trials OR double OR single OR triple OR blind OR mask OR placebo OR random OR methodology latin square OR crossover OR cross over OR crossover procedure OR drug comparison OR comparative study OR comparative trial OR comparative trials OR control OR controls OR prospective OR volunteer OR volunteers OR evaluation and follow up OR prospective study)

20.4

(hyperhidrosis OR axillary hyperhidrosis OR hyperhidrosis of axillae OR hyperhidrosis of axilla OR hyperhidrosis of the axillae OR hyperhidrosis of the axilla) AND (randomized controlled trial OR controlled study OR randomization or double blind procedure OR single blind procedure OR clinical trial* OR double OR single OR triple OR blind OR mask OR placebo OR random OR methodology latin square OR crossover OR cross over OR crossover procedure OR drug comparison OR comparative study OR comparative trial* OR control* OR prospective OR volunteer* OR evaluation and follow up OR prospective study)

20.5

hyperhidrosis OR axillary hyperhidrosis OR hyperhidrosis of axillae OR hyperhidrosis of axilla OR hyperhidrosis of the axillae OR hyperhidrosis of the axilla AND randomized controlled trial OR controlled study OR randomization or double blind procedure OR single blind procedure OR clinical trial OR clinical trials OR double OR single OR triple OR blind OR mask OR placebo OR random OR methodology latin square OR crossover OR cross over OR crossover procedure OR drug comparison OR comparative study OR comparative trial OR comparative trials OR control OR controls OR prospective OR volunteer OR volunteers OR evaluation and follow up OR prospective study

21.1

((motion pictures as topic) OR (motion pictures) OR (motion picture) OR film OR films) AND ((mental health) OR psychiatry)

21.2

("motion pictures as topic" OR "motion pictures" OR "motion picture" OR film OR films) AND ("mental health" OR psychiatry)

21.3

(mpictures as topic OR motion pictures OR motion picture OR film OR films) AND (mental health OR psychiatry)

21.4

(motion pictures as topic OR motion picture* OR film*) AND (mental health OR psychiatry)

21.5

(motion pictures as topic OR motion pictures OR motion picture OR film OR films) AND (mental health OR psychiatry)

22.1

((aids vaccines) OR (hiv vaccines) OR (aids vaccine) OR (hiv vaccine)) AND ((side effects) OR (undesirable effects) OR (adverse effects)) AND ((young adult) OR (young adults))

22.2

("aids vaccines" OR "hiv vaccines" OR "aids vaccine" OR "hiv vaccine") AND ("side effects" OR "undesirable effects" OR "adverse effects") AND ("young adult" OR "young adults")

22.3

(aids vaccines OR hiv vaccines OR aids vaccine OR hiv vaccine) AND (side effects OR undesirable effects OR adverse effects) AND (young adult OR young adults)

22.4

(aids vaccine* OR hiv vaccine*) AND (side effects OR undesirable effects OR adverse effects) AND (young adult*)

22.5

(aids vaccines OR hiv vaccines OR aids vaccine OR hiv vaccine) AND (side effects OR undesirable effects OR adverse effects) AND (young adult OR young adults)

23.1

((hepatitis C) OR (parenterally-transmitted non-A, non-B hepatitis) OR (parenterally transmitted non A, non B hepatitis) OR PT-NANBH OR (hepatitis, viral, non-A, Non-B, parenterally-transmitted)) AND ((quality of life OR life qualities OR life quality))

23.2

("hepatitis C" OR "parenterally-transmitted non-A, non-B hepatitis" OR "parenterally transmitted non A, non B hepatitis" OR PT-NANBH OR "hepatitis, viral, non-A, non-B, parenterally-transmitted") AND ("quality of life" OR "life qualities" OR "life quality")

23.3

(hepatitis C OR parenterally-transmitted non-A, non-B hepatitis OR parenterally transmitted non A, non B hepatitis OR PT-NANBH OR hepatitis, viral, non-A, non-B, parenterally-transmitted) AND (quality of life OR life qualities OR life quality)

23.4

(hepatitis C OR parenterally-transmitted non-A, non-B hepatitis OR parenterally transmitted non A, non B hepatitis OR PT-NANBH OR hepatitis, viral, non-A, Non-B, parenterally-transmitted) AND (quality of life OR life qualit*)

23.5

(hepatitis C OR parenterally-transmitted non-A, non-B hepatitis OR parenterally transmitted non A, non B hepatitis OR PT-NANBH OR hepatitis, viral, non-A, non-B, parenterally-transmitted) AND (quality of life OR life qualities OR life quality)

24.1

((blood transfusion) OR (blood transfusions)) AND ((adverse effects) OR (side effects) OR (undesirable effects) OR (injurious effects))

24.2

("blood transfusion" OR "blood transfusions") AND ("adverse effects" OR "side effects" OR "undesirable effects" OR "injurious effects")

24.3

(blood transfusion OR blood transfusions) AND (adverse effects OR side effects OR undesirable effects OR injurious effects)

24.4

(blood transfusion*) AND (adverse effects OR side effects OR undesirable effects OR injurious effects)

24.5

blood transfusion OR blood transfusions AND adverse effects OR side effects OR undesirable effects OR injurious effects

25.1

((fatty liver) OR steatohepatitis OR steatohepatitides OR (visceral steatosis) OR (steatosis of liver) OR (liver steatosis) OR (liver steatoses)) AND ((levulose OR (fleboplast levulosa) OR (levulosa grifols) OR (grifols brand of fructose) OR (levulosado vitulia) OR (ern brand of fructose) OR (levulosa braun) OR (levulosado braun) OR (braun brand of fructose) OR (levulosa ife) OR (instituto farmacologico brand of fructose) OR (levulosado bieffe medito) OR (bieffe brand of fructose) OR (apir levulosa) OR (levulosa mein) OR (fresenius kabi brand of fructose) OR (levulosa

ibys) OR (plast apyr levulosa mein) OR (levulosa Baxter) OR levulosa OR (baxter brand of fructose))

25.2

("fatty liver" OR steatohepatitis OR steatohepatitides OR "visceral steatosis" OR "steatosis of liver" OR "liver steatosis" OR "liver steatoses") AND (levulose OR "fleboplast levulosa" OR "levulosa grifols" OR "grifols brand of fructose" OR "levulosado vitulia" OR "ern brand of fructose" OR "levulosa braun" OR "levulosado braun" OR "braun brand of fructose" OR "levulosa ife" OR "instituto farmacologico brand of fructose" OR "levulosado bieffe medito" OR "bieffe brand of fructose" OR "apir levulosa" OR "levulosa mein" OR "fresenius kabi brand of fructose" OR "levulosa ibys" OR "plast apyr levulosa mein" OR "levulosa baxter" OR levulosa OR "baxter brand of fructose")

25.3

(fatty liver OR steatohepatitis OR steatohepatitides OR visceral steatosis OR steatosis of liver OR liver steatosis OR liver steatoses) AND (levulose OR fleboplast levulosa OR levulosa grifols OR grifols brand of fructose OR levulosado vitulia OR ern brand of fructose OR levulosa braun OR levulosado braun OR braun brand of fructose OR levulosa ife OR instituto farmacologico brand of fructose OR levulosado bieffe medito OR bieffe brand of fructose OR apir levulosa OR levulosa mein OR fresenius kabi brand of fructose OR levulosa ibys OR plast apyr levulosa mein OR levulosa baxter OR levulosa OR baxter brand of fructose)

25.4

(fatty liver OR steatohepatit* OR visceral steatosis OR steatosis of liver OR liver steatos*) AND (levulose OR fleboplast levulosa OR levulosa grifols OR grifols brand of fructose OR levulosado vitulia OR ern brand of fructose OR levulosa* braun OR braun brand of fructose OR levulosa ife OR instituto farmacologico brand of fructose OR levulosado bieffe medito OR bieffe brand of fructose OR apir levulosa OR levulosa mein OR fresenius kabi brand of fructose OR levulosa ibys OR plast apyr levulosa mein OR levulosa baxter OR levulosa OR baxter brand of fructose)

25.5

(fatty liver OR steatohepatitis OR steatohepatitides OR visceral steatosis OR steatosis of liver OR liver steatosis OR liver steatoses) AND (levulose OR fleboplast levulosa OR levulosa grifols OR grifols brand of fructose OR levulosado vitulia OR ern brand of fructose OR levulosa braun OR levulosado braun OR braun brand of fructose OR levulosa ife OR instituto farmacologico brand of fructose OR levulosado bieffe medito OR bieffe brand of fructose OR apir levulosa OR levulosa mein OR fresenius kabi brand of fructose OR levulosa ibys OR plast apyr levulosa mein OR levulosa baxter OR levulosa OR baxter brand of fructose)

26.1

((occupational therapy) OR (occupational therapies)) AND ((social work) OR (social service) OR (social services) OR (social workers) OR (social worker))

26.2

("occupational therapy" OR "occupational therapies") AND ("social work" OR "social service" OR "social services" OR "social workers" OR "social worker")

26.3

(occupational therapy OR occupational therapies) AND (social work OR social service OR social services OR social workers OR social worker)

26.4

(occupational therap*) AND (social work* OR social service*)

26.5

(occupational therapy OR occupational therapies) AND (social work OR social service OR social services OR social workers OR social worker)

27.1

((frail ederly) OR (frail elders) OR (frail elder) OR (functionally-impaired elderly) OR (functionally impaired elderly) OR (frail older adults) OR (frail older adult)) AND ((accidental falls) OR (accidental fall)) AND (incidence OR incidences)

27.2

("frail ederly" OR "frail elders" OR "frail elder" OR "functionally-impaired elderly" OR "functionally impaired elderly" OR "frail older adults" OR "frail older adult") AND ("accidental falls" OR "accidental fall") AND (incidence OR incidences)

27.3

(frail ederly OR frail elders OR frail elder OR functionally-impaired elderly OR elderly, functionally-impaired OR functionally impaired elderly OR frail older adults OR frail older adult) AND (accidental falls OR accidental fall) AND (incidence OR incidences)

27.3

frail eder* OR functionally-impaired elderly OR functionally impaired elderly OR frail older adult* AND accidental fall* AND incidence*

27.4

(frail ederly OR frail elders OR frail elder OR functionally-impaired elderly OR elderly, functionally-impaired OR functionally impaired elderly OR frail older adults OR frail older adult) AND (accidental falls OR accidental fall) AND (incidence OR incidences)

28.1

((breast feeding) OR breastfeeding OR (exclusive breast feeding) OR (exclusive breastfeeding)) AND (obesity) AND (child OR children)

28.2

("breast feeding" OR breastfeeding OR "exclusive breast feeding" OR "exclusive breastfeeding") AND (obesity) AND (child OR children)

28.2

(breast feeding OR breastfeeding OR exclusive breast feeding OR exclusive breastfeeding) AND (obesity) AND (child OR children)

28.4

(breast feeding OR breastfeeding OR exclusive breast feeding OR exclusive breastfeeding) AND (obesity) AND (child*)

28.4

(breast feeding OR breastfeeding OR exclusive breast feeding OR exclusive breastfeeding) AND obesity AND child OR children

29.1

((mother-child relations) OR (mother child relations) OR (mother-child relation) OR (mother-child

relationship) OR (mother child relationship) OR (mother-child relationships)) AND (chronic bronchitis) AND (child or children)

29.2

("mother-child relations" OR "mother child relations" OR "mother-child relation" OR "mother-child relationship" OR "mother child relationship" OR "mother-child relationships") AND "chronic bronchitis" AND (child or children)

29.3

(mother-child relations OR mother child relations OR mother-child relation OR mother-child relationship OR mother child relationship OR mother-child relationships) AND chronic bronchitis AND (child or children)

29.4

(mother-child relation* OR mother child relation*) AND (chronic bronchitis) AND (child*)

29.5

mother-child relations OR mother child relations OR mother-child relation OR mother-child relationship OR mother child relationship OR mother-child relationships AND chronic bronchitis AND child or children

30.1

((knee replacement arthroplasties) OR (knee replacement arthroplasty) OR (total knee replacements) OR (total knee replacement)) AND ((clinical protocols) OR (clinical protocol) OR (treatment protocols) OR (treatment protocol) OR (clinical research protocol) OR (clinical research protocols))

30.2

("knee replacement arthroplasties" OR "knee replacement arthroplasty" OR "total knee replacements" OR "total knee replacement") AND ("clinical protocols" OR "clinical protocol" OR "treatment protocols" OR "treatment protocol" OR "clinical research protocol" OR "clinical research protocols")

30.3

(knee replacement arthroplasties OR knee replacement arthroplasty OR total knee replacements OR total knee replacement) AND (clinical protocols OR clinical protocol OR treatment protocols OR treatment protocol OR clinical research protocol OR clinical research protocols)

30.4

(knee replacement arthroplast* OR total knee replacement*) AND (clinical protocol* OR treatment protocol* OR clinical research protocol*)

30.5

knee replacement arthroplasties OR knee replacement arthroplasty OR total knee replacements OR total knee replacement AND clinical protocols OR clinical protocol OR treatment protocols OR treatment protocol OR clinical research protocol OR clinical research protocols

31.1

((artificial respiration) OR (artificial respirations) OR (mechanical ventilations) OR (mechanical ventilation)) AND ((high-frequency ventilation) OR (high-frequency ventilations) OR (high frequency ventilation) OR (high frequency ventilations) OR (high-frequency oscillation

ventilation) OR (high-frequency oscillation ventilations) OR (high frequency oscillation ventilation) OR (high-frequency positive pressure ventilation) OR (high frequency positive pressure ventilation)) AND (hypercapnia)

31.2

("artificial respiration" OR "artificial respirations" OR "mechanical ventilations" OR "mechanical ventilation") AND ("high-frequency ventilation" OR "high-frequency ventilations" OR "high frequency ventilation" OR "high frequency ventilations" OR "high-frequency oscillation ventilation" OR "high-frequency oscillation ventilations" OR "high frequency oscillation ventilation" OR "high-frequency positive pressure ventilation" OR "high frequency positive pressure ventilation") AND hypercapnia

31.3

(artificial respiration OR artificial respirations OR mechanical ventilations OR mechanical ventilation) AND (high-frequency ventilation OR high-frequency ventilations OR high frequency ventilation OR high frequency ventilations OR high-frequency oscillation ventilation OR high-frequency oscillation ventilations OR high frequency oscillation ventilation OR high-frequency positive pressure ventilation OR high frequency positive pressure ventilation) AND hypercapnia

31.4

(artificial respiration* OR mechanical ventilation*) AND (high-frequency ventilation* OR high frequency ventilation* OR high-frequency oscillation ventilation* OR high-frequency positive pressure ventilation OR high frequency positive pressure ventilation) AND hypercapnia

31.5

artificial respiration OR artificial respirations OR mechanical ventilations OR mechanical ventilation AND high-frequency ventilation OR high-frequency ventilations OR high frequency ventilation OR high frequency ventilations OR high-frequency oscillation ventilation OR high-frequency oscillation ventilations OR high frequency oscillation ventilation OR high-frequency positive pressure ventilation OR high frequency positive pressure ventilation AND hypercapnia

32.1

((aid to families with dependent children) OR (family allowances) OR (family allowance)) AND ((social work) OR (social service) OR (social services) OR (social workers) OR (social worker))

32.2

("aid to families with dependent children" OR "family allowances" OR "family allowance") AND ("social work" OR "social service" OR "social services" OR "social workers" OR "social worker")

32.3

(aid to families with dependent children OR family allowances OR family allowance) AND (social work OR social service OR social services OR social workers OR social worker)

32.4

(aid to families with dependent children OR family allowance*) AND (social work* OR social service*)

32.5

aid to families with dependent children OR family allowances OR family allowance AND social work OR social service OR social services OR social workers OR social worker

33.1

((kidney neoplasms) OR (kidney neoplasm) OR (renal neoplasms) OR (renal neoplasm) OR (cancer of kidney) OR (kidney cancers) OR (renal cancer) OR (renal cancers) OR (cancer of the kidney) OR (kidney cancer)) AND ((drug therapy) or (drug therapies) OR pharmacotherapy OR pharmacotherapies OR chemotherapy OR chemotherapies) AND ((quality of life OR life qualities OR life quality))

33.2

("kidney neoplasms" OR "kidney neoplasm" OR "renal neoplasms" OR "renal neoplasm" OR "cancer of kidney" OR "kidney cancers" OR "renal cancer" OR "renal cancers" OR "cancer of the kidney" OR "kidney cancer") AND ("drug therapy" OR "drug therapies" OR pharmacotherapy OR pharmacotherapies OR chemotherapy OR chemotherapies) AND ("quality of life" OR "life qualities" OR "life quality")

33.3

(kidney neoplasms OR kidney neoplasm OR renal neoplasms OR renal neoplasm OR cancer of kidney OR kidney cancers OR renal cancer OR renal cancers OR cancer of the kidney OR kidney cancer) AND (drug therapy OR drug therapies OR pharmacotherapy OR pharmacotherapies OR chemotherapy OR chemotherapies) AND (quality of life OR life qualities OR life quality)

33.4

(kidney neoplasm* OR renal neoplasm* OR cancer of kidney OR kidney cancer* OR renal cancer* OR cancer of the kidney) AND (drug therap* OR pharmacotherapy* OR chemotherapy* OR chemotherapies) AND (quality of life OR life qualit*)

33.5

kidney neoplasms OR kidney neoplasm OR renal neoplasms OR renal neoplasm OR cancer of kidney OR kidney cancers OR renal cancer OR renal cancers OR cancer of the kidney OR kidney cancer AND drug therapy OR drug therapies OR pharmacotherapy OR pharmacotherapies OR chemotherapy OR chemotherapies AND quality of life OR life qualities OR life quality

34.1

((occupational diseases) OR (occupational disease) OR (occupational illnesses) OR (occupational illnesse)) AND ((mental disorders) OR (mental disorder) OR (psychiatric diagnosis) OR (behavior disorders)) AND ((mental health services) OR (mental hygiene service) OR (mental health service) OR (mental hygiene services))

34.2

("occupational diseases" OR "occupational disease" OR "occupational illnesses" OR "occupational illnesse") AND ("mental disorders" OR "mental disorder" OR "psychiatric diagnosis" OR "behavior disorders") AND ("mental health services" OR "mental hygiene service" OR "mental health service" OR "mental hygiene services")

34.3

(occupational diseases OR occupational disease OR occupational illnesses OR occupational illnesse) AND (mental disorders OR mental disorder OR psychiatric diagnosis OR behavior disorders) AND (mental health services OR mental hygiene service OR mental health service OR mental hygiene services)

34.4

(occupational disease* OR occupational illnesse*) AND (mental disorder* OR psychiatric diagnosis OR behavior disorders) AND (mental health service* OR mental health service*)

34.5

occupational diseases OR occupational disease OR occupational illnesses OR occupational illnesse AND mental disorders OR mental disorder OR psychiatric diagnosis OR behavior disorders AND mental health services OR mental hygiene service OR mental health service OR mental hygiene services

35.1

((papillomavirus infections) OR (papillomavirus infection)) AND ((bacterial vaginosis) OR (bacterial vaginitides) OR (bacterial vaginoses) OR (bacterial vaginitis) OR (nonspecific vaginitis))

35.2

("papillomavirus infections" OR "papillomavirus infection") AND ("bacterial vaginosis" OR "bacterial vaginitides" OR "bacterial vaginoses" OR "bacterial vaginitis" OR "nonspecific vaginitis")

35.3

(papillomavirus infections OR papillomavirus infection) AND (bacterial vaginosis OR bacterial vaginitides OR bacterial vaginoses OR bacterial vaginitis OR nonspecific vaginitis)

35.4

(papillomavirus infection*) AND (bacterial vagin* OR nonspecific vaginitis)

35.5

papillomavirus infections OR papillomavirus infection AND bacterial vaginosis OR bacterial vaginitides OR bacterial vaginoses OR bacterial vaginitis OR nonspecific vaginitis

36.1

((dietary fiber) OR (dietary fibers) OR (wheat bran) OR (wheat brans) Or roughage OR roughages)) AND ((intestinal neoplasms) OR (intestinal neoplasm) OR (intestines neoplasms) OR (intestines neoplasm) OR (cancer of intestines) OR (intestines cancers) OR (cancer of the intestines) OR (intestines cancer) OR (intestinal cancer) OR (intestinal cancers)) AND (prevention OR (preventive therapy) OR prophylaxis OR (preventive measures) OR control)

36.2

("dietary fiber" OR "dietary fibers" OR "wheat bran" OR "wheat brans" OR roughage OR roughages) AND ("intestinal neoplasms" OR "intestinal neoplasm" OR "intestines neoplasms" OR "intestines neoplasm" OR "cancer of intestines" OR "intestines cancers" OR "cancer of the intestines" OR "intestines cancer" OR "intestinal cancer" OR "intestinal cancers") AND (prevention OR "preventive therapy" OR prophylaxis OR "preventive measures" OR control)

36.3

(dietary fiber OR dietary fibers OR wheat bran OR wheat brans Or roughage OR roughages) AND (intestinal neoplasms OR intestinal neoplasm OR intestines neoplasms OR intestines neoplasm OR cancer of intestines OR intestines cancers OR cancer of the intestines OR intestines cancer OR intestinal cancer OR intestinal cancers) AND (prevention OR preventive therapy OR prophylaxis OR preventive measures OR control)

36.4

(dietary fiber* OR wheat bran* Or roughage*) AND (intestin* neoplasm* OR cancer of intestines OR intestin* cancer* OR cancer of the intestines OR) AND (prevention OR preventive therapy OR prophylaxis OR preventive measures OR control)

36.5

dietary fiber OR dietary fibers OR wheat bran OR wheat brans Or roughage OR roughages AND intestinal neoplasms OR intestinal neoplasm OR intestines neoplasms OR intestines neoplasm OR cancer of intestines OR intestines cancers OR cancer of the intestines OR intestines cancer OR intestinal cancer OR intestinal cancers AND prevention OR preventive therapy OR prophylaxis OR preventive measures OR control

37.1

((papillomavirus infections) OR (papillomavirus infection)) AND ((bacterial vaginosis) OR (bacterial vaginitides) OR (bacterial vaginoses) OR (bacterial vaginitis) OR (nonspecific vaginitis)) AND (prevention OR (preventive therapy) OR prophylaxis OR (preventive measures) OR control)

37.2

("papillomavirus infections" OR "papillomavirus infection") AND ("bacterial vaginosis" OR "bacterial vaginitides" OR "bacterial vaginoses" OR "bacterial vaginitis" OR "nonspecific vaginitis") AND (prevention OR "preventive therapy" OR prophylaxis OR "preventive measures" OR control)

37.3

(papillomavirus infections OR papillomavirus infection) AND (bacterial vaginosis OR bacterial vaginitides OR bacterial vaginoses OR bacterial vaginitis OR nonspecific vaginitis) AND (prevention OR preventive therapy OR prophylaxis OR preventive measures OR control)

37.4

(papillomavirus infection*) AND (bacterial vagin* OR nonspecific vaginitis) AND (prevention OR preventive therapy OR prophylaxis OR preventive measures OR control)

37.5

papillomavirus infections OR papillomavirus infection AND bacterial vaginosis OR bacterial vaginitides OR bacterial vaginoses OR bacterial vaginitis OR nonspecific vaginitis AND prevention OR preventive therapy OR prophylaxis OR preventive measures OR control

38.1

((complexity theory) OR chaos OR (complexity science) OR (complexity thinking) OR (complexity system) OR (complexity systems) OR (chaos theory) OR (chaos theories) OR (nonlinear model) OR (nonlinear models) OR (nonlinear models) OR (non-linear models) OR (non-linear model) OR (non linear models) OR (non-linear model)) AND ((management in healthcare organization) OR (management in healthcare organizations) OR (health manager) OR (health managers) OR (nurse administrator) OR (nurse administrators) OR (nurse executives) OR (nurse executive) OR (nurse managers) OR (nurse manager))

38.2

("complexity theory" OR chaos OR "complexity science" OR "complexity thinking" OR "complexity system" OR "complexity systems" OR "chaos theory" OR "chaos theories" OR "nonlinear model" OR "nonlinear models" OR "nonlinear models" OR "non-linear models" OR "non-linear model" OR "non linear models" OR "non-linear model") AND ("management in healthcare organization" OR "management in healthcare organizations" OR "health manager" OR "health managers" OR "nurse

administrator” OR “nurse administrators” OR “nurse executives” OR “nurse executive” OR “nurse managers” OR “nurse manager”)

38.3

(complexity theory OR chaos OR complexity science OR complexity thinking OR complexity system OR complexity systems OR chaos theory OR chaos theories OR nonlinear model OR nonlinear models OR nonlinear models OR non-linear models OR non-linear model OR non linear models OR non-linear model) AND (management in healthcare organization OR management in healthcare organizations OR health manager OR health managers OR nurse administrator OR nurse administrators OR nurse executives OR nurse executive OR nurse managers OR nurse manager)

38.4

(complexity theory OR chaos OR complexity science OR complexity thinking OR complexity system* OR chaos theor* OR nonlinear model* OR nonlinear models OR non-linear model* OR non linear models*) AND (management in healthcare organization* OR health manager* OR nurse administrator* OR nurse executive* OR nurse manager*)

38.5

complexity theory OR chaos OR complexity science OR complexity thinking OR complexity system OR complexity systems OR chaos theory OR chaos theories OR nonlinear model OR nonlinear models OR nonlinear models OR non-linear models OR non-linear model OR non linear models OR non-linear model AND management in healthcare organization OR management in healthcare organizations OR health manager OR health managers OR nurse administrator OR nurse administrators OR nurse executives OR nurse executive OR nurse executives OR nurse managers OR nurse manager

39.1

((allergic keratoconjunctivitis) OR (atopic conjunctivites) OR (atopic conjunctivitis) OR (allergic conjunctivitis) OR (allergic conjunctivites) OR (vernal conjunctivitis) OR (vernal conjunctivites) OR (vernal keratoconjunctivites) OR (vernal keratoconjunctivitis) OR (giant papillary conjunctivitis) OR (giant papillary conjunctivites)) AND ((anti-allergic agents) OR (anti allergic agents) OR (antiallergy agents) OR (antiallergy agents) OR (antiallergic drugs) OR (anti-allergy drugs) OR (anti allergy drugs) OR antiallergics OR (antiallergic agents) OR anti-allergics OR (anti allergics) OR (histamine antagonists) OR antihistamines OR (ophthalmic solutions) OR eyedrops OR (eye drops) OR (artificial tears) OR (anti inflammatory agents) OR antiinflammatories OR (antiinflammatory agents) OR (anti-inflammatory agents) OR (anti inflammatory agents) OR anti-inflammatories OR (anti inflammatories) OR (non steroidal anti inflammatory agents) OR (nonsteroidal anti inflammatory agents) OR NSAIDs OR (non steroidal antiinflammatory agents) OR (nonsteroidal antiinflammatory agents) OR (non-steroidal anti-inflammatory agents) OR (non steroidal anti inflammatory agents) OR (nonsteroidal anti-inflammatory agents) OR (nonsteroidal anti inflammatory agents) OR (non-steroidal anti-rheumatic agents) OR (non steroidal anti rheumatic agents) OR (non-steroidal antirheumatic agents) OR (aspirin-like agents) OR (aspirin like agents) OR (anti inflammatory analgesics) OR (anti-inflammatory analgesics) OR immunomodulations OR (immunomodulatory therapy) OR (immunomodulatory therapies) OR (conjunctival papilla surgery) OR (conjunctival papilla surgeries) OR (conjunctival papilla resection) OR (conjunctival papilla resections) OR (complementary therapies) OR (complementary therapy) OR (complementary medicine) OR (alternative medicine) OR (alternative therapies) OR (alternative therapy))

39.2

("allergic keratoconjunctivitis" OR "atopic conjunctivites" OR "atopic conjunctivitis" OR "allergic conjunctivitis" OR "allergic conjunctivides" OR "vernal conjunctivitis" OR "vernal conjunctivides" OR "vernal keratoconjunctivites" OR "vernal keratoconjunctivitis" OR "giant papillary conjunctivitis" OR "giant papillary conjunctivides") AND ("anti-allergic agents" OR "anti allergic agents" OR "antiallergy agents" OR "antiallergy agents" OR "antiallergic drugs" OR "anti-allergy drugs" OR "anti allergy drugs" OR antiallergics OR "antiallergic agents" OR anti-allergics OR "anti allergics" OR "histamine antagonists" OR antihistamines OR "ophthalmic solutions" OR eyedrops OR "eye drops" OR "artificial tears" OR "anti inflammatory agents" OR antiinflammatories OR "antiinflammatory agents" OR "anti-inflammatory agents" OR "anti inflammatory agents" OR anti-inflammatories OR "anti inflammatories" OR "non steroidal anti inflammatory agents" OR "nonsteroidal anti inflammatory agents" OR NSAIDs OR "non steroidal antiinflammatory agents" OR "nonsteroidal antiinflammatory agents" OR "non-steroidal anti-inflammatory agents" OR "non steroidal anti inflammatory agents" OR "non-steroidal anti-rheumatic agents" OR "non steroidal anti rheumatic agents" OR "non-steroidal antirheumatic agents" OR "aspirin-like agents) OR "aspirin like agents" OR "anti inflammatory analgesics" OR "anti-inflammatory analgesics" OR immunomodulations OR "immunomodulatory therapy" OR "immunomodulatory therapies" OR "conjunctival papilla surgery" OR "conjunctival papilla surgeries" OR "conjunctival papilla resection" OR "conjunctival papilla resections" OR "complementary therapies" OR "complementary therapy" OR "complementary medicine" OR "alternative medicine" OR "alternative therapies" OR "alternative therapy")

39.3

(allergic keratoconjunctivitis OR atopic conjunctivites OR atopic conjunctivitis OR allergic conjunctivitis OR allergic conjunctivides OR vernal conjunctivitis OR vernal conjunctivides OR vernal keratoconjunctivites OR vernal keratoconjunctivitis OR giant papillary conjunctivitis OR giant papillary conjunctivides) AND (anti-allergic agents OR anti allergic agents OR antiallergy agents OR antiallergy agents OR antiallergic drugs OR anti-allergy drugs OR anti allergy drugs OR antiallergics OR antiallergic agents OR anti-allergics OR anti allergics OR histamine antagonists OR antihistamines OR ophthalmic solutions OR eyedrops OR eye drops OR artificial tears OR anti inflammatory agents OR antiinflammatories OR antiinflammatory agents OR anti-inflammatory agents OR anti inflammatory agents OR anti-inflammatories OR anti inflammatories OR non steroidal anti inflammatory agents OR nonsteroidal anti inflammatory agents OR NSAIDs OR non steroidal antiinflammatory agents OR nonsteroidal antiinflammatory agents OR non-steroidal anti-inflammatory agents OR non steroidal anti inflammatory agents OR non-steroidal anti-rheumatic agents OR non steroidal anti rheumatic agents OR non-steroidal antirheumatic agents OR aspirin-like agents OR aspirin like agents OR anti inflammatory analgesics OR anti-inflammatory analgesics OR immunomodulations OR immunomodulatory therapy OR immunomodulatory therapies OR conjunctival papilla surgery OR conjunctival papilla surgeries OR conjunctival papilla resection OR conjunctival papilla resections OR complementary therapies OR complementary therapy OR complementary medicine OR alternative medicine OR alternative therapies OR alternative therapy)

39.4

(allergic keratoconjunctivitis OR atopic conjunctiviti* OR allergic conjunctiviti* OR vernal conjunctiviti* OR R vernal keratoconjunctiviti* OR giant papillary conjunctivitis*) AND (anti-allergic agents OR anti allergic agents OR antiallergy agent* OR antiallergic drugs OR anti-allergy drugs OR anti allergy drugs OR antiallergics OR antiallergic agents OR anti-allergics OR anti allergics OR histamine antagonists OR antihistamines OR ophthalmic solutions OR eyedrops OR eye drops OR artificial tears OR anti inflammatory agents OR antiinflammatories OR antiinflammatory agents OR

anti-inflammatory agents OR anti inflammatory agents OR anti-inflammatories OR anti inflammatories OR non steroidal anti inflammatory agents OR nonsteroidal anti inflammatory agents OR NSAIDs OR non steroidal antiinflammatory agents OR nonsteroidal antiinflammatory agents OR non-steroidal anti-inflammatory agents OR non steroidal anti inflammatory agents OR non-steroidal anti-inflammatory agents OR nonsteroidal anti inflammatory agents OR non-steroidal anti-rheumatic agents OR non steroidal anti rheumatic agents OR non-steroidal antirheumatic agents OR aspirin-like agents OR aspirin like agents OR anti inflammatory analgesics OR anti-inflammatory analgesics OR immunomodulations OR immunomodulatory therapy OR immunomodulatory therapies OR conjunctival papilla surger* OR conjunctival papilla resection OR conjunctival papilla resections OR complementary therap* OR complementary medicine OR alternative medicine OR alternative therap*)

39.5

allergic keratoconjunctivitis OR atopic conjunctivites OR atopic conjunctivitis OR allergic conjunctivitis OR allergic conjunctivites OR vernal conjunctivitis OR vernal conjunctivites OR vernal keratoconjunctivites OR vernal keratoconjunctivitis OR giant papillary conjunctivitis OR giant papillary conjunctivite AND anti-allergic agents OR anti allergic agents OR antiallergy agents OR antiallergy agents OR antiallergic drugs OR anti-allergy drugs OR anti allergy drugs OR antiallergics OR antiallergic agents OR anti-allergics OR anti allergics OR histamine antagonists OR antihistamines OR ophthalmic solutions OR eyedrops OR eye drops OR artificial tears OR anti inflammatory agents OR antiinflammatories OR antiinflammatory agents OR anti-inflammatory agents OR anti inflammatory agents OR anti-inflammatory agents OR anti inflammatories OR non steroidal anti inflammatory agents OR nonsteroidal anti inflammatory agents OR NSAIDs OR non steroidal antiinflammatory agents OR nonsteroidal antiinflammatory agents OR non-steroidal anti-inflammatory agents OR non steroidal anti inflammatory agents OR nonsteroidal anti-inflammatory agents OR non-steroidal anti-rheumatic agents OR non steroidal anti rheumatic agents OR non-steroidal antirheumatic agents OR aspirin-like agents OR aspirin like agents OR anti inflammatory analgesics OR anti-inflammatory analgesics OR immunomodulations OR immunomodulatory therapy OR immunomodulatory therapies OR conjunctival papilla surgery OR conjunctival papilla surgeries OR conjunctival papilla resection OR conjunctival papilla resections OR complementary therapies OR complementary therapy OR complementary medicine OR alternative medicine OR alternative therapies OR alternative therapy

40.1

((abdominal obesities) OR (abdominal obesity) OR (central obesity) OR (central obesities) OR (central obesity) OR (visceral obesities) OR (visceral obesity) OR (omental obesity) OR (upper trunk fat)) AND ((impaired glucose tolerance) OR (glucose intolerances) OR (glucose intolerance) OR (ketosis resistant diabetes mellitus) OR (maturity onset diabetes mellitus) OR (non insulin dependent diabetes mellitus) OR (type 2 diabetes mellitus) OR (slow onset diabetes mellitus) OR (stable diabetes mellitus) OR (type II diabetes mellitus) OR MODY OR NIDDM OR (adult onset diabetes mellitus) OR (noninsulin dependent diabetes mellitus) OR (metabolic syndrome)) AND (incidence OR (follow up studies) OR (follow up study) OR prognosis OR prognoses OR episode OR cohort OR (cohort studies) OR (cohort study) OR (controlled trial) OR (controlled trials))

40.2

("abdominal obesities" OR "abdominal obesity" OR "central obesity" OR "central obesities" OR "central obesity" OR "visceral obesities" OR "visceral obesity" OR "omental obesity" OR "upper trunk fat") AND ("impaired glucose tolerance" OR "glucose intolerances" OR "glucose intolerance" OR "ketosis resistant diabetes mellitus" OR "maturity onset diabetes mellitus" OR "non insulin dependent diabetes mellitus" OR "type 2 diabetes mellitus" OR "slow onset diabetes mellitus" OR "stable diabetes mellitus" OR "type II diabetes mellitus" OR MODY OR NIDDM OR "adult onset diabetes mellitus" OR "noninsulin dependent diabetes mellitus" OR "metabolic syndrome") AND

(incidence OR "follow up studies" OR "follow up study" OR prognosis OR prognoses OR episode OR cohort OR "cohort studies" OR "cohort study" OR "controlled trial" OR "controlled trials")

40.3

(abdominal obesities OR abdominal obesity OR central obesity OR central obesities OR central obesity OR visceral obesities OR visceral obesity OR omental obesity OR upper trunk fat) AND (impaired glucose tolerance OR glucose intolerances OR glucose intolerance OR ketosis resistant diabetes mellitus OR maturity onset diabetes mellitus OR non insulin dependent diabetes mellitus OR type 2 diabetes mellitus OR slow onset diabetes mellitus OR stable diabetes mellitus OR type II diabetes mellitus OR MODY OR NIDDM OR adult onset diabetes mellitus OR noninsulin dependent diabetes mellitus OR metabolic syndrome) AND (incidence OR follow up studies OR follow up study OR prognosis OR prognoses OR episode OR cohort OR cohort studies OR cohort study OR controlled trial OR controlled trials)

40.4

(abdominal obesit* OR central obesit* OR visceral obesity* OR omental obesity OR upper trunk fat) AND (impaired glucose tolerance OR glucose intolerance* OR ketosis resistant diabetes mellitus OR maturity onset diabetes mellitus OR non insulin dependent diabetes mellitus OR type 2 diabetes mellitus OR slow onset diabetes mellitus OR stable diabetes mellitus OR type II diabetes mellitus OR MODY OR NIDDM OR adult onset diabetes mellitus OR noninsulin dependent diabetes mellitus OR metabolic syndrome) AND (incidence OR follow up stud* OR prognos* OR episode OR cohort OR cohort stud* OR controlled trial*)

40.5

abdominal obesities OR abdominal obesity OR central obesity OR central obesities OR central obesity OR visceral obesities OR visceral obesity OR omental obesity OR upper trunk fat AND impaired glucose tolerance OR glucose intolerances OR glucose intolerance OR ketosis resistant diabetes mellitus OR maturity onset diabetes mellitus OR non insulin dependent diabetes mellitus OR type 2 diabetes mellitus OR slow onset diabetes mellitus OR stable diabetes mellitus OR type II diabetes mellitus OR MODY OR NIDDM OR adult onset diabetes mellitus OR noninsulin dependent diabetes mellitus OR metabolic syndrome AND incidence OR follow up studies OR follow up study OR prognosis OR prognoses OR episode OR cohort OR cohort studies OR cohort study OR controlled trial OR controlled trials

41.1

(chemotherapy OR (adjuvant chemotherapy) OR (adjuvant drug therapy) OR (adjuvant treatment) OR (adjuvant drug therapy) OR (systemic chemotherapy) OR (combined antineoplastic agent) OR (combined antineoplastic agents) OR (antineoplastic drug combinations) OR (antineoplastic drug combination) OR (anticancer drug combinations) OR (anticancer drug combination) OR (antineoplastic combined chemotherapy regimens) OR (antineoplastic chemotherapy protocols) OR (antineoplastic chemotherapy protocol) OR (cancer chemotherapy protocols) OR (cancer chemotherapy protocol)) AND ((*retroperitoneal lymph* node dissection) OR (lymph node excisions) OR lymphadenectomy OR lymphadenectomies OR (lymph node dissection) OR (lymph node dissections)) AND ((nonsemitomatous germ cell testicular cancer) OR (testicular neoplasm) OR (testis neoplasm) OR (testis neoplasms) OR (testicular neoplasms) OR (tumor of rete testis) OR (rete testis tumor) OR (rete testis tumors) OR (cancer of testis) OR (testis cancers) OR (testis cancer) OR (cancer of the testes) OR (cancer of the testis) OR (testicular cancer) OR (testicular cancers) OR (non-seminomatous germ-cell tumors) OR RLND)

41.2

(chemotherapy OR "adjuvant chemotherapy" OR "adjuvant drug therapy" OR "adjuvant treatment" OR "adjuvant drug therapy" OR "systemic chemotherapy" OR "combined antineoplastic agent" OR

“combined antineoplastic agents” OR “antineoplastic drug combinations” OR “antineoplastic drug combination” OR “anticancer drug combinations” OR “anticancer drug combination” OR “antineoplastic combined chemotherapy regimens” OR “antineoplastic chemotherapy protocols” OR “antineoplastic chemotherapy protocol” OR “cancer chemotherapy protocols” OR “cancer chemotherapy protocol”) AND (“*retroperitoneal lymph* node dissection” OR “lymph node excisions” OR lymphadenectomy OR lymphadenectomies OR “lymph node dissection” OR “lymph node dissections”) AND (“nonsemitomatous germ cell testicular cancer” OR “testicular neoplasm” OR “testis neoplasm” OR “testis neoplasms” OR “testicular neoplasms” OR “tumor of rete testis” OR “rete testis tumor” OR “rete testis tumors” OR “cancer of testis” OR “testis cancers” OR “testis cancer” OR “cancer of the testes” OR “cancer of the testis” OR “testicular cancer” OR “testicular cancers” OR “non-seminomatous germ-cell tumors” OR RLND)

41.3

(chemotherapy OR adjuvant chemotherapy OR adjuvant drug therapy OR adjuvant treatment OR adjuvant drug therapy OR systemic chemotherapy OR combined antineoplastic agent OR combined antineoplastic agents OR antineoplastic drug combinations OR antineoplastic drug combination) OR anticancer drug combinations OR anticancer drug combination OR antineoplastic combined chemotherapy regimens OR antineoplastic chemotherapy protocols OR antineoplastic chemotherapy protocol OR cancer chemotherapy protocols OR cancer chemotherapy protocol) AND (*retroperitoneal lymph* node dissection OR lymph node excisions OR lymphadenectomy OR lymphadenectomies OR lymph node dissection OR lymph node dissections) AND (nonsemitomatous germ cell testicular cancer OR testicular neoplasm OR testis neoplasm OR testis neoplasms OR testicular neoplasms OR tumor of rete testis OR rete testis tumor OR rete testis tumors OR cancer of testis OR testis cancers OR testis cancer OR cancer of the testes OR cancer of the testis OR testicular cancer OR testicular cancers OR non-seminomatous germ-cell tumors OR RLND)

41.4

(chemotherapy OR adjuvant chemotherapy OR adjuvant drug therapy OR adjuvant treatment OR adjuvant drug therapy OR systemic chemotherapy OR combined antineoplastic agent OR combined antineoplastic agents OR antineoplastic drug combination*) OR anticancer drug combination* OR antineoplastic combined chemotherapy regimens OR antineoplastic chemotherapy protocol* OR cancer chemotherapy protocol*) AND (*retroperitoneal lymph* node dissection OR lymph node excisions OR lymphadenectomy OR lymphadenectomies OR lymph node dissection*) AND (nonsemitomatous germ cell testicular cancer OR testicular neoplasm* OR testis neoplasm* OR tumor of rete testis OR rete testis tumor* OR cancer of testis OR testis cancer* OR cancer of the testes OR cancer of the testis OR testicular cancer* OR non-seminomatous germ-cell tumors OR RLND)

41.5

chemotherapy OR adjuvant chemotherapy OR adjuvant drug therapy OR adjuvant treatment OR adjuvant drug therapy OR systemic chemotherapy OR combined antineoplastic agent OR combined antineoplastic agents OR antineoplastic drug combinations OR antineoplastic drug combination) OR anticancer drug combinations OR anticancer drug combination OR antineoplastic combined chemotherapy regimens OR antineoplastic chemotherapy protocols OR antineoplastic chemotherapy protocol OR cancer chemotherapy protocols OR cancer chemotherapy protocol) AND *retroperitoneal lymph* node dissection OR lymph node excisions OR lymphadenectomy OR lymphadenectomies OR lymph node dissection OR lymph node dissections) AND nonsemitomatous germ cell testicular cancer OR testicular neoplasm OR testis neoplasm OR testis neoplasms OR testicular neoplasms OR tumor of rete testis OR rete testis tumor OR rete testis tumors OR cancer of testis OR testis cancers OR testis cancer OR cancer of the testes OR cancer of the testis OR testicular cancer OR testicular cancers OR non-seminomatous germ-cell tumors OR RLND

42.1

((macular edema) OR (macular oedema) OR maculopathy OR maculopathies OR (macula lutea) OR (cystoid central retinal edema) OR (cystoid macular edema)) AND ((diabetic retinopathy) OR (diabetic retinopathies)) AND ((laser therapies) OR (laser therapy) OR (laser vaporization) OR (laser ablation) OR (laser tissue ablation) OR (pulsed laser tissue ablation) OR (laser photoablation of tissue) OR (nonablative laser treatment) OR (nonablative laser treatments) OR (laser scalpel) OR (laser scalpels) OR (laser surgery) OR (laser surgeries) OR (laser knives) OR (laser knife))

42.2

("macular edema" OR "macular oedema" OR maculopathy OR maculopathies OR "macula lutea" OR "cystoid central retinal edema" OR "cystoid macular edema") AND ("diabetic retinopathy" OR "diabetic retinopathies") AND ("laser therapies" OR "laser therapy" OR "laser vaporization" OR "laser ablation" OR "laser tissue ablation" OR "pulsed laser tissue ablation" OR "laser photoablation of tissue" OR "nonablative laser treatment" OR "nonablative laser treatments" OR "laser scalpel" OR "laser scalpels" OR "laser surgery" OR "laser surgeries" OR "laser knives" OR "laser knife")

42.3

(macular edema OR macular oedema OR maculopathy OR maculopathies OR macula lutea OR cystoid central retinal edema OR cystoid macular edema) AND (diabetic retinopathy OR diabetic retinopathies) AND (laser therapies OR laser therapy OR laser vaporization OR laser ablation OR laser tissue ablation OR pulsed laser tissue ablation OR laser photoablation of tissue OR nonablative laser treatment OR nonablative laser treatments OR laser scalpel OR laser scalpels OR laser surgery OR laser surgeries OR laser knives OR laser knife)

42.4

(macular edema OR macular oedema OR maculopath* OR macula lutea OR cystoid central retinal edema OR cystoid macular edema) AND diabetic retinopath* AND (laser therap* OR laser vaporization OR laser ablation OR laser tissue ablation OR pulsed laser tissue ablation OR laser photoablation of tissue OR nonablative laser treatment* OR laser scalpel* OR laser surger* OR laser knife*)

42.5

macular edema OR macular oedema OR maculopathy OR maculopathies OR macula lutea OR cystoid central retinal edema OR cystoid macular edema AND diabetic retinopathy OR diabetic retinopathie AND laser therapies OR laser therapy OR laser vaporization OR laser ablation OR laser tissue ablation OR pulsed laser tissue ablation OR laser photoablation of tissue OR nonablative laser treatment OR nonablative laser treatments OR laser scalpel OR laser scalpels OR laser surgery OR laser surgeries OR laser knives OR laser knife

43.1

((overactive bladder) OR (overactive urinary bladder) OR (overactive detrusor) OR (overactive detrusor function)) AND ((electrical stimulation) OR (electrical stimulations) OR (electric stimulations) OR (electric stimulation) OR (electric stimulation therapy) OR (therapeutic electrical stimulation) OR electrotherapy OR (therapeutic electric stimulation) OR (electrical stimulation therapy) OR (transcutaneous electrical stimulation) OR (percutaneous electric nerve stimulation) OR (percutaneous electrical nerve stimulation) OR (transdermal electrostimulation) OR (transcutaneous electrical nerve stimulation) OR (transcutaneous nerve stimulation) OR (transcutaneous electric stimulation) OR TENS OR electroanalgesia OR (analgesic cutaneous electrostimulation))

43.2

("overactive bladder" OR "overactive urinary bladder" OR "overactive detrusor" OR "overactive detrusor function") AND ("electrical stimulation" OR "electrical stimulations" OR "electric stimulations" OR "electric stimulation" OR "electric stimulation therapy" OR "therapeutic electrical stimulation" OR electrotherapy OR "therapeutic electric stimulation" OR "electrical stimulation therapy" OR "transcutaneous electrical stimulation" OR "percutaneous electric nerve stimulation" OR "percutaneous electrical nerve stimulation" OR "transdermal electrostimulation" OR "transcutaneous electrical nerve stimulation" OR "transcutaneous nerve stimulation" OR "transcutaneous electric stimulation" OR TENS OR electroanalgesia OR "analgesic cutaneous electrostimulation")

43.3

(overactive bladder OR overactive urinary bladder OR overactive detrusor OR overactive detrusor function) AND (electrical stimulation OR electrical stimulations OR electric stimulations OR electric stimulation OR electric stimulation therapy OR therapeutic electrical stimulation OR electrotherapy OR therapeutic electric stimulation OR electrical stimulation therapy OR transcutaneous electrical stimulation OR percutaneous electric nerve stimulation OR percutaneous electrical nerve stimulation OR transdermal electrostimulation OR transcutaneous electrical nerve stimulation OR transcutaneous nerve stimulation OR transcutaneous electric stimulation OR TENS OR electroanalgesia OR analgesic cutaneous electrostimulation)

43.4

(overactive bladder OR overactive urinary bladder OR overactive detrusor OR overactive detrusor function) AND (electrical stimulation* OR electric stimulation* OR electric* stimulation therapy OR therapeutic electric* stimulation OR electrotherapy OR transcutaneous electrical stimulation OR percutaneous electric* nerve stimulation OR transdermal electrostimulation OR transcutaneous electric* nerve stimulation OR transcutaneous nerve stimulation OR TENS OR electroanalgesia OR analgesic cutaneous electrostimulation)

43.5

overactive bladder OR overactive urinary bladder OR overactive detrusor OR overactive detrusor function AND electrical stimulation OR electrical stimulations OR electric stimulations OR electric stimulation OR electric stimulation therapy OR therapeutic electrical stimulation OR electrotherapy OR therapeutic electric stimulation OR electrical stimulation therapy OR transcutaneous electrical stimulation OR percutaneous electric nerve stimulation OR percutaneous electrical nerve stimulation OR transdermal electrostimulation OR transcutaneous electrical nerve stimulation OR transcutaneous nerve stimulation OR transcutaneous electric stimulation OR TENS OR electroanalgesia OR analgesic cutaneous electrostimulation

44.1

((flail chest) OR (stove in chest) OR (chest injuries) OR (chest injury) OR (thoracicInjuries) OR (thoracic injury) OR (rib fractures) OR (rib fracture) OR (blunt thoracic trauma) OR (flail chest injury) OR (injured chest wall) OR (chest wall trauma) OR (chest wall) OR (chest trauma)) AND ((thoracic surgical procedure) OR (thoracic surgical procedures) OR (artificial respiration) OR (artificial respirations) OR (mechanical ventilations) OR (mechanical ventilation) OR (intratracheal intubation) OR (intratracheal intubations) OR (endotracheal intubation) OR (endotracheal intubations))

44.2

("flail chest" OR "stove in chest" OR "chest injuries" OR "chest injury" OR thoracicInjuries OR "thoracic injury" OR "rib fractures" OR "rib fracture" OR "blunt thoracic trauma" OR "flail chest injury" OR "injured chest wall" OR "chest wall trauma" OR "chest wall" OR "chest trauma") AND

("thoracic surgical procedure" OR "thoracic surgical procedures" OR "artificial respiration" OR "artificial respirations" OR "mechanical ventilations" OR "mechanical ventilation" OR "intratracheal intubation" OR "intratracheal intubations" OR "endotracheal intubation" OR "endotracheal intubations")

44.3

(flail chest OR stove in chest OR chest injuries OR chest injury OR thoracicInjuries OR thoracic injury OR rib fractures OR rib fracture OR blunt thoracic trauma OR flail chest injury OR injured chest wall OR chest wall trauma OR chest wall OR chest trauma) AND (thoracic surgical procedure OR thoracic surgical procedures OR artificial respiration OR artificial respirations OR mechanical ventilations OR mechanical ventilation OR intratracheal intubation OR intratracheal intubations OR endotracheal intubation OR endotracheal intubations)

44.4

(flail chest OR stove in chest OR chest injur* OR thoracicInjuries OR thoracic injur* OR rib fracture OR blunt thoracic trauma OR flail chest injury OR injured chest wall OR chest wall trauma OR chest wall OR chest trauma) AND (thoracic surgical procedure* OR artificial respiration* OR mechanical ventilation* OR intratracheal intubation* OR endotracheal intubation*)

44.5

flail chest OR stove in chest OR chest injuries OR chest injury OR thoracicInjuries OR thoracic injury OR rib fractures OR rib fracture OR blunt thoracic trauma OR flail chest injury OR injured chest wall OR chest wall trauma OR chest wall OR chest trauma AND thoracic surgical procedure OR thoracic surgical procedures OR artificial respiration OR artificial respirations OR mechanical ventilations OR mechanical ventilation OR intratracheal intubation OR intratracheal intubations OR endotracheal intubation OR endotracheal intubations

45.1

((transmission-based precautions) OR (standard precautions) OR (universal precaution) OR (universal precautions) OR (contact precautions) OR (airways precautions) OR (aerosol precautions)) AND ((public health education for professionals) OR (health professionals) OR (health professional) OR (nurse clinician) OR (nurse clinicians) OR (clinical nurse specialist) OR (clinical nurse specialists) OR (clinical nurse specialist) OR physician OR physicians OR nurse OR (nursing personnel) OR (nursing residents) OR (nursing resident) OR (medical residents) OR (medical resident) OR caregiver OR caregivers OR (care givers) OR (care giver) OR carers OR carer OR (family caregivers) OR (family caregiver) OR (spouse caregivers) OR (spouse caregiver))

45.2

("transmission-based precautions" OR "standard precautions" OR "universal precaution" OR "universal precautions" OR "contact precautions" OR "airways precautions" OR "aerosol precautions") AND ("public health education for professionals" OR "health professionals" OR "health professional" OR "nurse clinician" OR "nurse clinicians" OR "clinical nurse specialist" OR "clinical nurse specialists" OR "clinical nurse specialist" OR physician OR physicians OR nurse OR "ursing personnel" OR "nursing residents" OR "nursing resident" OR "medical residents" OR "medical resident" OR caregiver OR caregivers OR "care givers" OR "care giver" OR carers OR carer OR "family caregivers" OR "family caregiver" OR "spouse caregivers" OR "spouse caregiver")

45.3

(transmission-based precautions OR standard precautions OR universal precaution OR universal precautions OR contact precautions OR airways precautions OR aerosol precautions) AND (public health education for professionals OR health professionals OR health professional OR nurse clinician OR nurse clinicians OR clinical nurse specialist OR clinical nurse specialists OR clinical

nurse specialist OR physician OR physicians OR nurse OR nursing personnel OR nursing residents OR nursing resident OR medical residents OR medical resident OR caregiver OR caregivers OR care givers OR care giver OR carers OR carer OR family caregivers OR family caregiver OR spouse caregivers OR spouse caregiver)

45.4

(transmission-based precautions OR standard precautions OR universal precaution* OR contact precautions OR airways precautions OR aerosol precautions) AND (public health education for professionals OR health professional* OR nurse clinician* OR clinical nurse specialist* OR clinical nurse specialist OR physician* OR nurse OR nursing personnel OR nursing resident* OR medical resident* OR caregiver* OR care giver* OR carer* OR family caregiver* OR spouse caregiver*)

45.5

transmission-based precautions OR standard precautions OR universal precaution OR universal precautions OR contact precautions OR airways precautions OR aerosol precautions AND public health education for professionals OR health professionals OR health professional OR nurse clinician OR nurse clinicians OR clinical nurse specialist OR clinical nurse specialists OR clinical nurse specialist OR physician OR physicians OR nurse OR nursing personnel OR nursing residents OR nursing resident OR medical residents OR medical resident OR caregiver OR caregivers OR care givers OR care giver OR carers OR carer OR family caregivers OR family caregiver OR spouse caregivers OR spouse caregiver

46.1

((anaesthesia-related mortality) OR (anesthesia-related mortality) OR (anaesthesia-related cardiac arrest) OR (anesthesia-related cardiac arrest) OR ((cardiac arrest) OR (heart arrest) OR asystole OR asystoles OR (cardiopulmonary arrest)) AND (anaesthesia OR anesthesia) AND (cross-sectional OR (cross-sectional study) OR (cross-sectional studies) OR (cross-sectional study) OR (cross-sectional studies) OR (cross sectional study) OR (cross sectional studies) OR prospective OR retrospective OR (prospective design) OR (retrospective design) OR (prospective study) OR (prospective studies) OR (retrospective study) OR (retrospective studies) OR (case series) OR review)

46.2

("anaesthesia-related mortality" OR "anesthesia-related mortality" OR "anaesthesia-related cardiac arrest" OR "anesthesia-related cardiac arrest" OR "cardiac arrest" OR "heart arrest" OR asystole OR asystoles OR cardiopulmonary arrest) AND (anaesthesia OR anesthesia) AND (cross-sectional OR cross-sectional study OR "cross-sectional studies" OR "cross-sectional study" OR "cross-sectional studies" OR "cross sectional study" OR "cross sectional studies" OR prospective OR retrospective OR "prospective design" OR "retrospective design" OR "prospective study" OR "prospective studies" OR "retrospective study" OR "retrospective studies" OR "case series" OR review)

46.3

(anaesthesia-related mortality OR anesthesia-related mortality OR anaesthesia-related cardiac arrest OR anesthesia-related cardiac arrest OR cardiac arrest OR heart arrest OR asystole OR asystoles OR cardiopulmonary arrest) AND (anaesthesia OR anesthesia) AND (cross-sectional OR cross-sectional study OR cross-sectional studies OR cross-sectional study OR cross-sectional studies OR cross sectional study OR cross sectional studies OR prospective OR retrospective OR prospective design OR retrospective design OR prospective study OR prospective studies OR retrospective study OR retrospective studies OR case series OR review)

46.4

(anaesthesia-related mortality OR anesthesia-related mortality OR anaesthesia-related cardiac arrest OR anesthesia-related cardiac arrest OR cardiac arrest OR heart arrest OR asystole* OR

cardiopulmonary arrest) AND (anaesthesia OR anesthesia) AND (cross-sectional OR cross-sectional stud* OR crosssectional stud* OR cross sectional stud* OR prospective OR retrospective OR prospective design OR retrospective design OR prospective stud* OR retrospective stud* OR case series OR review)

46.5

anaesthesia-related mortality OR anesthesia-related mortality OR anaesthesia-related cardiac arrest OR anesthesia-related cardiac arrest OR cardiac arrest OR heart arrest OR asystole OR asystoles OR cardiopulmonary arrest AND anaesthesia OR anesthesia AND cross-sectional OR cross-sectional study OR cross-sectional studies OR crosssectional study OR crosssectional studies OR cross sectional study OR cross sectional studies OR prospective OR retrospective OR prospective design OR retrospective design OR prospective study OR prospective studies OR retrospective study OR retrospective studies OR case series OR review

47.1

((fibroblast cell culture) OR fibroblast OR (cell culture technique) OR (cell culture techniques) OR (cell culture) OR (cell cultures) OR (primary cell culture) OR (primary cell cultures) OR (fibroblast implant) OR (fibroblast implants) OR (fibroblast cell implantation) OR (fibroblast cell implantations) OR (fibroblast cell transplantation) OR (fibroblast cell transplantations)) AND ((bowing glottic) OR (glottic incompetence) OR (glottic insufficiency) OR (glottic insufficiencies))

47.2

("fibroblast cell culture" OR fibroblast OR "cell culture technique" OR "cell culture techniques" OR "cell culture" OR "cell cultures" OR "primary cell culture" OR "primary cell cultures" OR "fibroblast implant" OR "fibroblast implants" OR "fibroblast cell implantation" OR "fibroblast cell implantations" OR "fibroblast cell transplantation" OR "fibroblast cell transplantations") AND ("bowing glottis" OR "glottic incompetence" OR "glottic insufficiency" OR "glottic insufficiencies")

47.3

(fibroblast cell culture OR fibroblast OR cell culture technique OR cell culture techniques OR cell culture OR cell cultures OR primary cell culture OR primary cell cultures OR fibroblast implant OR fibroblast implants OR fibroblast cell implantation OR fibroblast cell implantations OR fibroblast cell transplantation OR fibroblast cell transplantations) AND (bowing glottic OR glottic incompetence OR glottic insufficiency OR glottic insufficiencies)

47.4

(fibroblast cell culture OR fibroblast OR cell culture technique* OR cell culture* OR primary cell culture* OR fibroblast implant* OR fibroblast cell implantation* OR fibroblast cell transplantation*) AND (bowing glottic OR glottic incompetence OR glottic insufficiency*)

47.5

fibroblast cell culture OR fibroblast OR cell culture technique OR cell culture techniques OR cell culture OR cell cultures OR primary cell culture OR primary cell cultures OR fibroblast implant OR fibroblast implants OR fibroblast cell implantation OR fibroblast cell implantations OR fibroblast cell transplantation OR fibroblast cell transplantations AND bowing glottic OR glottic incompetence OR glottic insufficiency OR glottic insufficiencies

48.1

((feeding behavior) OR (feeding behaviors) OR (eating behavior) OR (eating behaviors) OR (feeding patterns) OR (feeding pattern) OR (food habits) OR (food habit) OR (dietary modification) OR (dietary modifications) OR (diet modification) OR (diet modifications) OR (dietary habits) OR (dietary habit) OR (diet habits) OR (diet habit)) AND ((intervention study) OR (intervention studies))

OR evaluation OR (food nutrition education)) AND ((pregnant women) OR (pregnant woman))

48.2

("feeding behavior" OR "feeding behaviors" OR "eating behavior" OR "eating behaviors" OR "feeding patterns" OR "feeding pattern" OR "food habits" OR "food habit" OR "dietary modification" OR "dietary modifications" OR "diet modification" OR "diet modifications" OR "dietary habits" OR "dietary habit" OR "diet habits" OR "diet habit") AND ("intervention study" OR "intervention studies" OR evaluation OR "food nutrition education") AND ("pregnant women" OR "pregnant woman")

48.3

(feeding behavior OR feeding behaviors OR eating behavior OR eating behaviors OR feeding patterns OR feeding pattern OR food habits OR food habit OR dietary modification OR dietary modifications OR diet modification OR diet modifications OR dietary habits OR dietary habit OR diet habits OR diet habit) AND (intervention study OR intervention studies OR evaluation OR food nutrition education) AND (pregnant women OR pregnant woman)

48.4

(feeding behavior* OR eating behavior* OR feeding pattern* OR food habit* OR dietary modification* OR diet modification* OR diet* habit*) AND (intervention stud* OR evaluation OR food nutrition education) AND (pregnant women OR pregnant woman)

48.5

feeding behavior OR feeding behaviors OR eating behavior OR eating behaviors OR feeding patterns OR feeding pattern OR food habits OR food habit OR dietary modification OR dietary modifications OR diet modification OR diet modifications OR dietary habits OR dietary habit OR diet habits OR diet habit AND intervention study OR intervention studies OR evaluation OR food nutrition education AND pregnant women OR pregnant woman

49.1

((fabry disease) OR (angiokeratoma corporis diffusum) OR (anderson-fabry disease) OR (anderson fabry disease) OR (fabry's disease) OR (fabrys disease)) AND ((agalsidase beta) OR (fabrazyme) OR (genzyme brand of agalsidase beta))

49.2

("fabry disease" OR "angiokeratoma corporis diffusum" OR "anderson-fabry disease" OR "anderson fabry disease" OR "fabry's disease" OR "fabrys disease") AND ("agalsidase beta" OR "fabrazyme" OR "genzyme brand of agalsidase beta")

49.3

(fabry disease OR angiokeratoma corporis diffusum OR anderson-fabry disease OR anderson fabry disease OR fabry's disease OR fabrys disease) AND (agalsidase beta OR fabrazyme OR genzyme brand of agalsidase beta)

49.4

(fabry* disease OR angiokeratoma corporis diffusum OR anderson-fabry disease OR anderson fabry disease) AND (agalsidase beta OR fabrazyme OR genzyme brand of agalsidase beta)

49.5

fabry disease OR angiokeratoma corporis diffusum OR anderson-fabry disease OR anderson fabry disease OR fabry's disease OR fabrys disease AND agalsidase beta OR fabrazyme OR genzyme brand of agalsidase beta

50.1

(prisons OR prison OR prisoners OR prisoner OR hostages OR hostage) AND (depression OR depressions OR (depressive symptoms) OR (depressive symptom) OR (emocional depression)) AND (prevalence OR prevalences)

50.2

(prisons OR prison OR prisoners OR prisoner OR hostages OR hostage) AND (depression OR depressions OR “depressive symptoms” OR “depressive symptom” OR “emocional depression”) AND (prevalence OR prevalences)

50.3

(prisons OR prison OR prisoners OR prisoner OR hostages OR hostage) AND (depression OR depressions OR depressive symptoms OR depressive symptom OR emocional depression) AND (prevalence OR prevalences)

50.4

(prison* OR hostage* AND (depression* OR depressive symptom* OR emocional depression) AND (prevalence*))

50.5

prisons OR prison OR prisoners OR prisoner OR hostages OR hostage AND depression OR depressions OR depressive symptoms OR depressive symptom OR emocional depression OR emocional depression AND prevalence OR prevalences

51.1

(maternal OR (maternal exposures) OR (maternal exposure) OR (maternal ages) OR (maternal age) OR mother OR (mothers' clubs) OR (mothers' club) OR (mother clubs)) AND ((prenatal maternal stress) OR (physiological stresses) OR (physiological stress) OR (metabolic stress) OR (metabolic stresses) OR stress OR (physiological stress response) OR (physiological stress responses) OR (physiological stress reactivity) OR (physiological stress reaction) OR (physiological stress reactions) OR (biological stress) OR (biological stresses) OR (metabolic stress response) OR (metabolic stress responses) OR (stress response) OR (stress responses) OR (psychological stresses) OR (life stress) OR (life stresses) OR (psychologic stress) OR (psychological stress) OR (mental suffering) OR suffering OR anguish OR (emotional stress) OR (post-traumatic stress disorder) OR (post traumatic stress disorders) OR PTSD OR (posttraumatic neuroses) OR (posttraumatic stress disorders) OR (posttraumatic stress disorder) OR (post-traumatic neuroses) OR (post traumatic neuroses) OR (chronic post-traumatic stress disorder) OR (chronic post traumatic stress disorder) OR (delayed onset post-traumatic stress disorder) OR (delayed onset post traumatic stress disorder) OR (acute post-traumatic stress disorder) OR (acute post traumatic stress disorder) OR (heat stress disorder) OR (heat stress disorders) OR (heat stress syndromes) OR (heat stress syndrome) OR (heat cramps) OR (heat cramp) OR (acute stress disorder) OR (acute stress disorders) OR (traumatic stress disorder) OR (traumatic stress disorders) OR (cold shock response) OR (cold-shock responses) OR (cold-stress Reaction) OR (cold stress reaction) OR (cold-stress reactions) OR (cold-stress response) OR (cold stress response) OR (cold-stress responses)) AND ((congenital malformation fetus) OR (maternal-fetal outcome) OR (maternal-fetal outcomes))

51.2

(maternal OR “maternal exposures” OR “maternal exposure” OR “maternal ages” OR “maternal age” OR mother OR “mothers' clubs” OR “mothers' club” OR “mother clubs”) AND (“prenatal maternal stress” OR “physiological stresses” OR “physiological stress” OR “metabolic stress” OR “metabolic stresses” OR stress OR “physiological stress response” OR “physiological stress

responses" OR "physiological stress reactivity" OR "physiological stress reaction" OR "physiological stress reactions" OR "biological stress" OR "biological stresses" OR "metabolic stress response" OR "metabolic stress responses" OR "stress response" OR "stress responses" OR "psychological stresses" OR "life stress" OR "life stresses" OR "psychologic stress" OR "psychological stress" OR "mental suffering" OR suffering OR anguish OR "emotional stress" OR "post-traumatic stress disorder" OR "post traumatic stress disorders" OR PTSD OR "posttraumatic neuroses" OR "posttraumatic stress disorders" OR "posttraumatic stress disorder" OR "post-traumatic neuroses" OR "post traumatic neuroses" OR "chronic post-traumatic stress disorder" OR "chronic post traumatic stress disorder" OR "delayed onset post-traumatic stress disorder" OR "delayed onset post traumatic stress disorder" OR "acute post-traumatic stress disorder" OR "acute post traumatic stress disorder" OR "heat stress disorder" OR "heat stress disorders" OR "heat stress syndromes" OR "heat stress syndrome" OR "heat cramps" OR "heat cramp" OR "acute stress disorder" OR "acute stress disorders" OR "traumatic stress disorder" OR "traumatic stress disorders" OR "cold shock response" OR "cold-shock responses" OR "cold-stress Reaction" OR "cold stress reaction" OR "cold-stress reactions" OR "cold-stress response" OR "cold stress response" OR "cold-stress responses") AND ("congenital malformation fetus" OR "maternal-fetal outcome" OR "maternal-fetal outcomes")

51.3

(maternal OR maternal exposures OR maternal exposure OR maternal ages OR maternal age OR mother OR mothers' clubs OR mothers' club OR mother clubs) AND (prenatal maternal stress OR physiological stresses OR physiological stress OR metabolic stress OR metabolic stresses OR stress OR physiological stress response OR physiological stress responses OR physiological stress reactivity OR physiological stress reaction OR physiological stress reactions OR biological stress OR biological stresses OR metabolic stress response OR metabolic stress responses OR stress response OR stress responses OR psychological stresses OR life stress OR life stresses OR psychologic stress OR psychological stress OR mental suffering OR suffering OR anguish OR emotional stress OR post-traumatic stress disorder OR post traumatic stress disorders OR PTSD OR posttraumatic neuroses OR posttraumatic stress disorders OR posttraumatic stress disorder OR post-traumatic neuroses OR post traumatic neuroses OR chronic post-traumatic stress disorder OR chronic post traumatic stress disorder OR delayed onset post-traumatic stress disorder OR delayed onset post traumatic stress disorder OR acute post-traumatic stress disorder OR acute post traumatic stress disorder OR heat stress disorder OR heat stress disorders OR heat stress syndromes OR heat stress syndrome OR heat cramps OR heat cramp OR acute stress disorder OR acute stress disorders OR traumatic stress disorder OR traumatic stress disorders OR cold shock response OR cold-shock responses OR cold-stress Reaction OR cold stress reaction OR cold-stress reactions OR cold-stress response OR cold stress response OR cold-stress responses) AND (congenital malformation fetus OR maternal-fetal outcome OR maternal-fetal outcomes)

51.4

(maternal OR maternal exposure* OR maternal age* OR mother OR mother* club*) AND (prenatal maternal stress OR physiological stress* OR metabolic stress* OR stress OR physiological stress response* OR physiological stress reactivity OR physiological stress reaction* OR biological stress* OR metabolic stress response* OR stress response* OR psychologic* stress* OR life stress* OR mental suffering OR suffering OR anguish OR emotional stress OR post-traumatic stress disorder OR post traumatic stress disorders OR PTSD OR posttraumatic neuroses OR posttraumatic stress disorder* OR post-traumatic neuroses OR post traumatic neuroses OR chronic post-traumatic stress disorder OR chronic post traumatic stress disorder OR delayed onset post-traumatic stress disorder OR delayed onset post traumatic stress disorder OR acute post-traumatic stress disorder OR acute post traumatic stress disorder OR heat stress disorder OR heat stress disorders OR heat stress syndrome* OR heat cramp* OR acute stress disorder* OR

traumatic stress disorder* OR cold shock response OR cold-shock responses OR cold-stress reaction OR cold stress reaction OR cold-stress reactions OR cold-stress response* OR cold stress response) AND (congenital malformation fetus OR maternal-fetal outcome*)

51.5

maternal OR maternal exposures OR maternal exposure OR maternal ages OR maternal age OR mother OR mothers' clubs OR mothers' club OR mother clubs AND prenatal maternal stress OR physiological stresses OR physiological stress OR metabolic stress OR metabolic stresses OR stress OR physiological stress response OR physiological stress responses OR physiological stress reactivity OR physiological stress reaction OR physiological stress reactions OR biological stress OR biological stresses OR metabolic stress response OR metabolic stress responses OR stress response OR stress responses OR psychological stresses OR life stress OR life stresses OR psychologic stress OR psychological stress OR mental suffering OR suffering OR anguish OR emotional stress OR post-traumatic stress disorder OR post traumatic stress disorders OR PTSD OR posttraumatic neuroses OR posttraumatic stress disorders OR posttraumatic stress disorder OR post-traumatic neuroses OR post traumatic neuroses OR chronic post-traumatic stress disorder OR chronic post traumatic stress disorder OR delayed onset post-traumatic stress disorder OR delayed onset post traumatic stress disorder OR acute post-traumatic stress disorder OR acute post traumatic stress disorder OR heat stress disorder OR heat stress disorders OR heat stress syndromes OR heat stress syndrome OR heat cramps OR heat cramp OR acute stress disorder OR acute stress disorders OR traumatic stress disorder OR traumatic stress disorders OR cold shock response OR cold-shock responses OR cold-stress Reaction OR cold stress reaction OR cold-stress reactions OR cold-stress response OR cold stress response OR cold-stress responses AND congenital malformation fetus OR maternal-fetal outcome OR maternal-fetal outcomes

52.1

(hypospadias) AND ((psychological sexual dysfunction) OR (psychological sexual dysfunctions) OR (psychosexual dysfunctions) OR (psychosexual dysfunction) OR (psychosexual disorder) OR (sexual aversion disorder) OR (sexual aversion disorders) OR (orgasmic disorder) OR (sexual arousal disorder) OR (sexual arousal disorders) OR (frigidity or hypoactive sexual desire disorder))

52.2

hypospadias AND (“psychological sexual dysfunction” OR “psychological sexual dysfunctions” OR “psychosexual dysfunctions” OR “psychosexual dysfunction” OR “psychosexual disorder” OR “sexual aversion disorder” OR “sexual aversion disorders” OR “orgasmic disorder” OR “sexual arousal disorder” OR “sexual arousal disorders” OR “frigidity or hypoactive sexual desire disorder”)

52.3

hypospadias AND (psychological sexual dysfunction OR psychological sexual dysfunctions OR psychosexual dysfunctions OR psychosexual dysfunction OR psychosexual disorder OR sexual aversion disorder OR sexual aversion disorders OR orgasmic disorder OR sexual arousal disorder OR sexual arousal disorders OR frigidity or hypoactive sexual desire disorder)

52.4

hypospadias AND (psychological sexual dysfunction* OR psychosexual dysfunction* OR psychosexual disorder OR sexual aversion disorder* OR orgasmic disorder OR sexual arousal disorder* OR frigidity or hypoactive sexual desire disorder)

52.5

Hypospadias AND psychological sexual dysfunction OR psychological sexual dysfunctions OR psychosexual dysfunctions OR psychosexual dysfunction OR psychosexual disorder OR sexual

aversion disorder OR sexual aversion disorders OR orgasmic disorder OR sexual arousal disorder OR sexual arousal disorders OR frigidity or hypoactive sexual desire disorder

53.1

((esophageal perforations) OR (esophageal perforation) OR (perforation of the esophagus) OR (esophagus perforation) OR (esophagus perforations) OR (ruptures of the esophagus) OR (iatrogenic perforations of the esophagus) OR (traumatic perforations of esophagus) OR (spontaneous perforations of the esophagus)) AND ((operative surgical procedure) OR (operative surgical procedures) OR (operative procedures) OR (operative procedure) OR (ghost surgery) OR esophagectomies OR esophagectomy OR (primary repair by suture) OR (primary closure) OR (suture closure) OR (primary repair) OR (simple suture) OR (surgical drainage) OR (chest tube) OR (chest tubes) OR (operative drainage) OR (non operative) OR (non-operative) OR nonoperative OR (anti-bacterial agents) OR (anti-bacterial agent) OR (anti-bacterial agents) OR (anti bacterial agents) OR (antibacterial agents) OR antibiotics OR (bacteriocidal agents) OR bacteriocides OR (anti-mycobacterial agents) OR (anti mycobacterial agents) OR (antimycobacterial agents) OR gastrostomies OR gastrostomy OR esophagostomies OR (cervical esophagostomy) OR (cervical esophagostomies) OR jejunostomies OR jejunostomy OR (nasogastric tube) OR (internal drainage) OR conservative OR resection OR (drainage alone) OR (surgical therapy) OR (clinical therapy) OR (investigational therapy) OR (investigational treatments) OR (investigational treatment) OR (experimental therapies) OR (experimental therapy) OR (investigational therapies) OR (innovative therapies) OR (innovative therapy) OR (medication therapy management) OR (drug therapy management) OR (medicare prescription drug improvement)) AND ((modernization act of 2003) OR (non-surgical) OR (non surgical) OR clinical OR (pleural drainage) OR (mediastinal drainage) OR exclusion)

53.2

("esophageal perforations" OR "esophageal perforation" OR "perforation of the esophagus" OR "esophagus perforation" OR "esophagus perforations" OR "ruptures of the esophagus" OR "iatrogenic perforations of the esophagus" OR "traumatic perforations of esophagus" OR "spontaneous perforations of the esophagus") AND ("operative surgical procedure" OR "operative surgical procedures" OR "operative procedures" OR "operative procedure" OR "ghost surgery" OR esophagectomies OR esophagectomy OR "primary repair by suture" OR "primary closure" OR "suture closure" OR "primary repair" OR "simple suture" OR "surgical drainage" OR "chest tube" OR "chest tubes" OR "operative drainage" OR "non operative" OR "non-operative" OR nonoperative OR "anti-bacterial agents" OR "anti-bacterial agent" OR "anti-bacterial agents" OR "anti bacterial agents" OR "antibacterial agents" OR antibiotics OR "bacteriocidal agents" OR bacteriocides OR "anti-mycobacterial agents" OR "anti mycobacterial agents" OR "antimycobacterial agents" OR gastrostomies OR gastrostomy OR esophagostomies OR "cervical esophagostomy" OR "cervical esophagostomies" OR jejunostomies OR jejunostomy OR "nasogastric tube" OR "internal drainage" OR conservative OR resection OR "drainage alone" OR "surgical therapy" OR "clinical therapy" OR "investigational therapy" OR "investigational treatments" OR "investigational treatment" OR "experimental therapies" OR "experimental therapy" OR "investigational therapies" OR "innovative therapies" OR "innovative therapy" OR "medication therapy management" OR "drug therapy management" OR "medicare prescription drug improvement") AND (" modernization act of 2003" OR "non-surgical" OR "non surgical" OR clinical OR "pleural drainage" OR "mediastinal drainage" OR exclusion")

53.3

(esophageal perforations OR esophageal perforation OR perforation of the esophagus OR esophagus perforation OR esophagus perforations OR ruptures of the esophagus OR iatrogenic perforations of the esophagus OR traumatic perforations of esophagus OR spontaneous perforations of the esophagus) AND (operative surgical procedure OR operative

surgical procedures OR operative procedures OR operative procedure OR ghost surgery OR esophagectomies OR esophagectomy OR primary repair by suture OR primary closure OR suture closure OR primary repair OR simple suture OR surgical drainage OR chest tube OR chest tubes OR operative drainage OR non operative OR non-operative OR nonoperative OR anti-bacterial agents OR anti-bacterial agent OR anti-bacterial agents OR anti bacterial agents OR antibacterial agents OR antibiotics OR bacteriocidal agents OR bacteriocides OR anti-mycobacterial agents OR anti mycobacterial agents OR antimycobacterial agents OR gastrostomies OR gastrostomy OR esophagostomies OR cervical esophagostomy OR cervical esophagostomies OR jejunostomies OR jejunostomy OR nasogastric tube OR internal drainage OR conservative OR resection OR drainage alone OR surgical therapy OR clinical therapy OR investigational therapy OR investigational treatments OR investigational treatment OR experimental therapies OR experimental therapy OR investigational therapies OR innovative therapies OR innovative therapy OR medication therapy management OR drug therapy management OR medicare prescription drug improvement) AND (modernization act of 2003 OR non-surgical OR non surgical OR clinical OR pleural drainage OR mediastinal drainage OR exclusion)

53.4

(esophageal perforation* OR perforation of the esophagus OR esophagus perforation OR ruptures of the esophagus OR iatrogenic perforations of the esophagus OR traumatic perforations of esophagus OR spontaneous perforations of the esophagus) AND (operative surgical procedure* OR operative procedure* OR ghost surgery OR esophagectom* OR primary repair by suture OR primary closure OR suture closure OR primary repair OR simple suture OR surgical drainage OR chest tube OR chest tubes OR operative drainage OR non operative OR non-operative OR nonoperative OR anti-bacterial agents OR anti-bacterial agent* OR anti bacterial agents OR antibacterial agents OR antibiotics OR bacteriocidal agents OR bacteriocides OR anti-mycobacterial agents OR anti mycobacterial agents OR antimycobacterial agents OR gastrostom* OR esophagostomies OR cervical esophagostom* OR jejunostom* OR nasogastric tube OR internal drainage OR conservative OR resection OR drainage alone OR surgical therapy OR clinical therapy OR investigational therapy OR investigational treatment* OR experimental therap* OR investigational therapies OR innovative therap* OR medication therapy management OR drug therapy management OR medicare prescription drug improvement) AND (modernization act of 2003 OR non-surgical OR non surgical OR clinical OR pleural drainage OR mediastinal drainage OR exclusion)

53.5

esophageal perforations OR esophageal perforation OR perforation of the esophagus OR esophagus perforation OR esophagus perforations OR ruptures of the esophagus OR iatrogenic perforations of the esophagus OR traumatic perforations of esophagus OR spontaneous perforations of the esophagus AND operative surgical procedure OR operative surgical procedures OR operative procedures OR operative procedure OR ghost surgery OR esophagectomies OR esophagectomy OR primary repair by suture OR primary closure OR suture closure OR primary repair OR simple suture OR surgical drainage OR chest tube OR chest tubes OR operative drainage OR non operative OR non-operative OR nonoperative OR anti-bacterial agents OR anti-bacterial agent OR anti-bacterial agents OR anti bacterial agents OR antibacterial agents OR antibiotics OR bacteriocidal agents OR bacteriocides OR anti-mycobacterial agents OR anti mycobacterial agents OR antimycobacterial agents OR gastrostomies OR gastrostomy OR esophagostomies OR cervical esophagostomy OR cervical esophagostomies OR jejunostomies OR jejunostomy OR nasogastric tube OR internal drainage OR conservative OR resection OR drainage alone OR surgical therapy OR clinical therapy OR investigational therapy OR investigational treatments OR investigational treatment OR experimental therapies OR experimental therapy OR investigational therapies OR innovative

therapies OR innovative therapy OR medication therapy management OR drug therapy management OR medicare prescription drug improvement AND modernization act of 2003 OR non-surgical OR non surgical OR clinical OR pleural drainage OR mediastinal drainage OR exclusion

54.1

((anticoagulants agents) OR (anticoagulant agent) OR (anticoagulants drugs) OR (anticoagulant drug) OR (indirect thrombin inhibitors) OR 4-hydroxycoumarins OR abciximab OR acenocoumarol OR (acid citrate dextrose) OR ancrod OR (antilipopolsaccharide factor) OR antistasin OR (antithrombin III) OR (antithrombin proteins) OR (antivitamins K) OR aprosulate OR ardeparin OR argatroban OR (beta 2-glycoprotein I) OR bivalirudin OR (blood coagulation factor inhibitors) OR bromadiolone OR bromfenacoum OR (calcium heparin) OR certoparin OR chlorophacinone OR (citrate phosphate dextrose) OR (citric acid) OR coumarin OR coumarins OR (cpda solutions) OR dalteparin OR danaparoid OR (dermatan sulfate) OR desirudin OR dextrans OR dicumarol OR difenacoum OR (DX 9065A) OR (edetic acid) OR efegatran OR enoxaparin OR (ethyl biscoumacetate) OR (ferulic acid) OR (fibrin fibrinogen degradation products) OR (fibrinogen fragment X) OR fluindione OR fondaparinux OR fucoidan OR gabexate OR (glucuronyl glucosamine glycan sulfate) OR heparin OR (heparin cofactor II) OR (low-molecular-weight heparin) OR heparinoids OR hirudins OR inogatran OR lamifiban OR laminaran OR lepirudin OR (lipoprotein-associated coagulation inhibitor) OR melagatran OR nadroparin OR nafamostat OR nitrophorin OR PENTA OR (pentosan sulfuric polyester) OR phenindione OR phenprocoumon OR plumbagin OR (protein C) OR (protein S) OR protocatchualdehyde OR reviparin OR (SDZ MTH 958) OR tanshinone OR tocopherylquinone OR troxerutin OR warfarin OR ximelagatran) AND ((acute pulmonary embolisms) OR (acute pulmonary embolism) OR (acute pulmonary thromboembolisms) OR (acute pulmonary thromboembolism) OR (acute subsegmental pulmonary embolism) OR (acute subsegmental pulmonary embolisms) OR (acute isolated subsegmental pulmonary embolism) OR (acute isolated subsegmental pulmonary embolisms))

54.2

("anticoagulants agents" OR "anticoagulant agent" OR "anticoagulants drugs" OR "anticoagulant drug" OR "indirect thrombin inhibitors" OR 4-hydroxycoumarins OR abciximab OR acenocoumarol OR "acid citrate dextrose" OR ancrod OR "antilipopolsaccharide factor" OR antistasin OR "antithrombin III" OR "antithrombin proteins" OR "antivitamins K" OR aprosulate OR ardeparin OR argatroban OR "beta 2-glycoprotein I" OR bivalirudin OR "blood coagulation factor inhibitors" OR bromadiolone OR bromfenacoum OR "calcium heparin" OR certoparin OR chlorophacinone OR "citrate phosphate dextrose" OR "citric acid" OR coumarin OR coumarins OR "cpda solutions" OR dalteparin OR danaparoid OR "dermatan sulfate" OR desirudin OR dextrans OR dicumarol OR difenacoum OR "DX 9065A" OR "edetic acid" OR efegatran OR enoxaparin OR "ethyl biscoumacetate" OR "ferulic acid" OR "fibrin fibrinogen degradation products" OR "fibrinogen fragment X" OR fluindione OR fondaparinux OR fucoidan OR gabexate OR "glucuronyl glucosamine glycan sulfate" OR heparin OR "heparin cofactor II" OR "low-molecular-weight heparin" OR heparinoids OR hirudins OR inogatran OR lamifiban OR laminaran OR lepirudin OR "lipoprotein-associated coagulation inhibitor" OR melagatran OR nadroparin OR nafamostat OR nitrophorin OR PENTA OR "pentosan sulfuric polyester" OR phenindione OR phenprocoumon OR plumbagin OR "protein C" OR "protein S" OR protocatchualdehyde OR reviparin OR "SDZ MTH 958" OR tanshinone OR tocopherylquinone OR troxerutin OR warfarin OR ximelagatran) AND ("acute pulmonary embolisms" OR "acute pulmonary embolism" OR "acute pulmonary thromboembolisms" OR "acute pulmonary thromboembolism" OR "acute subsegmental pulmonary embolism" OR "acute subsegmental pulmonary embolisms" OR "acute isolated subsegmental pulmonary embolism" OR "acute isolated subsegmental pulmonary embolisms")

54.3

(anticoagulants agents OR anticoagulant agent OR anticoagulants drugs OR anticoagulant drug OR indirect thrombin inhibitors OR 4-hydroxycoumarins OR abciximab OR acenocoumarol OR acid citrate dextrose OR ancrod OR antilipopolsaccharide factor OR antistasin OR antithrombin III OR antithrombin proteins OR antivitamins K OR aprosulate OR ardeparin OR argatroban OR beta 2-glycoprotein I OR bivalirudin OR blood coagulation factor inhibitors OR bromadiolone OR bromfenacoum OR calcium heparin OR certoparin OR chlorophacinone OR citrate phosphate dextrose OR citric acid OR coumarin OR coumarins OR cpda solutions OR dalteparin OR danaparoid OR dermatan sulfate OR desirudin OR dextrans OR dicumarol OR difenacoum OR DX 9065A OR edetic acid OR efegatran OR enoxaparin OR ethyl biscoumacetate OR ferulic acid OR fibrin fibrinogen degradation products OR fibrinogen fragment X OR fluindione OR fondaparinux OR fucoidan OR gabexate OR glucuronyl glucosamine glycan sulfate OR heparin OR heparin cofactor II OR low-molecular-weight heparin OR heparinoids OR hirudins OR inogatran OR lamifiban OR laminaran OR lepirudin OR lipoprotein-associated coagulation inhibitor OR melagatran OR nadroparin OR nafamostat OR nitrophorin OR PENTA OR pentosan sulfuric polyester OR phenindione OR phenprocoumon OR plumbagin OR protein C OR protein S OR protocatechualdehyde OR reviparin OR SDZ MTH 958 OR tanshinone OR tocopherylquinone OR troxerutin OR warfarin OR ximelagatran) AND (acute pulmonary embolisms OR acute pulmonary embolism OR acute pulmonary thromboembolisms OR acute pulmonary thromboembolism OR acute subsegmental pulmonary embolism OR acute subsegmental pulmonary embolisms OR acute isolated subsegmental pulmonary embolism OR acute isolated subsegmental pulmonary embolisms)

54.4

(anticoagulant* agent* OR anticoagulant* drug* OR indirect thrombin inhibitors OR 4-hydroxycoumarins OR abciximab OR acenocoumarol OR acid citrate dextrose OR ancrod OR antilipopolsaccharide factor OR antistasin OR antithrombin III OR antithrombin proteins OR antivitamins K OR aprosulate OR ardeparin OR argatroban OR beta 2-glycoprotein I OR bivalirudin OR blood coagulation factor inhibitors OR bromadiolone OR bromfenacoum OR calcium heparin OR certoparin OR chlorophacinone OR citrate phosphate dextrose OR citric acid OR coumarin* OR cpda solutions OR dalteparin OR danaparoid OR dermatan sulfate OR desirudin OR dextrans OR dicumarol OR difenacoum OR DX 9065A OR edetic acid OR efegatran OR enoxaparin OR ethyl biscoumacetate OR ferulic acid OR fibrin fibrinogen degradation products OR fibrinogen fragment X OR fluindione OR fondaparinux OR fucoidan OR gabexate OR glucuronyl glucosamine glycan sulfate OR heparin OR heparin cofactor II OR low-molecular-weight heparin OR heparinoids OR hirudins OR inogatran OR lamifiban OR laminaran OR lepirudin OR lipoprotein-associated coagulation inhibitor OR melagatran OR nadroparin OR nafamostat OR nitrophorin OR PENTA OR pentosan sulfuric polyester OR phenindione OR phenprocoumon OR plumbagin OR protein C OR protein S OR protocatechualdehyde OR reviparin OR SDZ MTH 958 OR tanshinone OR tocopherylquinone OR troxerutin OR warfarin OR ximelagatran) AND (acute pulmonary embolism* OR acute pulmonary thromboembolism* OR acute subsegmental pulmonary embolism* OR acute isolated subsegmental pulmonary embolism*)

54.5

anticoagulants agents OR anticoagulant agent OR anticoagulants drugs OR anticoagulant drug OR indirect thrombin inhibitors OR 4-hydroxycoumarins OR abciximab OR acenocoumarol OR acid citrate dextrose OR ancrod OR (antilipopolsaccharide factor OR antistasin OR antithrombin III OR antithrombin proteins OR antivitamins K OR aprosulate OR ardeparin OR argatroban OR beta 2-glycoprotein I OR bivalirudin OR blood coagulation factor inhibitors OR bromadiolone OR bromfenacoum OR calcium heparin OR certoparin OR chlorophacinone OR citrate phosphate dextrose OR citric acid OR coumarin OR coumarins OR cpda solutions OR dalteparin OR danaparoid OR dermatan sulfate OR desirudin OR dextrans OR dicumarol OR difenacoum OR DX

9065A OR edetic acid OR efegatran OR enoxaparin OR ethyl biscoumacetate OR ferulic acid OR fibrin fibrinogen degradation products OR fibrinogen fragment X OR fluindione OR fondaparinux OR fucoidan OR gabexate OR glucuronyl glucosamine glycan sulfate OR heparin OR heparin cofactor II OR low-molecular-weight heparin OR heparinoids OR hirudins OR inogatran OR lamifiban OR laminaran OR lepirudin OR lipoprotein-associated coagulation inhibitor OR melagatran OR nadroparin OR nafamostat OR nitrophorin OR PENTA OR pentosan sulfuric polyester OR phenindione OR phenprocoumon OR plumbagin OR protein C OR (protein S OR protocatechualdehyde OR reviparin OR SDZ MTH 958 OR tanshinone OR tocopherylquinone OR troxerutin OR warfarin OR ximelagatran AND acute pulmonary embolisms OR acute pulmonary embolism OR acute pulmonary thromboembolisms OR acute pulmonary thromboembolism OR acute subsegmental pulmonary embolism OR acute subsegmental pulmonary embolisms OR acute isolated subsegmental pulmonary embolism OR acute isolated subsegmental pulmonary embolisms

55.1

((coronary diseases) OR (coronary disease) OR (coronary heart disease) OR (coronary heart diseases) OR (coronariopathy patients)) AND ((myocardial revascularizations) OR (myocardial revascularization) OR (internal mammary artery implantation)) AND ((inhalation anesthesia) OR (insufflation anesthesia) OR isoflurane OR (fluorinated hydrocarbons sevoflurane) OR (fluoromethyl-2,2,2-trifluoro-1-trifluoromethylethyl ether) OR sevoflurane OR (fluoromethyl hexafluoroisopropyl ether) OR ultane OR (BAX 3084) OR halothane OR 1,1,1-trifluoro-2-chloro-2-bromoethane OR ftorotan OR narcotan OR fluothane OR enflurane OR etran OR alyrane OR (baxter anaesthesia brand of enflurane) OR (astrazeneca brand of enflurane) OR ethrane OR (abbott brand of enflurane) OR enlirane OR (zeneca brand of enflurane) OR enfran OR (pisa brand of enflurane) OR propofol OR 2,6-diisopropylphenol OR (2,6 diisopropylphenol) OR disoprofol OR 2,6-bis(1-methylethyl)phenol OR diprivan OR (zeneca brand of propofol) OR disoprivan OR (astra brand of propofol) OR (astrazeneca brand of propofol) OR fresofol OR (alpha brand of propofol) OR ICI-35,868 OR (ICI 35,868) OR ICI35,868 OR (ICI-35868) OR (ICI 35868) OR ICI35868 OR recofol OR (pisa brand of propofol) OR (schering brand of propofol) OR (curamed brand of propofol) OR (propofol abbott) OR (abbott brand of propofol) OR (propofol Fresenius) OR (fresenius kabi brand of propofol) OR (propofol MCT) OR (fresenius brand of propofol) OR (propofol rovi) OR (rovi brand of propofol) OR propofol-lipuro OR (braun brand of propofol) OR aquafol OR (parnell brand of propofol) OR ivofol OR (juste brand of propofol) OR (intravenous anesthesia) OR (intravenous anesthetics))

55.2

("coronary diseases" OR "coronary disease" OR "coronary heart disease" OR "coronary heart diseases" OR "coronariopathy patients") AND ("myocardial revascularizations" OR "myocardial revascularization" OR "internal mammary artery implantation") AND ("inhalation anesthesia" OR "insufflation anesthesia" OR isoflurane OR "fluorinated hydrocarbons" sevoflurane OR "fluoromethyl-2,2,2-trifluoro-1-trifluoromethyl"ethyl ether" OR sevoflurane OR "fluoromethyl hexafluoroisopropyl ether" OR ultane OR "BAX 3084" OR halothane OR 1,1,1-trifluoro-2-chloro-2-bromoethane OR ftorotan OR narcotan OR fluothane OR enflurane OR etran OR alyrane OR "baxter anaesthesia brand of enflurane" OR "astrazeneca brand of enflurane" OR ethrane OR "abbott brand of enflurane" OR enlirane OR "zeneca brand of enflurane" OR enfran OR "pisa brand of enflurane" OR propofol OR 2,6-diisopropylphenol OR "2,6 diisopropylphenol" OR disoprofol OR 2,6-bis(1-methylethyl)phenol OR diprivan OR "zeneca brand of propofol" OR disoprivan OR "astra brand of propofol" OR "astrazeneca brand of propofol" OR fresofol OR "alpha brand of propofol" OR ICI-35,868 OR "ICI 35,868" OR ICI35,868 OR ICI-35868 OR "ICI 35868" OR ICI35868 OR recofol OR "pisa brand of propofol" OR "schering brand of propofol" OR "curamed brand of propofol" OR "propofol abbott" OR "abbott brand of propofol" OR "propofol fresenius" OR "fresenius kabi brand of propofol" OR "propofol MCT" OR "fresenius brand of propofol" OR "propofol rovi" OR

“rovi brand of propofol” OR propofol-lipuro OR “braun brand of propofol” OR aquafol OR “parnell brand of propofol” OR ivofol OR “juste brand of propofol” OR “intravenous anesthesia” OR “intravenous anesthetics”)

55.3

(coronary diseases OR coronary disease OR coronary heart disease OR coronary heart diseases OR coronariopathy patients) AND (myocardial revascularizations OR myocardial revascularization OR internal mammary artery implantation) AND (inhalation anesthesia OR insufflation anesthesia OR isoflurane OR fluorinated hydrocarbons sevoflurane OR fluoromethyl-2,2,2-trifluoro-1-trifluoromethylethyl ether OR sevoflurane OR fluoromethyl hexafluoroisopropyl ether OR ultane OR BAX 3084 OR halothane OR 1,1,1-trifluoro-2-chloro-2-bromoethane or ftorotan OR narcotan OR fluothane OR enflurane OR etran OR alyrane OR baxter anaesthesia brand of enflurane OR astrazeneca brand of enflurane OR ethrane OR abbot brand of enflurane OR enlirane OR zeneca brand of enflurane OR enfran OR pisa brand of enflurane OR propofol OR 2,6-diisopropylphenol OR 2,6 diisopropylphenol OR disoprofol OR 2,6-bis(1-methylethyl)phenol OR diprivan OR zeneca brand of propofol OR disoprivan OR astra brand of propofol OR astrazeneca brand of propofol OR fresofol OR alpha brand of propofol OR ICI-35,868 OR ICI 35,868 OR ICI35,868 OR ICI-35868 OR ICI 35868 OR ICI35868 OR recofol OR pisa brand of propofol OR schering brand of propofol OR curamed brand of propofol OR propofol abbot OR abbot brand of propofol OR propofol fresenius OR fresenius kabi brand of propofol OR propofol MCT OR fresenius brand of propofol OR propofol rovi OR rovi brand of propofol OR propofol-lipuro OR braun brand of propofol OR aquafol OR parnell brand of propofol OR ivofol OR juste brand of propofol OR intravenous anesthesia OR intravenous anesthetics)

55.4

(coronary disease* OR coronary heart disease* OR coronariopathy patients) AND (myocardial revascularization* OR internal mammary artery implantation) AND (inhalation anesthesia OR insufflation anesthesia OR isoflurane OR fluorinated hydrocarbons sevoflurane OR fluoromethyl-2,2,2-trifluoro-1-trifluoromethylethyl ether OR sevoflurane OR fluoromethyl hexafluoroisopropyl ether OR ultane OR BAX 3084 OR halothane OR 1,1,1-trifluoro-2-chloro-2-bromoethane or ftorotan OR narcotan OR fluothane OR enflurane OR etran OR alyrane OR baxter anaesthesia brand of enflurane OR astrazeneca brand of enflurane OR ethrane OR abbot brand of enflurane OR enlirane OR zeneca brand of enflurane OR enfran OR pisa brand of enflurane OR propofol OR 2,6-diisopropylphenol OR 2,6 diisopropylphenol OR disoprofol OR 2,6-bis(1-methylethyl)phenol OR diprivan OR zeneca brand of propofol OR disoprivan OR astra brand of propofol OR astrazeneca brand of propofol OR fresofol OR alpha brand of propofol OR ICI-35,868 OR ICI 35,868 OR ICI35,868 OR ICI-35868 OR ICI 35868 OR ICI35868 OR recofol OR pisa brand of propofol OR schering brand of propofol OR curamed brand of propofol OR propofol abbot OR abbot brand of propofol OR propofol fresenius OR fresenius kabi brand of propofol OR propofol MCT OR fresenius brand of propofol OR propofol rovi OR rovi brand of propofol OR propofol-lipuro OR braun brand of propofol OR aquafol OR parnell brand of propofol OR ivofol OR juste brand of propofol OR intravenous anesthesia*)

55.5

coronary diseases OR coronary disease OR coronary heart disease OR coronary heart diseases OR coronariopathy patients AND myocardial revascularizations OR myocardial revascularization OR internal mammary artery implantation
AND inhalation anesthesia OR insufflation anesthesia OR isoflurane OR fluorinated hydrocarbons sevoflurane OR fluoromethyl-2,2,2-trifluoro-1-trifluoromethylethyl ether OR sevoflurane OR fluoromethyl hexafluoroisopropyl ether OR ultane OR BAX 3084 OR halothane OR 1,1,1-trifluoro-2-chloro-2-bromoethane or ftorotan OR narcotan OR fluothane OR enflurane OR etran OR alyrane OR baxter anaesthesia brand of enflurane OR astrazeneca brand of enflurane OR ethrane OR

abbott brand of enflurane OR enlirane OR zeneca brand of enflurane OR enfran OR pisa brand of enflurane OR propofol OR 2,6-diisopropylphenol OR 2,6 diisopropylphenol OR disoprofol OR 2,6-bis1-methylethylphenol OR diprivan OR zeneca brand of propofol OR disoprivan OR astra brand of propofol OR astrazeneca brand of propofol OR fresofol OR alpha brand of propofol OR ICI-35,868 OR ICI 35,868 OR ICI35,868 OR ICI-35868 OR ICI 35868 OR ICI35868 OR refofol OR pisa brand of propofol OR schering brand of propofol OR curamed brand of propofol OR propofol abbott OR abbott brand of propofol OR propofol fresenius OR fresenius kabi brand of propofol OR propofol MCT OR fresenius brand of propofol OR propofol rovi OR rovi brand of propofol OR propofol-lipuro OR braun brand of propofol OR aquafol OR parnell brand of propofol OR ivofol OR juste brand of propofol OR intravenous anesthesia OR intravenous anesthetics

56.1

((primary peritonitis) OR (secondary peritonitis) OR peritonitis) AND ((peritoneal dialyses) OR (peritoneal dialysis)) AND (vancomycin OR (vancomycin hydrochloride) OR (vancomycin sulfate) OR vancomycin-ratiopharm OR (ratiopharm brand of vancomycin hydrochloride) OR (vancomycin hexal) OR (hexal brand of vancomycin hydrochloride) OR (vancomycine dakota) OR (dakota brand of vancomycin hydrochloride) OR ab-vancomycin OR (curasan brand of vancomycin hydrochloride) OR diatracin OR (dista brand of vancomycin hydrochloride) OR (vanco azupharma) OR (azupharma brand of vancomycin hydrochloride) OR vanco-cell OR (cell pharm brand of vancomycin hydrochloride) OR vanco-saar OR (mip brand of vancomycin hydrochloride) OR vancocin OR (Eli Lilly Brand of vancomycin hydrochloride) OR (vancomycin Lilly) OR (Lilly brand of vancomycin hydrochloride) OR vancocine OR (vancocin HCl) OR (vancomicina abbott) OR (abbott brand of vancomycin hydrochloride) OR (vancomicina chiesi) OR (chiesi brand of vancomycin hydrochloride) OR (vancomicina combino phar) OR (combino brand of vancomycin hydrochloride) OR (vancomicina Norman) OR (Norman brand of vancomycin hydrochloride) OR (vancomycin phosphate) OR (decahydrate vancomycin phosphate) OR cephalosporins OR (cephalosporin antibiotics) OR (cephalosporin antibiotics) OR (cephalosporanic acids) OR (third generation cephalosporin) OR cefazolin OR cephalozin OR cefamedin OR (cefazolin sodium) OR (sodium cephalozin) OR (cephazolin sodium) OR kefzol OR totacef OR cefamezine OR cepamezine OR ancef OR gramaxin OR ciprofloxacin OR (ciprofloxacin hydrochloride) OR cipro OR bay-09867 OR (bay 09867) OR bay09867 OR ciprinol OR aminoglycosides OR gentamicins OR gentamycins OR garamycin OR genticin OR (gentamicin sulfate) OR (gentamicin sulfate) OR gentamycin OR gentamicin OR gentavet OR g-myticin OR g myticin OR gmyticin OR gentacycol OR ceftazidime OR LY-139381 OR (LY 139381) OR LY139381 OR fortum OR GR-20263 OR (GR 20263) OR GR20263 OR tazidime OR fortaz)

56.2

("primary peritonitis" OR "secondary peritonitis" OR peritonitis) **AND** ("peritoneal dialyses" OR "peritoneal dialysis") AND (vancomycin OR "vancomycin hydrochloride" OR "vancomycin sulfate" OR vancomycin-ratiopharm OR "ratiopharm brand of vancomycin hydrochloride" OR "vancomycin hexal" OR "hexal brand of vancomycin hydrochloride" OR "vancomycine dakota" OR "dakota brand of vancomycin hydrochloride" OR ab-vancomycin OR "curasan brand of vancomycin hydrochloride" OR diatracin OR "dista brand of vancomycin hydrochloride" OR "vanco azupharma" OR "azupharma brand of vancomycin hydrochloride" OR vanco-cell OR "cell pharm brand of vancomycin hydrochloride" OR vanco-saar OR "mip brand of vancomycin hydrochloride" OR vancocin OR "Eli Lilly Brand of vancomycin hydrochloride" OR "vancomycin Lilly" OR "Lilly brand of vancomycin hydrochloride" OR vancocine OR "vancocin HCl" OR "vancomicina abbott" OR "abbott brand of vancomycin hydrochloride" OR "vancomicina chiesi" OR "chiesi brand of vancomycin hydrochloride" OR "vancomicina combino phar" OR "combino brand of vancomycin hydrochloride" OR "vancomicina Norman" OR "Norman brand of vancomycin hydrochloride" OR "vancomycin phosphate" OR "decahydrate vancomycin phosphate" OR cephalosporins OR "cephalosporin antibiotics" OR "cephalosporin antibiotics" OR "cephalosporanic acids" OR "third generation

cephalosporin" OR cefazolin OR cephalazolin OR cefamedin OR "cefazolin sodium" OR "sodium cephalazolin" OR "cephazolin sodium" OR kefzol OR totacef OR cefamezine OR cephamazine OR ancef OR gramaxin OR ciprofloxacin OR "ciprofloxacin hydrochloride" OR cipro OR bay-09867 OR "bay 09867" OR bay09867 OR ciprinol OR aminoglycosides OR gentamicins OR gentamycins OR garamycin OR gentacin OR "gentamicin sulfate" OR "gentamicin sulfate" OR gentamycin OR gentamicin OR gentavet OR g-myticin OR g myticin OR gmyticin OR gentacycol OR ceftazidime OR LY-139381 OR "LY 139381" OR LY139381 OR fortum OR GR-20263 OR "GR 20263" OR GR20263 OR tazidime OR fortaz")

56.3

(primary peritonitis OR secondary peritonitis OR peritonitis) AND (peritoneal dialyses OR peritoneal dialysis) AND (vancomycin OR vancomycin hydrochloride OR vancomycin sulfate OR vancomycin-ratiopharm OR ratiopharm brand of vancomycin hydrochloride OR vancomycin hexal OR hexal brand of vancomycin hydrochloride OR vancomycine dakota OR dakota brand of vancomycin hydrochloride OR ab-vancomycin OR curasan brand of vancomycin hydrochloride OR diatracin OR dista brand of vancomycin hydrochloride OR vanco azupharma OR azupharma brand of vancomycin hydrochloride OR vanco-cell OR cell pharm brand of vancomycin hydrochloride OR vanco-saar OR mip brand of vancomycin hydrochloride OR vancocin OR Eli Lilly Brand of vancomycin hydrochloride OR vancomycin Lilly OR Lilly brand of vancomycin hydrochloride OR vancocine OR vancocin HCl OR vancomicina abbott OR abbott brand of vancomycin hydrochloride OR vancomicina chiesi OR chiesi brand of vancomycin hydrochloride OR vancomicina combinophar OR combinophar brand of vancomycin hydrochloride OR vancomicina Norman OR Norman brand of vancomycin hydrochloride OR vancomycin phosphate OR decahydrate vancomycin phosphate OR cephalosporins OR cephalosporin antibiotics OR cephalosporin antibiotics OR cephalosporanic acids OR third generation cephalosporin OR cefazolin OR cephalazolin OR cefamedin OR cefazolin sodium OR sodium cephalazolin OR cephalazolin sodium OR kefzol OR totacef OR cefamezine OR cephamazine OR ancef OR gramaxin OR ciprofloxacin OR ciprofloxacin hydrochloride OR cipro OR bay-09867 OR bay 09867 OR bay09867 OR ciprinol OR aminoglycosides OR gentamicins OR gentamycins OR garamycin OR gentacin OR gentamicin sulfate OR gentamicin sulfate OR gentamycin OR gentamicin OR gentavet OR g-myticin OR g myticin OR gmyticin OR gentacycol OR ceftazidime OR LY-139381 OR LY 139381 OR LY139381 OR fortum OR GR-20263 OR GR 20263 OR GR20263 OR tazidime OR fortaz)

56.4

(primary peritonitis OR secondary peritonitis OR peritonitis) AND (peritoneal dialys*) AND (vancomycin OR vancomycin hydrochloride OR vancomycin hydrochloride OR vancomycin sulfate OR vancomycin-ratiopharm OR ratiopharm brand of vancomycin hydrochloride OR vancomycin hexal OR hexal brand of vancomycin hydrochloride OR vancomycine dakota OR dakota brand of vancomycin hydrochloride OR ab-vancomycin OR curasan brand of vancomycin hydrochloride OR diatracin OR dista brand of vancomycin hydrochloride OR vanco azupharma OR azupharma brand of vancomycin hydrochloride OR vanco-cell OR cell pharm brand of vancomycin hydrochloride OR vanco-saar OR mip brand of vancomycin hydrochloride OR vancocin OR Eli Lilly Brand of vancomycin hydrochloride OR vancomycin Lilly OR Lilly brand of vancomycin hydrochloride OR vancocine OR vancocin HCl OR vancomicina abbott OR abbott brand of vancomycin hydrochloride OR vancomicina chiesi OR chiesi brand of vancomycin hydrochloride OR vancomicina combinophar OR combinophar brand of vancomycin hydrochloride OR vancomicina Norman OR Norman brand of vancomycin hydrochloride OR vancomycin phosphate OR decahydrate vancomycin phosphate OR cephalosporins OR cephalosporin antibiotics OR cephalosporin antibiotics OR cephalosporanic acids OR third generation cephalosporin OR cefazolin OR cephalazolin OR cefamedin OR cefazolin sodium OR sodium cephalazolin OR cephalazolin sodium OR kefzol OR totacef OR cefamezine OR cephamazine OR ancef OR gramaxin OR ciprofloxacin OR ciprofloxacin hydrochloride OR cipro OR bay-09867 OR bay 09867 OR bay09867 OR ciprinol OR aminoglycosides OR gentamicins OR

gentamycins OR garamycin OR gentacin OR gentamicin sulfate OR gentamicin sulfate OR gentamycin OR gentamicin OR gentavet OR g-myticin OR g myticin OR gmyticin OR gentacycol OR ceftazidime OR LY-139381 OR LY 139381 OR LY139381 OR fortum OR GR-20263 OR GR 20263 OR GR20263 OR tazidime OR fortaz)

56.5

primary peritonitis OR secondary peritonitis OR peritonitis AND peritoneal dialyses OR peritoneal dialysis AND vancomycin OR vancomycin hydrochloride OR vancomycin sulfate OR vancomycin-ratiopharm OR ratiopharm brand of vancomycin hydrochloride OR vancomycin hexal OR hexal brand of vancomycin hydrochloride OR vancomycine dakota OR dakota brand of vancomycin hydrochloride OR ab-vancomycin OR curasan brand of vancomycin hydrochloride OR diatracin OR dista brand of vancomycin hydrochloride OR vanco azupharma OR azupharma brand of vancomycin hydrochloride OR vanco-cell OR cell pharm brand of vancomycin hydrochloride OR vanco-saar OR mip brand of vancomycin hydrochloride OR vancocin OR Eli Lilly Brand of vancomycin hydrochloride OR vancomycin Lilly OR Lilly brand of vancomycin hydrochloride OR vancocine OR vancocin HCl OR vancomicina abbott OR abbott brand of vancomycin hydrochloride OR vancomicina chiesi OR chiesi brand of vancomycin hydrochloride OR vancomicina combino phar OR combino brand of vancomycin hydrochloride OR vancomicina Norman OR Norman brand of vancomycin hydrochloride OR vancomycin phosphate OR decahydrate vancomycin phosphate OR cephalosporins OR cephalosporin antibiotics OR cephalosporin antibiotics OR cephalosporanic acids OR third generation cephalosporin OR cefazolin OR cephalozin OR cefamedin OR cefazolin sodium OR sodium cephalozin OR cephalozin sodium OR kefzol OR totacef OR cefamezine OR cepamezine OR ancef OR gramaxin OR ciprofloxacin OR ciprofloxacin hydrochloride OR cipro OR bay-09867 OR bay 09867 OR bay09867 OR ciprinol OR aminoglycosides OR gentamicins OR gentamycins OR garamycin OR gentacin OR gentamicin sulfate OR gentamicin sulfate OR gentamycin OR gentamicin OR gentavet OR g-myticin OR g myticin OR gmyticin OR gentacycol OR ceftazidime OR LY-139381 OR LY 139381 OR LY139381 OR fortum OR GR-20263 OR GR 20263 OR GR20263 OR tazidime OR fortaz

57.1

(immunoexpression p53) OR (immunoexpression ki67) OR p53 OR (oncoprotein p53) OR (TRP53 protein) OR (p53 tumor suppressor protein) OR (pp53 phosphoprotein) OR (TP53 protein) OR (cellular tumor antigen p53) OR (p53 antigen) OR (Ki67 antigen) OR (MIB1 protein) OR (MIB1 antigen) OR (antigen Ki67) OR (MIB1 monoclonal antibody)) AND ((preneoplastic laryngeal lesions) OR (preneoplastic laryngeal lesion) OR (laryngeal edemas) OR (laryngeal edema) OR (laryngeal neoplasms) OR (larynx neoplasms) OR (larynx neoplasm) OR (cancer of larynx) OR (larynx cancers) OR (laryngeal cancer) OR (laryngeal cancers) OR (larynx cancer) OR (larynx cancers) OR (cancer of the larynx) OR papilloma OR papillomas OR (squamous cell papilloma) OR (squamous cell papillomas) OR papillomatosis OR (papillomavirus type 16) OR (human papillomatoses) OR (papillomavirus 16) OR HPV16 OR (human papillomavirus type 16) OR (papillomavirus type 18) OR (human papillomatoses) OR (papillomavirus 18) OR HPV18 OR (HPV 18) OR (human papillomavirus type 18) OR (vocal cyst) OR (laryngeal cyst) OR (vocal fold nodules) OR (vocal fold nodule) OR (vocal folds nodule) OR (vocal folds nodules) OR (vocal nodules) OR (vocal nodule) OR (vocal cord nodule) OR (vocal cord nodules) OR (vocal cords nodules) OR (vocal cords nodule) OR (vocal cords disorder) OR (vocal cords disorders) OR (vocal fold disorder) OR (vocal fold disorders) OR (vocal folds disorder) OR (vocal folds disorders) OR (vocal cord disorder) OR (vocal cord disorders) OR (Reinke edema) OR (Reinke's edema) OR (laryngeal polyp) OR (laryngeal polyps) OR leukoplakias OR (leukoplakic lesions) OR (leukoplakic lesion) OR leukokeratosis OR leukokeratoses)

57.2

("immunoexpression p53" OR "immunoexpression ki67" OR p53 OR "oncoprotein p53" OR "TRP53

protein" OR "p53 tumor suppressor protein" OR "pp53 phosphoprotein" OR "TP53 protein" OR "cellular tumor antigen p53" OR "p53 antigen" OR "Ki67 antigen" OR "MIB1 protein" OR "MIB1 antigen" OR "antigen Ki67" OR "MIB1 monoclonal antibody") AND ("preneoplastic laryngeal lesions" OR "preneoplastic laryngeal lesion" OR "laryngeal edemas" OR "laryngeal edema" OR "laryngeal neoplasms" OR "larynx neoplasms" OR "larynx neoplasm" OR "cancer of larynx" OR "larynx cancers" OR "laryngeal cancer" OR "laryngeal cancers" OR "larynx cancer" OR "larynx cancers" OR "cancer of the larynx" OR papilloma OR papillomas OR "squamous cell papilloma" OR "squamous cell papillomas" OR papillomatosis OR "papillomavirus type 16" OR "human papillomatoses" OR "papillomavirus 16" OR HPV16 OR "human papillomavirus type 16" OR "papillomavirus type 18" OR "human papillomatoses" OR "papillomavirus 18" OR HPV18 OR "HPV 18" OR "human papillomavirus type 18" OR "vocal cyst" OR "laryngeal cyst" OR "vocal fold nodules" OR "vocal fold nodule" OR "vocal folds nodule" OR "vocal folds nodules" OR "vocal nodules" OR "vocal nodule" OR "vocal cord nodule" OR "vocal cord nodules" OR "vocal cords nodules" OR "vocal cords nodule" OR "vocal cords disorder" OR "vocal cords disorders" OR "vocal fold disorder" OR "vocal fold disorders" OR "vocal folds disorder" OR "vocal folds disorders" OR "vocal cord disorder" OR "vocal cord disorders" OR "Reinke edema" OR "Reinke's edema" OR "laryngeal polyp" OR "laryngeal polyps" OR leukoplakias OR "leukoplakic lesions" OR "leukoplakic lesion" OR leukokeratosis OR leukokeratoses)

57.3

(immunoexpression p53 OR immunoexpression ki67 OR p53 OR oncoprotein p53 OR TRP53 protein OR p53 tumor suppressor protein OR pp53 phosphoprotein OR TP53 protein OR cellular tumor antigen p53 OR p53 antigen OR Ki67 antigen OR MIB1 protein OR MIB1 antigen OR antigen Ki67 OR MIB1 monoclonal antibody) AND (preneoplastic laryngeal lesions OR preneoplastic laryngeal lesion OR laryngeal edemas OR laryngeal edema OR laryngeal neoplasms OR larynx neoplasms OR larynx neoplasm OR cancer of larynx OR larynx cancers OR laryngeal cancer OR laryngeal cancers OR larynx cancer OR larynx cancers OR cancer of the larynx OR papilloma OR papillomas OR squamous cell papilloma OR squamous cell papillomas OR papillomatosis OR papillomavirus type 16 OR human papillomatoses OR papillomavirus 16 OR HPV16 OR human papillomavirus type 16 OR papillomavirus type 18 OR human papillomatoses OR papillomavirus 18 OR HPV18 OR HPV 18 OR human papillomavirus type 18 OR vocal cyst OR laryngeal cyst OR vocal fold nodules OR vocal fold nodule OR vocal folds nodule OR vocal folds nodules OR vocal nodules OR vocal nodule OR vocal cord nodule OR vocal cord nodules OR vocal cords nodules OR vocal cords nodule OR vocal cords disorder OR vocal cords disorders OR vocal fold disorder OR vocal fold disorders OR vocal folds disorder OR vocal folds disorders OR vocal cord disorder OR vocal cord disorders OR Reinke edema OR Reinke's edema OR laryngeal polyp OR laryngeal polyps OR leukoplakias OR leukoplakic lesions OR leukoplakic lesion OR leukokeratosis OR leukokeratoses)

57.4

(immunoexpression p53 OR immunoexpression ki67 OR p53 OR oncoprotein p53 OR TRP53 protein OR p53 tumor suppressor protein OR pp53 phosphoprotein OR TP53 protein OR cellular tumor antigen p53 OR p53 antigen OR Ki67 antigen OR MIB1 protein OR MIB1 antigen OR antigen Ki67 OR MIB1 monoclonal antibody) AND (preneoplastic laryngeal lesion* OR laryngeal edema* OR laryngeal neoplasm* OR larynx neoplasm OR cancer of larynx OR larynx cancers OR laryngeal cancer* OR larynx cancer* OR cancer of the larynx OR papilloma* OR squamous cell papilloma* OR papillomatosis OR papillomavirus type 16 OR human papillomatoses OR papillomavirus 16 OR HPV16 OR human papillomavirus type 16 OR papillomavirus type 18 OR human papillomatoses OR papillomavirus 18 OR HPV18 OR HPV 18 OR human papillomavirus type 18 OR vocal cyst OR laryngeal cyst OR vocal fold* nodule* OR vocal nodules OR vocal nodule OR vocal cord* nodule* OR vocal cords disorder* OR vocal fold* disorder* OR vocal folds disorder OR vocal cord disorder* OR Reinke edema OR Reinke's edema OR laryngeal polyp* OR

leukoplakias OR leukoplakic lesions OR leukoplakic lesion OR leukokeratos*)

57.5

immunoexpression p53 OR immunoexpression ki67 OR p53 OR oncoprotein p53 OR TRP53 protein OR p53 tumor suppressor protein OR pp53 phosphoprotein OR TP53 protein OR cellular tumor antigen p53 OR p53 antigen OR Ki67 antigen OR MIB1 protein OR MIB1 antigen OR antigen Ki67 OR MIB1 monoclonal antibody AND preneoplastic laryngeal lesions OR preneoplastic laryngeal lesion OR laryngeal edemas OR laryngeal edema OR laryngeal neoplasms OR larynx neoplasms OR larynx neoplasm OR cancer of larynx OR larynx cancers OR laryngeal cancer OR laryngeal cancers OR larynx cancer OR larynx cancers OR cancer of the larynx OR papilloma OR papillomas OR squamous cell papilloma OR squamous cell papillomas OR papillomatosis OR papillomavirus type 16 OR human papillomatosis OR papillomavirus 16 OR HPV16 OR human papillomavirus type 16 OR papillomavirus type 18 OR human papillomatosis OR papillomavirus 18 OR HPV18 OR HPV 18 OR human papillomavirus type 18 OR vocal cyst OR laryngeal cyst OR vocal fold nodules OR vocal fold nodule OR vocal folds nodule OR vocal folds nodules OR vocal nodules OR vocal nodule OR vocal cord nodule OR vocal cord nodules OR vocal cords nodules OR vocal cords nodule OR vocal cords disorder OR vocal cords disorders OR vocal fold disorder OR vocal fold disorders OR vocal folds disorder OR vocal folds disorders OR vocal cord disorder OR vocal cord disorders OR Reinke edema OR Reinke's edema OR laryngeal polyp OR laryngeal polyps OR leukoplakias OR leukoplakic lesions OR leukoplakic lesion OR leukokeratosis OR leukokeratoses

58.1

((complexity theory) OR chaos OR (complexity science) OR (complexity thinking) OR (complexity system) OR (complexity systems) OR (chaos theory) OR (chaos theories) OR (nonlinear model) OR (nonlinear models) OR (non-linear models) OR (non-linear model) OR (non linear models) OR (non linear model)) AND ((management in healthcare organization) OR (management in healthcare organizations) OR (health manager) OR (nurse administrator) OR (nurse administrators) OR (nurse executives) OR (nurse executive) OR (nurse managers) OR (nurse manager))

58.2

("complexity theory" OR chaos OR "complexity science" OR "complexity thinking" OR "complexity system" OR "complexity systems" OR "chaos theory" OR "chaos theories" OR "nonlinear model" OR "nonlinear models" OR "non-linear models" OR "non-linear model" OR "non linear models" OR "non linear model") AND ("management in healthcare organization" OR "management in healthcare organizations" OR "health manager" OR "nurse administrator" OR "nurse administrators" OR "nurse executives" OR "nurse executive" OR "nurse managers" OR "nurse manager")

58.3

(complexity theory OR chaos OR complexity science OR complexity thinking OR complexity system OR complexity systems OR chaos theory OR chaos theories OR nonlinear model OR nonlinear models OR non-linear models OR non-linear model OR non linear models OR non linear model) AND (management in healthcare organization OR management in healthcare organizations OR health manager OR nurse administrator OR nurse administrators OR nurse executives OR nurse executive OR nurse managers OR nurse manager)

58.4

(complexity theory OR chaos OR complexity science OR complexity thinking OR complexity system* OR chaos theor* OR nonlinear model* OR non-linear model*I OR non linear model*) AND (management in healthcare organization * OR health manager OR nurse administrator* OR nurse executive* OR nurse manager*)

58.5

complexity theory OR chaos OR complexity science OR complexity thinking OR complexity system OR complexity systems OR chaos theory OR chaos theories OR nonlinear model OR nonlinear models OR non-linear models OR non-linear model OR non linear models OR non linear model AND management in healthcare organization OR management in healthcare organizations OR health manager OR nurse administrator OR nurse administrators OR nurse executives OR nurse executive OR nurse managers OR nurse manager

59.1

((operative surgical procedure) OR (operative surgical procedures) OR (operative procedures) OR (operative procedure) OR (ghost surgery) OR (surgical antibacterial prophylaxis) OR (surgical prophylaxis) OR surgery OR surgeries) AND ((anti-bacterial agents) OR (anti bacterial agents) OR (antibacterial agents) OR antibiotics OR (bacteriocidal agents) OR bacteriocides OR (anti-mycobacterial agents) OR (anti mycobacterial agents) OR (antimycobacterial agents) OR (antibiotic prophylaxis) OR (antibiotic premedication) OR (antibiotic premedications)) AND ((liver transplantation) OR (liver transplantations) OR (hepatic transplantation) OR (liver grafting) OR (liver graftings) OR (hepatic transplantation) OR (hepatic transplantations))

59.2

("operative surgical procedure" OR "operative surgical procedures" OR "operative procedures" OR "operative procedure" OR "ghost surgery" OR "surgical antibacterial prophylaxis" OR "surgical prophylaxis" OR surgery OR surgeries) AND ("anti-bacterial agents" OR "anti bacterial agents" OR "antibacterial agents" OR antibiotics OR "bacteriocidal agents" OR bacteriocides OR "anti-mycobacterial agents" OR "anti mycobacterial agents" OR "antimycobacterial agents" OR "antibiotic prophylaxis" OR "antibiotic premedication" OR "antibiotic premedications") AND ("liver transplantation" OR "liver transplantations" OR "hepatic transplantation" OR "liver grafting" OR "liver graftings" OR "hepatic transplantation" OR "hepatic transplantations")

59.3

(operative surgical procedure OR operative surgical procedures OR operative procedures OR operative procedure OR ghost surgery OR surgical antibacterial prophylaxis OR surgical prophylaxis OR surgery OR surgeries) AND (anti-bacterial agents OR anti bacterial agents OR antibacterial agents OR antibiotics OR bacteriocidal agents OR bacteriocides OR anti-mycobacterial agents OR anti mycobacterial agents OR antimycobacterial agents OR antibiotic prophylaxis OR antibiotic premedication OR antibiotic premedications) AND (liver transplantation OR liver transplantations OR hepatic transplantation OR liver grafting OR liver graftings OR hepatic transplantation OR hepatic transplantations)

59.4

(operative surgical procedure* OR operative procedure* OR ghost surgery OR surgical antibacterial prophylaxis OR surgical prophylaxis OR surger*) AND (anti-bacterial agents OR anti bacterial agents OR antibacterial agents OR antibiotics OR bacteriocidal agents OR bacteriocides OR anti-mycobacterial agents OR anti mycobacterial agents OR antimycobacterial agents OR antibiotic prophylaxis OR antibiotic premedication*) AND (liver transplantation* OR hepatic transplantation* OR liver grafting*)

59.5

operative surgical procedure OR operative surgical procedures OR operative procedures OR operative procedure OR ghost surgery OR surgical antibacterial prophylaxis OR surgical prophylaxis OR surgery OR surgeries AND anti-bacterial agents OR anti bacterial agents OR antibacterial agents OR antibiotics OR bacteriocidal agents OR bacteriocides OR anti-mycobacterial agents OR anti mycobacterial agents OR antimycobacterial agents OR antibiotic

prophylaxis OR antibiotic premedication OR antibiotic premedications AND liver transplantation OR liver transplantations OR hepatic transplantation OR liver grafting OR liver graftings OR hepatic transplantation OR hepatic transplantations

60.1

((granulomatous disease) OR (granulomatous diseases) OR (respiratory tract granulomas) OR (respiratory tract granuloma) OR leprosius OR (hansen disease) OR (hansens disease) OR tuberculoses OR (Kochs disease) OR (Kochs disease) OR (Koch disease) OR syphilis OR (great pox) OR histoplasmoses OR paracoccidioidomycoses OR (South American blastomycosis) OR blastomycoses OR (North American blastomycosis) OR (Gilchrist disease) OR (Gilchrists disease) OR leishmaniasis OR (mucocutaneous leishmaniasis) OR (mucocutaneous leishmaniasis) OR sarcoidoses OR (Besnier Boeck Schaumann syndrome) OR (Boeck disease) OR (Schaumanns syndrome) OR (Schaumanns syndromes) OR (Boecks sarcoid) OR (Boeck sarcoid) OR (Schaumann disease) OR (Schaumann syndrome) OR (Besnier Boeck disease) OR (Boecks disease)) AND ((speech pathology) OR (speech pathologies) OR (speech therapy) OR (speech therapies) OR (voice training) OR (voice trainings) OR (voice therapy) OR (voice therapies) OR (vocal treatment) OR (vocal treatments) OR (voice treatment) OR (voice treatments) OR (vocal rehabilitation) OR (vocal rehabilitations) OR (voice rehabilitation) OR (voice rehabilitations) OR (speech language pathology) OR (speech language pathologies) OR (speech language therapy) OR (speech language therapies))

60.2

("granulomatous disease" OR "granulomatous diseases" OR "respiratory tract granulomas" OR "respiratory tract granuloma" OR leprosius OR "hansen disease" OR "hansens disease" OR tuberculoses OR "Kochs disease" OR "Kochs disease" OR "Koch disease" OR syphilis OR "great pox" OR histoplasmoses OR paracoccidioidomycoses OR "South American blastomycosis" OR blastomycoses OR "North American blastomycosis" OR "Gilchrist disease" OR "Gilchrists disease" OR leishmaniasis OR "mucocutaneous leishmaniasis" OR "mucocutaneous leishmaniasis" OR sarcoidoses OR "Besnier Boeck Schaumann syndrome" OR "Boeck disease" OR "Schaumanns syndrome" OR "Schaumanns syndromes" OR "Boecks sarcoid" OR "Boeck sarcoid" OR "Schaumann disease" OR "Schaumann syndrome" OR "Besnier Boeck disease" OR "Boecks disease") AND ("speech pathology" OR "speech pathologies" OR "speech therapy" OR "speech therapies" OR "voice training" OR "voice trainings" OR "voice therapy" OR "voice therapies" OR "vocal treatment" OR "vocal treatments" OR "voice treatment" OR "voice treatments" OR "vocal rehabilitation" OR "vocal rehabilitations" OR "voice rehabilitation" OR "voice rehabilitations" OR "speech language pathology" OR "speech language pathologies" OR "speech language therapy" OR "speech language therapies")

60.3

(granulomatous disease OR granulomatous diseases OR respiratory tract granulomas OR respiratory tract granuloma OR leprosius OR hansen disease OR hansens disease OR tuberculoses OR Kochs disease OR Kochs disease OR Koch disease OR syphilis OR great pox OR histoplasmoses OR paracoccidioidomycoses OR South American blastomycosis OR blastomycoses OR North American blastomycosis OR Gilchrist disease OR Gilchrists disease OR leishmaniasis OR mucocutaneous leishmaniasis OR mucocutaneous leishmaniasis OR sarcoidoses OR Besnier Boeck Schaumann syndrome OR Boeck disease OR Schaumanns syndrome OR Schaumanns syndromes OR Boecks sarcoid OR Boeck sarcoid OR Schaumann disease OR Schaumann syndrome OR Besnier Boeck disease OR Boecks disease) AND (speech pathology OR speech pathologies OR speech therapy OR speech therapies OR voice training OR voice trainings OR voice therapy OR voice therapies OR vocal treatment OR vocal treatments OR voice treatment OR voice treatments OR vocal rehabilitation OR vocal rehabilitations OR voice rehabilitation OR voice rehabilitations OR speech language pathology OR speech language pathologies OR speech language therapy OR speech language therapies)

60.4

(granulomatous disease* OR respiratory tract granuloma* OR leprosy OR hansen disease* OR tuberculosis OR Kochs disease* Koch disease OR syphilis OR great pox OR histoplasmoses OR paracoccidioidomycoses OR South American blastomycosis OR blastomycoses OR North American blastomycosis OR Gilchrist disease OR Gilchrist's disease OR leishmaniasis OR mucocutaneous leishmaniasis OR mucocutaneous leishmaniasis OR sarcoidosis OR Besnier Boeck Schaumann syndrome OR Boeck disease OR Schaumann's syndrome* OR Boeck's sarcoid OR Boeck sarcoid OR Schaumann disease OR Schaumann syndrome OR Besnier Boeck disease OR Boeck's disease) AND (speech patholog* OR speech therap* OR voice training* OR voice therap* OR vocal treatment* OR voice treatment OR vocal rehabilitation* OR voice rehabilitation* OR speech language pathology* OR speech language therap*)

60.5

granulomatous disease OR granulomatous diseases OR respiratory tract granulomas OR respiratory tract granuloma OR leprosy OR hansen disease OR hansen's disease OR tuberculosis OR Kochs disease OR Koch's disease OR Koch disease OR syphilis OR great pox OR histoplasmoses OR paracoccidioidomycoses OR South American blastomycosis OR blastomycoses OR North American blastomycosis OR Gilchrist disease OR Gilchrist's disease OR leishmaniasis OR mucocutaneous leishmaniasis OR mucocutaneous leishmaniasis OR sarcoidosis OR Besnier Boeck Schaumann syndrome OR Boeck disease OR Schaumann's syndrome OR Schaumann's syndromes OR Boeck's sarcoid OR Boeck sarcoid OR Schaumann disease OR Schaumann syndrome OR Besnier Boeck disease OR Boeck's disease AND speech pathology OR speech pathologies OR speech therapy OR speech therapies OR voice training OR voice trainings OR voice therapy OR voice therapies OR vocal treatment OR vocal treatments OR voice treatment OR voice treatments OR vocal rehabilitation OR vocal rehabilitations OR voice rehabilitation OR voice rehabilitations OR speech language pathology OR speech language pathologies OR speech language therapy OR speech language therapies

61.1

((obstructive sleep apnea) OR (syndrome sleep apnea obstructive) OR (obstructive sleep apnea) OR (obstructive sleep apnea syndrome) OR (upper airway resistance sleep apnea syndrome)) AND ((bariatric surgery) OR (bariatric surgeries)) AND (polysomnographies OR (sleep monitoring) OR somnography OR somnographies)

61.2

("obstructive sleep apneas" OR "syndrome sleep apnea obstructive" OR "obstructive sleep apnea" OR "obstructive sleep apnea syndrome" OR "upper airway resistance sleep apnea syndrome") AND ("bariatric surgery" OR "bariatric surgeries") AND (polysomnographies OR "sleep monitoring" OR somnography OR somnographies)

61.3

(obstructive sleep apneas OR syndrome sleep apnea obstructive OR obstructive sleep apnea OR obstructive sleep apnea syndrome OR upper airway resistance sleep apnea syndrome) AND (bariatric surgery OR bariatric surgeries) AND (polysomnographies OR sleep monitoring OR somnography OR somnographies)

61.4

(obstructive sleep apnea* OR syndrome sleep apnea obstructive OR upper airway resistance sleep apnea syndrome) AND (bariatric surger*) AND (polysomnographies OR sleep monitoring OR somnography OR somnographies)

61.5

obstructive sleep apneas OR syndrome sleep apnea obstructive OR obstructive sleep apnea

OR obstructive sleep apnea syndrome OR upper airway resistance sleep apnea syndrome AND bariatric surgery OR bariatric surgeries AND polysomnographies OR sleep monitoring OR somnography OR somnographies

62.1

((burn units) OR (burn centers) AND surgery AND (plastic statistics on sequelae) AND (disability or disabilities)

62.2

("burn units" OR "burn centers") AND surgery AND ("plastic statistics on sequelae") AND (disability OR disabilities)

62.3

(burn units OR burn centers) AND surgery AND (plastic statistics on sequelae) AND (disability or disabilities)

62.4

(burn units OR burn centers) AND surgery AND (plastic statistics on sequelae AND disability*)

62.5

burn units OR burn centers AND surgery AND plastic statistics on sequelae AND disability OR disabilities

63.1

((platelet aggregation inhibitors) OR (blood platelet antiaggregants) OR (platelet antiaggregants) OR (blood platelet aggregation inhibitors) OR (platelet inhibitors) OR (antiplatelet agents) OR (antiplatelet drugs) OR (blood platelet antagonists)) AND ((endovascular intervention) OR (endovascular interventions))

63.2

("platelet aggregation inhibitors" OR "blood platelet antiaggregants" OR "platelet antiaggregants" OR "blood platelet aggregation inhibitors" OR "platelet inhibitors" OR "antiplatelet agents" OR "antiplatelet drugs" OR "blood platelet antagonists") AND ("endovascular intervention" OR "endovascular interventions")

63.3

(platelet aggregation inhibitors OR blood platelet antiaggregants OR platelet antiaggregants OR blood platelet aggregation inhibitors OR platelet inhibitors OR antiplatelet agents OR antiplatelet drugs OR blood platelet antagonists) AND (endovascular intervention OR endovascular interventions)

63.4

(platelet aggregation inhibitors OR blood platelet antiaggregants OR platelet antiaggregants OR blood platelet aggregation inhibitors OR platelet inhibitors OR antiplatelet agents OR antiplatelet drugs OR blood platelet antagonists) AND (endovascular intervention*)

63.5

platelet aggregation inhibitors OR blood platelet antiaggregants OR platelet antiaggregants OR blood platelet aggregation inhibitors OR platelet inhibitors OR antiplatelet agents OR antiplatelet drugs OR blood platelet antagonists
AND endovascular intervention OR endovascular interventions

64.1

((acquired immunodeficiency syndrome) OR aids OR hiv OR (human immunodeficiency virus)) AND ((vulnerable population) OR (sensitive population) OR (sensate population group)) AND (adult OR adults)

66.2

("acquired immunodeficiency syndrome") OR aids OR hiv OR ("human immunodeficiency virus") AND ("vulnerable population" OR "sensitive population" OR "sensate population group") AND (adult OR adults)

64.3

(acquired immunodeficiency syndrome OR aids OR hiv OR human immunodeficiency virus) AND (vulnerable population OR sensitive population OR sensate population group) AND (adult OR adults)

64.4

(acquired immunodeficiency syndrome OR aids OR hiv OR human immunodeficiency virus) AND (vulnerable population OR sensitive population OR sensate population group) AND (adult*)

64.5

acquired immunodeficiency syndrome OR aids OR hiv OR human immunodeficiency virus AND vulnerable population OR sensitive population OR sensate population group AND adult OR adults

65.1

(stroke OR (cerebral stroke) OR (brain vascular accident) OR (acute cerebrovascular accident)) AND (complications OR sequels OR sequelae) AND (mortality OR death)

65.2

(stroke OR "cerebral stroke" OR "brain vascular accident" OR "acute cerebrovascular accident") AND (complications OR sequels OR sequelae) AND (mortality OR death)

65.3

(stroke OR cerebral stroke OR brain vascular accident OR acute cerebrovascular accident) AND (complications OR sequels OR sequelae) AND (mortality OR death)

65.4

(stroke OR cerebral stroke OR brain vascular accident OR acute cerebrovascular accident) AND (complication* OR sequel*) AND (mortality OR death)

65.5

stroke OR cerebral stroke OR brain vascular accident OR acute cerebrovascular accident AND complications OR sequels OR sequelae AND mortality OR death

66.1

(hypertension OR (high blood pressure) OR (high blood pressures)) AND (complications OR (associated disease) OR (coexistent conditions) OR sequels OR (concomitant conditions) OR (concomitant disease) OR sequelae OR (associated conditions) OR (coexistent disease)) AND (cardiomegaly OR (heart enlargement) OR (enlarged heart) OR (cardiac hypertrophy) OR (heart hypertrophy))

66.2

(hypertension OR "high blood pressure" OR "high blood pressures") AND (complications OR "associated disease" OR "coexistent conditions" OR sequels OR "concomitant conditions" OR

“concomitant disease” OR sequelae OR “associated conditions” OR “coexistent disease”) AND (cardiomegaly OR “heart enlargement” OR “enlarged heart” OR “cardiac hypertrophy” OR “heart hypertrophy”)

66.3

(hypertension OR high blood pressure OR high blood pressures) AND (complications OR associated disease OR coexistent conditions OR sequels OR concomitant conditions OR concomitant disease OR sequelae OR associated conditions OR coexistent disease) AND (cardiomegaly OR heart enlargement OR enlarged heart OR cardiac hypertrophy OR heart hypertrophy)

66.4

(hypertension OR high blood pressure*) AND (complications OR associated disease OR coexistent conditions OR sequels OR concomitant conditions OR concomitant disease OR sequelae OR associated conditions OR coexistent disease) AND (cardiomegaly OR heart enlargement OR enlarged heart OR cardiac hypertrophy OR heart hypertrophy)

66.5

hypertension OR high blood pressure OR high blood pressures AND complications OR associated disease OR coexistent conditions OR sequels OR concomitant conditions OR concomitant disease OR sequelae OR associated conditions OR coexistent disease AND cardiomegaly OR heart enlargement OR enlarged heart OR cardiac hypertrophy OR heart hypertrophy

67.1

((lung grafting) OR (lung graftings) OR (lung transplantation) OR (lung transplantations)) AND (sequels OR sequeale OR complications)

67.2

(“lung grafting” OR “lung graftings” OR “lung transplantation” OR “lung transplantations”) AND (sequels OR sequeale OR complications)

67.3

(lung grafting OR lung graftings OR lung transplantation OR lung transplantations) AND (sequels OR sequeale OR complications)

67.4

(lung grafting* OR lung transplantation*) AND (sequel* OR complications)

67.5

lung grafting OR lung graftings OR lung transplantation OR lung transplantations AND sequels OR sequeale OR complications

68.1

((lung neoplasms) OR (pulmonary neoplasms) OR (lung neoplasm) OR (pulmonary neoplasm)) AND (surgery OR (general surgery)) AND (complications OR sequels OR sequelae)

68.2

(“lung neoplasms” OR “pulmonary neoplasms” OR “lung neoplasm” OR “pulmonary neoplasm”) AND (surgery OR “general surgery”) AND (complications OR sequels OR sequelae)

68.3

(lung neoplasms OR pulmonary neoplasms OR lung neoplasm OR pulmonary neoplasm) AND (surgery OR general surgery) AND (complications OR sequels OR sequelae)

68.4
 (lung neoplasm* OR pulmonary neoplasm*) AND (surgery OR general surgery) AND
 (complications OR sequel*)

68.5
 lung neoplasms OR pulmonary neoplasms OR lung neoplasm OR pulmonary neoplasm AND
 surgery OR general surgery
 AND complications OR sequels OR sequelae

69.1
 (copd OR (chronic obstructive pulmonary disease)) AND ((risk factors) AND (complications OR
 associated disease) OR (coexistent conditions) OR sequels or sequelae)

69.2
 (copd OR "chronic obstructive pulmonary disease") AND ("risk factors") AND (complications OR
 "associated disease" OR "coexistent conditions" OR sequels OR sequelae)

69.3
 (copd OR chronic obstructive pulmonary disease) AND (risk factors) AND (complications OR
 associated disease OR coexistent conditions OR sequels OR sequelae)

69.4
 (copd OR chronic obstructive pulmonary disease) AND (risk factors) AND (complications OR
 associated disease OR coexistent conditions OR sequel*)

69.5
 copd OR chronic obstructive pulmonary disease AND risk factors AND complications OR
 associated disease OR coexistent conditions OR sequels OR sequelae

70.1
 ((breathing exercises) OR (breathing exercise) OR (respiratory muscle training) OR Qigong OR (Qi
 Gong) OR (Ch'i Kung)) AND (thoracotomy OR thoracotomies)

70.2
 ("breathing exercises" OR "breathing exercise" OR "respiratory muscle training" OR Qigong OR "Qi
 Gong" OR "Ch'i Kung") AND (thoracotomy OR thoracotomies)

70.3
 (breathing exercises OR breathing exercise OR respiratory muscle training OR Qigong OR Qi
 Gong OR Ch'i Kung) AND (thoracotomy OR thoracotomies)

70.4
 (breathing exercise* OR respiratory muscle training OR Qigong OR Qi Gong OR Ch'i Kung) AND
 thoracotom*

70.5
 breathing exercises OR breathing exercise OR respiratory muscle training OR Qigong OR Qi Gong
 OR Ch'i Kung
 AND thoracotomy OR thoracotomies

71.1
 (sphenoid sinus) AND ((magnetic resonance imaging) OR (NMR imaging) OR zeugmatography
 OR (MR tomography) OR (NMR tomography) OR (proton spin tomography) OR (magnetization

transfer contrast imaging) OR (MRI scans) OR (MRI scan) OR fMRI OR (functional MRIs) OR (functional magnetic resonance imaging) OR (chemical shift imaging))

71.2

“sphenoid sinus” AND (“magnetic resonance imaging” OR “NMR imaging” OR zeugmatography OR “MR tomography” OR “NMR tomography” OR “proton spin tomography” OR “magnetization transfer contrast imaging” OR “MRI scans” OR “MRI scan” OR fMRI OR “functional MRIs” OR “functional magnetic resonance imaging” OR “chemical shift imaging”)

71.3

(sphenoid sinus) AND (magnetic resonance imaging OR NMR imaging OR zeugmatography OR MR tomography OR NMR tomography OR proton spin tomography OR magnetization transfer contrast imaging OR MRI scans OR MRI scan or fMRI OR functional MRIs OR functional magnetic resonance imaging OR chemical shift imaging)

71.4

(sphenoid sinus) AND (magnetic resonance imaging OR NMR imaging OR zeugmatography OR MR tomography OR NMR tomography OR proton spin tomography OR magnetization transfer contrast imaging OR MRI scan* OR fMRI OR functional MRIs OR functional magnetic resonance imaging OR chemical shift imaging)

71.5

sphenoid sinus AND magnetic resonance imaging OR NMR imaging OR zeugmatography OR MR tomography OR NMR tomography OR proton spin tomography OR magnetization transfer contrast imaging OR MRI scans OR MRI scan OR fMRI OR functional MRIs OR functional magnetic resonance imaging OR chemical shift imaging

72.1

((sleep apnea syndromes) OR (sleep apnea syndrome) OR (sleep apnea) OR (sleep apneas) OR (sleep disordered breathing)) AND (children OR child) AND (carbohydrate metabolism)

72.2

(“sleep apnea syndromes” OR “sleep apnea syndrome” OR “sleep apnea” OR “sleep apneas” OR “sleep disordered breathing”) AND (children OR child) AND (“carbohydrate metabolism”)

72.3

(sleep apnea syndromes OR sleep apnea syndrome OR sleep apnea OR sleep apneas OR sleep disordered breathing) AND (children OR child) AND (carbohydrate metabolism)

72.4

(sleep apnea syndrome* OR sleep apnea* OR sleep disordered breathing) AND child* AND (carbohydrate metabolism)

72.5

sleep apnea syndromes OR sleep apnea syndrome OR sleep apnea OR sleep apneas OR sleep disordered breathing
AND children OR child AND carbohydrate metabolism

73.1

(miRNAs OR miRNA OR (micro RNA) OR (RNA micro) OR microRNA OR (primary microRNA) OR (microRNA primary) OR (primary miRNA) OR (miRNA primary) OR pri-miRNA OR (pri miRNA) OR (RNA small temporal) OR (temporal RNA small) OR stRNA OR (small temporal RNA) OR pre-

miRNA OR (pre miRNA)) AND ((lung adenocarcinoma) OR (adenocarcinoma of lung))

73.2

(miRNAs OR miRNA OR "micro RNA" OR "RNA micro" OR microRNA OR "primary microRNA" OR "microRNA primary" OR "primary miRNA" OR "miRNA primary" OR pri-miRNA OR "pri miRNA" OR "RNA small temporal" OR "temporal RNA small" OR stRNA OR "small temporal RNA" OR pre-miRNA OR "pre miRNA") AND ("lung adenocarcinoma" OR "adenocarcinoma of lung")

73.3

(miRNAs OR miRNA OR micro RNA OR RNA micro OR microRNA OR primary microRNA OR microRNA primary OR primary miRNA OR miRNA primary OR pri-miRNA OR pri miRNA OR RNA small temporal OR temporal RNA small OR stRNA OR small temporal RNA OR pre-miRNA OR pre miRNA) AND (lung adenocarcinoma OR adenocarcinoma of lung)

73.4

(miRNA* OR micro RNA OR RNA micro OR microRNA OR primary microRNA OR microRNA primary OR primary miRNA OR miRNA primary OR pri-miRNA OR pri miRNA OR RNA small temporal OR temporal RNA small OR stRNA OR small temporal RNA OR pre-miRNA OR pre miRNA) AND (lung adenocarcinoma OR adenocarcinoma of lung)

73.5

miRNAs OR miRNA OR micro RNA OR RNA micro OR microRNA OR primary microRNA OR microRNA primary OR primary miRNA OR miRNA primary OR pri-miRNA OR pri miRNA OR RNA small temporal OR temporal RNA small OR stRNA OR small temporal RNA OR pre-miRNA OR pre miRNA AND lung adenocarcinoma OR adenocarcinoma of lung

74.1

((attention deficit hyperactivity disorder) OR (attention deficit disorders with hyperactivity) OR (attention deficit hyperactivity disorders) OR (hyperkinetic syndrome) OR (minimal brain dysfunction) OR (attention deficit disorder) OR (attention deficit disorders)) AND (child or children) AND (zoloft OR altruline OR (parke davis brand of sertraline hydrochloride) OR lustral OR (pfizer brand of sertraline hydrochloride) OR (roerig brand of sertraline hydrochloride) OR (apo-sertraline OR (apo sertraline) OR (apotex brand of sertraline hydrochloride) OR aremis OR (esteve brand of sertraline hydrochloride) OR besitrán OR sealdin OR (lacer brand of sertraline hydrochloride) OR gladem OR (Boehringer Ingelheim brand of sertraline hydrochloride) OR novo-sertraline OR (novo sertraline) OR (novopharm brand of sertraline hydrochloride) OR ratio-sertraline OR (ratio sertraline) OR (ratiopharm brand of sertraline hydrochloride) OR rhoxal-sertraline OR (rhoxal sertraline) OR (rhoxalpharma brand of sertraline hydrochloride) OR (sertraline hydrochloride) OR gen-sertraline OR (gen sertraline) OR (genpharm brand of sertraline hydrochloride))

74.2

("attention deficit hyperactivity disorder" OR "attention deficit disorders with hyperactivity" OR "attention deficit hyperactivity disorders" OR "hyperkinetic syndrome" OR "minimal brain dysfunction" OR "attention deficit disorder" OR "attention deficit disorders") AND (child or children" AND (zoloft OR altruline OR "parke davis brand of sertraline hydrochloride" OR lustral OR "pfizer brand of sertraline hydrochloride" OR "roerig brand of sertraline hydrochloride" OR "apo-sertraline OR "apo sertraline" OR "apotex brand of sertraline hydrochloride" OR aremis OR "esteve brand of sertraline hydrochloride" OR besitrán OR sealdin OR "lacer brand of sertraline hydrochloride" OR gladem OR "Boehringer Ingelheim brand of sertraline hydrochloride" OR novo-sertraline OR "novo sertraline" OR "novopharm brand of sertraline hydrochloride" OR ratio-sertraline OR "ratio sertraline" OR "ratiopharm brand of sertraline hydrochloride" OR rhoxal-sertraline OR "rhoxal sertraline" OR "rhoxalpharma brand of sertraline hydrochloride" OR "sertraline hydrochloride" OR

OR gen-sertraline OR "gen sertraline" OR "genpharm brand of sertraline hydrochloride"

74.3

(attention deficit hyperactivity disorder OR attention deficit disorders with hyperactivity OR attention deficit hyperactivity disorders OR hyperkinetic syndrome OR minimal brain dysfunction OR attention deficit disorder OR attention deficit disorders) AND (child or children) AND (zoloft OR altruline OR parke davis brand of sertraline hydrochloride OR lustral OR pfizer brand of sertraline hydrochloride OR roerig brand of sertraline hydrochloride OR apo-sertraline OR apo sertraline OR apotex brand of sertraline hydrochloride OR aremis OR esteve brand of sertraline hydrochloride OR besitran OR sealdin OR lacer brand of sertraline hydrochloride OR gladem OR Boehringer Ingelheim brand of sertraline hydrochloride OR novo-sertraline OR novo sertraline OR novopharm brand of sertraline hydrochloride OR ratio-sertraline OR ratio sertraline OR ratiopharm brand of sertraline hydrochloride OR rhoxal-sertraline OR rhoxal sertraline OR rhoxalpharma brand of sertraline hydrochloride OR sertraline hydrochloride OR gen-sertraline OR gen sertraline OR genpharm brand of sertraline hydrochloride)

74.4

(attention deficit hyperactivity disorder OR attention deficit disorders with hyperactivity OR attention deficit hyperactivity disorders OR hyperkinetic syndrome OR minimal brain dysfunction OR attention deficit disorder*) AND child* AND (zoloft OR altruline OR parke davis brand of sertraline hydrochloride OR lustral OR pfizer brand of sertraline hydrochloride OR roerig brand of sertraline hydrochloride OR apo-sertraline OR apo sertraline OR apotex brand of sertraline hydrochloride OR aremis OR esteve brand of sertraline hydrochloride OR besitran OR sealdin OR lacer brand of sertraline hydrochloride OR gladem OR Boehringer Ingelheim brand of sertraline hydrochloride OR novo-sertraline OR novo sertraline OR novopharm brand of sertraline hydrochloride OR ratio-sertraline OR ratio sertraline OR ratiopharm brand of sertraline hydrochloride OR rhoxal-sertraline OR rhoxal sertraline OR rhoxalpharma brand of sertraline hydrochloride OR sertraline hydrochloride OR gen-sertraline OR gen sertraline OR genpharm brand of sertraline hydrochloride)

74.5

attention deficit hyperactivity disorder OR attention deficit disorders with hyperactivity OR attention deficit hyperactivity disorders OR hyperkinetic syndrome OR minimal brain dysfunction OR attention deficit disorder OR attention deficit disorders AND child or children AND zoloft OR altruline OR parke davis brand of sertraline hydrochloride OR lustral OR pfizer brand of sertraline hydrochloride OR roerig brand of sertraline hydrochloride OR apo-sertraline OR apo sertraline OR apotex brand of sertraline hydrochloride OR aremis OR esteve brand of sertraline hydrochloride OR besitran OR sealdin OR lacer brand of sertraline hydrochloride OR gladem OR Boehringer Ingelheim brand of sertraline hydrochloride OR novo-sertraline OR novo sertraline OR novopharm brand of sertraline hydrochloride OR ratio-sertraline OR ratio sertraline OR ratiopharm brand of sertraline hydrochloride OR rhoxal-sertraline OR rhoxal sertraline OR rhoxalpharma brand of sertraline hydrochloride OR sertraline hydrochloride OR gen-sertraline OR gen sertraline OR genpharm brand of sertraline hydrochloride

75.1

((urinary bladder neoplasm) OR (bladder tumors) OR (bladder tumor) OR (bladder neoplasms) OR (bladder neoplasm) OR (urinary bladder cancer) OR (cancer of bladder) OR (cancer of the bladder) OR (bladder cancer) OR (bladder cancers)) AND ((occupational health) OR (industrial hygiene) OR (industrial health) OR (occupational safety) OR (employee health)) AND ((occupational disease) OR (occupational illnesses) OR (occupational illness) OR (occupational diseases))

75.2

("urinary bladder neoplasm" OR "bladder tumors" OR "bladder tumor" OR "bladder neoplasms" OR "bladder neoplasm" OR "urinary bladder cancer" OR "cancer of bladder" OR "cancer of the bladder" OR "bladder cancer" OR "bladder cancers") AND ("occupational health" OR "industrial hygiene" OR "industrial health" OR "occupational safety" OR "employee health") AND ("occupational disease" OR "occupational illnesses" OR "occupational illness" OR "occupational diseases")

75.3

(urinary bladder neoplasm OR bladder tumors OR bladder tumor OR bladder neoplasms OR bladder neoplasm OR urinary bladder cancer OR cancer of bladder OR cancer of the bladder OR bladder cancer OR bladder cancers) AND (occupational health OR industrial hygiene OR industrial health OR occupational safety OR employee health) AND (occupational disease OR occupational illnesses OR occupational illness OR occupational diseases)

75.4

(urinary bladder neoplasm OR bladder tumor* OR bladder neoplasm* OR urinary bladder cancer OR cancer of bladder OR cancer of the bladder OR bladder cancer*) AND (occupational health OR industrial hygiene OR industrial health OR occupational safety OR employee health) AND (occupational disease* OR occupational illness*)

75.5

urinary bladder neoplasm OR bladder tumors OR bladder tumor OR bladder neoplasms OR bladder neoplasm OR urinary bladder cancer OR cancer of bladder OR cancer of the bladder OR bladder cancer OR bladder cancers AND occupational health OR industrial hygiene OR industrial health OR occupational safety OR employee health AND occupational disease OR occupational illnesses OR occupational illness OR occupational diseases

76.1

((neck neoplasms head) OR (cancer of head and neck) OR (head and neck cancer) OR (cancer of the head and neck) OR (upper aerodigestive tract neoplasms) OR (UADT neoplasms) OR (UADT neoplasm) OR (head neoplasms) OR (neck neoplasms) OR (cancer of head) OR (head cancer) OR (cancer of the head) OR (cancer of neck) OR (neck cancer) OR (cancer of the neck)) AND ((occupational health) OR (industrial hygiene) OR (industrial health) OR (occupational safety) OR (employee health)) AND ((occupational disease) OR (occupational illnesses) OR (occupational illness) OR (occupational diseases))

76.2

("neck neoplasms head" OR "cancer of head and neck" OR "head and neck cancer" OR "cancer of the head and neck" OR "upper aerodigestive tract neoplasms" OR "UADT neoplasms" OR "UADT neoplasm" OR "head neoplasms" OR "neck neoplasms" OR "cancer of head" OR "head cancer" OR "cancer of the head" OR "cancer of neck" OR "neck cancer" OR "cancer of the neck") AND ("occupational health" OR "industrial hygiene" OR "industrial health" OR "occupational safety" OR "employee health") AND ("occupational disease" OR "occupational illnesses" OR "occupational illness" OR "occupational diseases")

76.3

(neck neoplasms head OR cancer of head and neck OR head and neck cancer OR cancer of the head and neck OR upper aerodigestive tract neoplasms OR UADT neoplasms OR UADT neoplasm OR head neoplasms OR neck neoplasms OR cancer of head OR head cancer OR cancer of the head OR cancer of neck OR neck cancer OR cancer of the neck) AND (occupational health OR industrial hygiene OR industrial health OR occupational safety OR employee health) AND (occupational disease OR occupational illnesses OR occupational illness OR occupational diseases)

76.4

(neck neoplasms head OR cancer of head and neck OR head and neck cancer OR cancer of the head and neck OR upper aerodigestive tract neoplasms OR UADT neoplasm* OR head neoplasm* OR cancer of head OR head cancer OR cancer of the head OR cancer of neck OR neck cancer OR cancer of the neck) AND (occupational health OR industrial hygiene OR industrial health OR occupational safety OR employee health) AND (occupational disease* OR occupational illness*)

76.5

neck neoplasms head OR cancer of head and neck OR head and neck cancer OR cancer of the head and neck OR upper aerodigestive tract neoplasms OR UADT neoplasms OR UADT neoplasm OR head neoplasms OR neck neoplasms OR cancer of head OR head cancer OR cancer of the head OR cancer of neck OR neck cancer OR cancer of the neck AND occupational health OR industrial hygiene OR industrial health OR occupational safety OR employee health AND occupational disease OR occupational illnesses OR occupational illness OR occupational diseases

77.1

(humans OR human OR (modern man) OR (homo sapiens) OR man) AND (bioethics OR (health care ethics) OR (biomedical ethics)) AND Brazil

77.2

(humans OR human "modern man" OR "homo sapiens" OR man) AND (bioethics OR "health care ethics" OR "biomedical ethics") AND Brazil

77.3

(humans OR human OR modern man OR homo sapiens OR man) AND (bioethics OR health care ethics OR biomedical ethics) AND Brazil

77.4

(human* OR modern man OR homo sapiens OR man) AND (bioethics OR health care ethics OR biomedical ethics AND Brazil)

77.5

humans OR human OR modern man OR homo sapiens OR man AND bioethics OR health care ethics OR biomedical ethics
AND Brazil

78.1

(hepatectomy OR hepatectomies) AND ((hepatocellular carcinoma) OR (hepatocellular cancer) OR (adult liver cancer) OR (hepatoma) OR (adult liver carcinoma)) AND ((therapy nutrition) OR (medical nutrition therapy) OR (nutritional support) OR (artificial feeding))

78.2

(hepatectomy OR hepatectomies) AND ("hepatocellular carcinoma" OR "hepatocellular cancer" OR "adult liver cancer" OR hepatoma OR "adult liver carcinoma") AND ("therapy nutrition" OR "medical nutrition therapy" OR "nutritional support" OR "artificial feeding")

78.3

(hepatectomy OR hepatectomies) AND (hepatocellular carcinoma OR hepatocellular cancer OR adult liver cancer OR hepatoma OR adult liver carcinoma) AND (therapy nutrition OR medical nutrition therapy OR nutritional support OR artificial feeding)

78.4

(hepatectom*) AND (hepatocellular carcinoma OR hepatocellular cancer OR adult liver cancer OR hepatoma OR adult liver carcinoma) AND (therapy nutrition OR medical nutrition therapy OR nutritional support OR artificial feeding)

78.5

hepatectomy OR hepatectomies AND hepatocellular carcinoma OR hepatocellular cancer OR adult liver cancer OR hepatoma OR adult liver carcinoma AND therapy nutrition OR medical nutrition therapy OR nutritional support OR artificial feeding

79.1

((apgar score) OR (brain hypoxia-ischemias) OR (brain ischemia-hypoxias) OR (brain ischemia-hypoxia) OR (brain ischemia hypoxia) OR (brain hypoxia-ischemia) OR (brain hypoxia ischemia) OR (hypoxic-ischemic encephalopathies) OR (ischemic-hypoxic encephalopathy) OR (ischemic hypoxic encephalopathy) OR (ischemic-hypoxic encephalopathies) OR (hypoxic-ischemic encephalopathy) OR (hypoxic ischemic encephalopathy) OR (anoxic-ischemic encephalopathies) OR (anoxic-ischemic encephalopathy) OR (anoxic ischemic encephalopathy) OR (cerebral hypoxia-ischemia) OR (cerebral hypoxia-ischemias) OR (cerebral hypoxia ischemia) OR (cerebral ischemia-hypoxia) OR (cerebral ischemia hypoxia) OR (cerebral ischemia-hypoxias) OR (brain anoxia-ischemias) OR (brain ischemia-anoxia) OR (brain ischemia anoxia) OR (brain ischemia-anoxias) OR (brain anoxia-ischemia) OR (brain anoxia ischemia) OR (cerebral anoxia-ischemias) OR (cerebral ischemia-anoxia) OR (cerebral ischemia-anoxias) OR (cerebral anoxia-ischemia) OR (cerebral anoxia ischemia)) AND ((hearing loss) OR (sensorineural hearing loss) OR (cochlear hearing loss) OR (bilateral deafness) OR (complete hearing loss) OR (prelingual deafness) OR (deaf-mutism) OR (deaf mutism) OR (acquired deafness) OR (extreme hearing loss) OR (auditory brain stem evoked response) OR (auditory brain stem evoked responses) OR (brain stem auditory evoked potential) OR (brain stem auditory evoked potentials) OR (acoustic evoked brainstem potential) OR (acoustic evoked brainstem potentials) OR (brainstem auditory evoked potential) OR (brainstem auditory evoked potentials) OR (auditory brainstem evoked response) OR (auditory brainstem evoked responses) OR (acoustic evoked brain stem potential) OR (acoustic evoked brain stem potentials) OR (auditory brainstem responses) OR (auditory brainstem response))

79.2

("apgar score" OR "brain hypoxia-ischemias" OR "brain ischemia-hypoxias" OR "brain ischemia-hypoxia" OR "brain ischemia hypoxia" OR "brain hypoxia-ischemia" OR "brain hypoxia ischemia" OR "hypoxic-ischemic encephalopathies" OR "ischemic-hypoxic encephalopathy" OR "ischemic hypoxic encephalopathy" OR "ischemic-hypoxic encephalopathies" OR "hypoxic-ischemic encephalopathy" OR "hypoxic ischemic encephalopathy" OR "anoxic-ischemic encephalopathies" OR "anoxic-ischemic encephalopathy" OR "anoxic ischemic encephalopathy" OR "cerebral hypoxia-ischemia" OR "cerebral hypoxia-ischemias" OR "cerebral hypoxia ischemia" OR "cerebral ischemia-hypoxia" OR "cerebral ischemia hypoxia" OR "cerebral ischemia-hypoxias" OR "brain anoxia-ischemias" OR "brain ischemia-anoxia" OR "brain ischemia anoxia" OR "brain ischemia-anoxias" OR "brain anoxia-ischemia" OR "brain anoxia ischemia" OR "cerebral anoxia-ischemias" OR "cerebral ischemia-anoxia" OR "cerebral ischemia-anoxias" OR "cerebral anoxia-ischemia" OR "cerebral anoxia ischemia") AND ("hearing loss" OR "sensorineural hearing loss" OR "cochlear hearing loss" OR "bilateral deafness" OR "complete hearing loss" OR "prelingual deafness" OR "deaf-mutism" OR "deaf mutism" OR "acquired deafness" OR "extreme hearing loss" OR "auditory brain stem evoked response" OR "auditory brain stem evoked responses" OR "brain stem auditory evoked potential" OR "brain stem auditory evoked potentials" OR "acoustic evoked brainstem potential" OR "acoustic evoked brainstem potentials" OR "brainstem auditory evoked potential" OR

“brainstem auditory evoked potentials” OR “auditory brainstem evoked response” OR “auditory brainstem evoked responses” OR “acoustic evoked brain stem potential” OR “acoustic evoked brain stem potentials” OR “auditory brainstem responses” OR “auditory brainstem response”)

79.3

(apgar score OR brain hypoxia-ischemias OR brain ischemia-hypoxias OR brain ischemia-hypoxia OR brain ischemia hypoxia OR brain hypoxia-ischemia OR brain hypoxia ischemia OR hypoxic-ischemic encephalopathies OR ischemic-hypoxic encephalopathy OR ischemic hypoxic encephalopathy OR ischemic-hypoxic encephalopathies OR hypoxic-ischemic encephalopathy OR hypoxic ischemic encephalopathy OR anoxic-ischemic encephalopathies OR anoxic-ischemic encephalopathy OR anoxic ischemic encephalopathy OR cerebral hypoxia-ischemia OR cerebral hypoxia-ischemias OR cerebral hypoxia ischemia OR cerebral ischemia-hypoxia OR cerebral ischemia hypoxia OR cerebral ischemia-hypoxias OR brain anoxia-ischemias OR brain ischemia-anoxia OR brain ischemia anoxia OR brain ischemia-anoxias OR brain anoxia-ischemia OR brain anoxia ischemia OR cerebral anoxia-ischemias OR cerebral ischemia-anoxia OR cerebral ischemia-anoxias OR cerebral anoxia-ischemia OR cerebral anoxia ischemia) AND (hearing loss OR sensorineural hearing loss OR cochlear hearing loss OR bilateral deafness OR complete hearing loss OR prelingual deafness OR deaf-mutism OR deaf mutism OR acquired deafness OR extreme hearing loss OR auditory brain stem evoked response OR auditory brain stem evoked responses OR brain stem auditory evoked potential OR brain stem auditory evoked potentials OR acoustic evoked brainstem potential OR acoustic evoked brainstem potentials OR brainstem auditory evoked potential OR brainstem auditory evoked potentials OR auditory brainstem evoked response OR auditory brainstem evoked responses OR acoustic evoked brain stem potential OR acoustic evoked brain stem potentials OR auditory brainstem responses OR auditory brainstem response)

79.4

(apgar score OR brain hypoxia-ischemia* OR brain ischemia-hypoxia* OR brain ischemia hypoxia OR brain hypoxia ischemia OR hypoxic-ischemic encephalopathy* OR ischemic-hypoxic encephalopath* OR ischemic hypoxic encephalopathy OR hypoxic ischemic encephalopathy OR anoxic-ischemic encephalopathy* OR anoxic ischemic encephalopathy OR cerebral hypoxia-ischemia* OR cerebral hypoxia ischemia OR cerebral ischemia-hypoxia* OR cerebral ischemia hypoxia OR brain anoxia-ischemias OR brain ischemia-anoxia* OR brain ischemia anoxia OR brain anoxia-ischemia* OR brain anoxia ischemia OR cerebral ischemia-anoxia* OR cerebral anoxia-ischemia OR cerebral anoxia ischemia) AND (hearing loss OR sensorineural hearing loss OR cochlear hearing loss OR bilateral deafness OR complete hearing loss OR prelingual deafness OR deaf-mutism OR deaf mutism OR acquired deafness OR extreme hearing loss OR auditory brain stem evoked response* OR brain stem auditory evoked potential* OR acoustic evoked brainstem potential* OR brainstem auditory evoked potential* OR auditory brainstem evoked response* OR acoustic evoked brain stem potential* OR auditory brainstem response)

79.5

apgar score OR brain hypoxia-ischemias OR brain ischemia-hypoxias OR brain ischemia-hypoxia OR brain ischemia hypoxia OR brain hypoxia-ischemia OR brain hypoxia ischemia OR hypoxic-ischemic encephalopathies OR ischemic-hypoxic encephalopathy OR ischemic hypoxic encephalopathy OR ischemic-hypoxic encephalopathies OR hypoxic-ischemic encephalopathy OR hypoxic ischemic encephalopathy OR anoxic-ischemic encephalopathies OR anoxic-ischemic encephalopathy OR anoxic ischemic encephalopathy OR cerebral hypoxia-ischemia OR cerebral hypoxia-ischemias OR cerebral hypoxia ischemia OR cerebral ischemia-hypoxia OR cerebral ischemia hypoxia OR cerebral ischemia-hypoxias OR brain anoxia-ischemias OR brain ischemia-anoxia OR brain ischemia anoxia OR brain ischemia-anoxias OR brain anoxia-

ischemia OR brain anoxia ischemia OR cerebral anoxia-ischemias OR cerebral ischemia-anoxia OR cerebral ischemia-anoxias OR cerebral anoxia-ischemia OR cerebral anoxia ischemia AND hearing loss OR sensorineural hearing loss OR cochlear hearing loss OR bilateral deafness OR complete hearing loss OR prelingual deafness OR deaf-mutism OR deaf mutism OR acquired deafness OR extreme hearing loss OR auditory brain stem evoked response OR auditory brain stem evoked responses OR brain stem auditory evoked potential OR brain stem auditory evoked potentials OR acoustic evoked brainstem potential OR acoustic evoked brainstem potentials OR brainstem auditory evoked potential OR brainstem auditory evoked potentials OR auditory brainstem evoked response OR auditory brainstem evoked responses OR acoustic evoked brain stem potential OR acoustic evoked brain stem potentials OR auditory brainstem responses OR auditory brainstem response

80.1

((tracheal diseases) OR (tracheal disease)) AND (tissue engineering) AND (transplant OR grafts OR graft OR (tissue transplants) OR (tissue transplant) OR (organ transplants) OR (organ transplant) OR (organ grafts) OR (organ graft) OR (cell transplants) OR (cell transplant) OR (tissue grafts) OR (tissue graft))

80.2

("tracheal diseases" OR "tracheal disease") AND ("tissue engineering") AND ("transplant OR grafts OR graft OR "tissue transplants" OR "tissue transplant" OR "organ transplants" OR "organ transplant" OR "organ grafts" OR "organ graft" OR "cell transplants" OR "cell transplant" OR "tissue grafts" OR "tissue graft")

80.3

(tracheal diseases OR tracheal disease) AND (tissue engineering) AND (transplant OR grafts OR graft OR tissue transplants OR tissue transplant OR organ transplants OR organ transplant OR organ grafts OR organ graft OR cell transplants OR cell transplant OR tissue grafts OR tissue graft)

80.4

(tracheal disease*) AND (tissue engineering) AND (transplant OR graft* OR tissue transplant* OR organ transplant* OR organ graft* OR cell transplant* OR tissue graft*)

80.5

tracheal diseases OR tracheal disease AND tissue engineering AND transplant OR grafts OR graft OR tissue transplants OR tissue transplant OR organ transplants OR organ transplant OR organ grafts OR organ graft OR cell transplants OR cell transplant OR tissue grafts OR tissue graft

81.1

((acute kidney injuries) OR (acute kidney injury) OR (acute renal injury) OR (acute renal injuries) OR (acute kidney failures) OR (acute renal failure) OR (acute renal failures) OR (acute kidney failure) OR (acute renal insufficiencies) OR (acute renal insufficiency) OR (acute kidney insufficiencies) OR (acute kidney insufficiency)) AND (melatonin)

81.2

("acute kidney injuries" OR "acute kidney injury" OR "acute renal injury" OR "acute renal injuries" OR "acute kidney failures" OR "acute renal failure" OR "acute renal failures" OR "acute kidney failure" OR "acute renal insufficiencies" OR "acute renal insufficiency" OR "acute kidney insufficiencies" OR "acute kidney insufficiency") AND (melatonin)

81.3

(acute kidney injuries OR acute kidney injury OR acute renal injury OR acute renal injuries OR

acute kidney failures OR acute renal failure OR acute renal failures OR acute kidney failure OR acute renal insufficiencies OR acute renal insufficiency OR acute kidney insufficiencies OR acute kidney insufficiency) AND (melatonin)

81.4

(acute kidney injuri* OR acute renal injur* OR acute kidney failure* OR acute renal failure* OR acute renal insufficienc* OR acute kidney insufficienc*) AND (melatonin)

81.5

acute kidney injuries OR acute kidney injury OR acute renal injury OR acute renal injuries OR acute kidney failures OR acute renal failure OR acute renal failures OR acute kidney failure OR acute renal insufficiencies OR acute renal insufficiency OR acute kidney insufficiencies OR acute kidney insufficiency AND melatonin

82.1

((bronchogenic carcinoma) OR (bronchogenic carcinomas) OR (bronchial carcinoma) OR (bronchial carcinomas)) AND ((maintenance chemotherapy) OR (maintenance chemotherapies))

82.2

("bronchogenic carcinoma" OR "bronchogenic carcinomas" OR "bronchial carcinoma" OR "bronchial carcinomas") AND ("maintenance chemotherapy" OR "maintenance chemotherapies")

82.3

(bronchogenic carcinoma OR bronchogenic carcinomas OR bronchial carcinoma OR bronchial carcinomas) AND (maintenance chemotherapy OR maintenance chemotherapies)

82.4

(bronchogenic carcinoma* OR bronchial carcinoma*) AND (maintenance chemotherap*)

82.5

bronchogenic carcinoma OR bronchogenic carcinomas OR bronchial carcinoma OR bronchial carcinomas AND maintenance chemotherapy OR maintenance chemotherapies

83.1

((electrical stimulation) OR (electrical stimulations) OR (electric stimulation) OR (electric stimulations) OR (stimulation therapy electric) OR (therapeutic electrical stimulation) OR (electric stimulation therapy) OR electrotherapy OR (therapeutic electric stimulation) OR (electrical stimulation therapy)) AND ((dysfunction erectile) OR impotence OR (male sexual impotence) OR (male impotence)) AND ((prostatectomy retropubic) OR (prostatectomies retropubic) OR prostatectomies OR prostatectomy)

83.2

("electrical stimulation" OR "electrical stimulations" OR "electric stimulation" OR "electric stimulations" OR "stimulation therapy electric" OR "therapeutic electrical stimulation" OR "electric stimulation therapy" OR electrotherapy OR "therapeutic electric stimulation" OR "electrical stimulation therapy") AND ("dysfunction erectile" OR impotence OR "male sexual impotence" OR "male impotence") AND ("prostatectomy retropubic" OR "prostatectomies retropubic" OR prostatectomies OR prostatectomy)

83.3

(electrical stimulation OR electrical stimulations OR electric stimulation OR electric stimulations OR stimulation therapy electric OR therapeutic electrical stimulation OR electric stimulation therapy OR

electrotherapy OR therapeutic electric stimulation OR electrical stimulation therapy) AND (dysfunction erectile OR impotence OR male sexual impotence OR male impotence) AND (prostatectomy retropubic OR prostatectomies retropubic OR prostatectomies OR prostatectomy)

83.4

(electric* stimulation* OR stimulation therapy electric OR therapeutic electric* stimulation OR electric* stimulation therapy OR electrotherapy) AND (dysfunction erectile OR impotence OR male sexual impotence OR male impotence) AND (prostatectom* retropubic OR prostatectomy*)

83.5

electrical stimulation OR electrical stimulations OR electric stimulation OR electric stimulations OR stimulation therapy electric OR therapeutic electrical stimulation OR electric stimulation therapy OR electrotherapy OR therapeutic electric stimulation OR electrical stimulation therapy AND dysfunction erectile OR impotence OR male sexual impotence OR male impotence AND prostatectomy retropubic OR prostatectomies retropubic OR prostatectomies OR prostatectomy

84.1

((cardiac failure) OR (myocardial failure) OR (left-sided heart failure) OR (left sided heart failure) OR (right-sided heart failure) OR (right sided heart failure) OR (congestive heart failure) OR (heart decompensation)) AND ((CPAP ventilation) OR (biphasic continuous positive airway pressure) OR (bilevel continuous positive airway pressure) OR (nasal continuous positive airway pressure) OR (nCPAP ventilation) OR (airway pressure release ventilation) OR (APRV ventilation mode) OR (APRV ventilation modes))

84.2

("cardiac failure" OR "myocardial failure" OR "left-sided heart failure" OR "left sided heart failure" OR "right-sided heart failure" OR "right sided heart failure" OR "congestive heart failure" OR "heart decompensation") AND ("CPAP ventilation" OR "biphasic continuous positive airway pressure" OR "bilevel continuous positive airway pressure" OR "nasal continuous positive airway pressure" OR "nCPAP ventilation" OR "airway pressure release ventilation" OR "APRV ventilation mode" OR "APRV ventilation modes")

84.3

(cardiac failure OR myocardial failure OR left-sided heart failure OR left sided heart failure OR right-sided heart failure OR right sided heart failure OR congestive heart failure OR heart decompensation) AND (CPAP ventilation OR biphasic continuous positive airway pressure OR bilevel continuous positive airway pressure OR nasal continuous positive airway pressure OR nCPAP ventilation OR airway pressure release ventilation OR APRV ventilation mode OR APRV ventilation modes)

84.4

(cardiac failure OR myocardial failure OR left-sided heart failure OR left sided heart failure OR right-sided heart failure OR right sided heart failure OR congestive heart failure OR heart decompensation) AND (CPAP ventilation OR biphasic continuous positive airway pressure OR bilevel continuous positive airway pressure OR nasal continuous positive airway pressure OR nCPAP ventilation OR airway pressure release ventilation OR APRV ventilation mode*)

84.5

cardiac failure OR myocardial failure OR left-sided heart failure OR left sided heart failure OR right-sided heart failure OR right sided heart failure OR congestive heart failure OR heart decompensation AND CPAP ventilation OR biphasic continuous positive airway pressure OR bilevel continuous positive airway pressure OR nasal continuous positive airway pressure OR

nCPAP ventilation OR airway pressure release ventilation OR APRV ventilation mode OR APRV ventilation modes

85.1

((face-hand test) OR face-hand OR (line bisection test) OR (star cancellation test) OR (Albert's test)) AND (strokes OR (cerebral stroke) OR (cerebral strokes) OR (brain vascular accident) OR (brain vascular accidents) OR (cerebrovascular apoplexy) OR (cerebrovascular stroke) OR (cerebrovascular strokes) OR CVA (cerebrovascular accident) OR CVAs (cerebrovascular accident) OR apoplexy OR (cerebrovascular accident) OR (cerebrovascular accidents) OR (acute stroke) OR (acute strokes) OR (acute cerebrovascular accident) OR (acute cerebrovascular accidents)) AND ((perceptual disorder) OR (somatosensory discrimination disorder) OR (somatosensory discrimination disorders) OR (sensory neglect) OR (sensory neglects) OR (hemisensory neglect) OR (hemisensory neglects) OR (hemispatial neglect) OR (hemispatial neglects))

85.2

("face-hand test" OR face-hand OR "line bisection test" OR "star cancellation test" OR "Albert's test") AND (strokes OR "cerebral stroke" OR "cerebral strokes" OR "brain vascular accident" OR "brain vascular accidents" OR "cerebrovascular apoplexy" OR "cerebrovascular stroke" OR "cerebrovascular strokes" OR CVA "cerebrovascular accident" OR CVAs "cerebrovascular accident" OR apoplexy OR "cerebrovascular accident" OR "cerebrovascular accidents" OR "acute stroke" OR "acute strokes" OR "acute cerebrovascular accident" OR "acute cerebrovascular accidents") AND ("perceptual disorder" OR "somatosensory discrimination disorder" OR "somatosensory discrimination disorders" OR "sensory neglect" OR "sensory neglects" OR "hemisensory neglect" OR "hemisensory neglects" OR "hemispatial neglect" OR "hemispatial neglects")

85.3

(face-hand test OR face-hand OR line bisection test OR star cancellation test OR Albert's test) AND (strokes OR cerebral stroke OR cerebral strokes OR brain vascular accident OR brain vascular accidents OR cerebrovascular apoplexy OR cerebrovascular stroke OR cerebrovascular strokes OR CVA cerebrovascular accident OR CVAs cerebrovascular accident OR apoplexy OR cerebrovascular accident OR cerebrovascular accidents OR acute stroke OR acute strokes OR acute cerebrovascular accident OR acute cerebrovascular accidents) AND (perceptual disorder OR somatosensory discrimination disorder OR somatosensory discrimination disorders OR sensory neglect OR sensory neglects OR hemisensory neglect OR hemisensory neglects OR hemispatial neglect OR hemispatial neglects)

85.4

(face-hand test OR face-hand OR line bisection test OR star cancellation test OR Albert's test) AND (strokes OR cerebral stroke* OR brain vascular accident* OR cerebrovascular apoplexy OR cerebrovascular stroke* OR CVA* cerebrovascular accident OR apoplexy OR cerebrovascular accident* OR acute stroke* OR acute cerebrovascular accident*) AND (perceptual disorder OR somatosensory discrimination disorder* OR sensory neglect OR sensory neglect* OR hemisensory neglects OR hemispatial neglect*)

85.5

face-hand test OR face-hand OR line bisection test OR star cancellation test OR Albert's test AND strokes OR cerebral stroke OR cerebral strokes OR brain vascular accident OR brain vascular accidents OR cerebrovascular apoplexy OR cerebrovascular stroke OR cerebrovascular strokes OR CVA cerebrovascular accident OR CVAs cerebrovascular accident OR apoplexy OR cerebrovascular accident OR cerebrovascular accidents OR acute stroke OR acute strokes OR

acute cerebrovascular accident OR acute cerebrovascular accidents AND perceptual disorder OR somatosensory discrimination disorder OR somatosensory discrimination disorders OR sensory neglect OR sensory neglects OR hemisensory neglect OR hemisensory neglects OR hemispatial neglect OR hemispatial neglects

86.1

((sleep apnea syndrome) OR (sleep apnea syndromes) OR (sleep apnea) OR (sleep apneas) OR (sleep hypopnea) OR sleep hypopneas) OR (sleep-disordered breathing) OR (sleep disordered breathing) OR (mixed central)) AND ((obstructive sleep apnea) OR (mixed sleep apnea) OR (mixed sleep apneas) OR (hypersomnia with periodic respiration)) AND ((CPAP ventilation) OR (biphasic continuous positive airway pressure) OR (bilevel continuous positive airway pressure) OR (nasal continuous positive airway pressure) OR (NCPAP ventilation) OR (airway pressure release ventilation) OR (APRV ventilation mode) OR (APRV ventilation modes)) AND (dream OR nightmare OR nightmares)

86.2

("sleep apnea syndrome" OR "sleep apnea syndromes" OR "sleep apnea" OR "sleep apneas" OR "sleep hypopnea" OR sleep hypopneas" OR "sleep-disordered breathing" OR "sleep disordered breathing" OR "mixed central") AND ("obstructive sleep apnea" OR "mixed sleep apnea" OR "mixed sleep apneas" OR "hypersomnia with periodic respiration") AND ("CPAP ventilation" OR "biphasic continuous positive airway pressure" OR "bilevel continuous positive airway pressure" OR "nasal continuous positive airway pressure" OR "NCPAP ventilation" OR "airway pressure release ventilation" OR "APRV ventilation mode" OR "APRV ventilation modes") AND (dream OR nightmare OR nightmares)

86.3

(sleep apnea syndrome OR sleep apnea syndromes OR sleep apnea OR sleep apneas OR sleep hypopnea OR sleep hypopneas OR sleep-disordered breathing OR sleep disordered breathing OR mixed central) AND (obstructive sleep apnea OR mixed sleep apnea OR mixed sleep apneas OR hypersomnia with periodic respiration) AND (CPAP ventilation OR biphasic continuous positive airway pressure OR bilevel continuous positive airway pressure OR nasal continuous positive airway pressure OR NCPAP ventilation OR airway pressure release ventilation OR APRV ventilation mode OR APRV ventilation modes) AND (dream OR nightmare OR nightmares)

86.4

(sleep apnea syndrome* OR sleep apnea* OR sleep hypopnea OR sleep-disordered breathing OR sleep disordered breathing OR mixed central) AND (obstructive sleep apnea OR mixed sleep apnea* OR hypersomnia with periodic respiration) AND (CPAP ventilation OR biphasic continuous positive airway pressure OR bilevel continuous positive airway pressure OR nasal continuous positive airway pressure OR NCPAP ventilation OR airway pressure release ventilation OR APRV ventilation mode*) AND (dream OR nightmare*)

86.5

sleep apnea syndrome OR sleep apnea syndromes OR sleep apnea OR sleep apneas OR sleep hypopnea OR sleep hypopneas OR sleep-disordered breathing OR sleep disordered breathing OR mixed central AND obstructive sleep apnea OR mixed sleep apnea OR mixed sleep apneas OR hypersomnia with periodic respiration AND CPAP ventilation OR biphasic continuous positive airway pressure OR bilevel continuous positive airway pressure OR nasal continuous positive airway pressure OR NCPAP ventilation OR airway pressure release ventilation OR APRV ventilation mode OR APRV ventilation modes AND dream OR nightmare OR nightmares

87.1

(sternotomies OR (median sternotomy) OR (median sternotomies)) AND ((operative surgical procedure) OR (operative surgical procedures) OR (operative procedures) OR (operative procedure) OR (ghost surgery))

87.2

(sternotomies OR "median sternotomy" OR "median sternotomies") AND ("operative surgical procedure" OR "operative surgical procedures" OR "operative procedures" OR "operative procedure" OR "ghost surgery")

87.3

(sternotomies OR median sternotomy OR median sternotomies) AND (operative surgical procedure OR operative surgical procedures OR operative procedures OR operative procedure OR ghost surgery)

87.4

(sternotomies OR median sternotom*) AND (operative surgical procedure* OR operative procedures OR operative procedure OR ghost surgery)

87.5

sternotomies OR median sternotomy OR median sternotomies AND operative surgical procedure OR operative surgical procedures OR operative procedures OR operative procedure OR ghost surgery

88.1

(thymomas OR (thymic carcinoma) OR (thymic carcinomas)) AND ((p53 genes) OR (p53 gene) OR (TP53 genes) OR (TP53 gene)) AND (survival OR (survival rate))

88.2

(thymomas OR "thymic carcinoma" OR "thymic carcinomas") AND ("p53 genes" OR "p53 gene" OR "TP53 genes" OR "TP53 gene") AND (survival OR "survival rate")

88.3

(thymomas OR thymic carcinoma OR thymic carcinomas) AND (p53 genes OR p53 gene OR TP53 genes OR TP53 gene) AND (survival OR survival rate)

88.4

(thymomas OR thymic carcinoma*) AND (p53 gene* OR TP53 gene*) AND (survival OR survival rate)

88.5

thymomas OR thymic carcinoma OR thymic carcinomas AND p53 genes OR p53 gene OR TP53 genes OR TP53 gene
AND survival OR survival rate

89.1

((acute neuromuscular disease) OR (neuromuscular disease) OR (Foley-Denny-Brown syndrome) OR (Foley Denny Brown syndrome) OR (benign fasciculation-cramp syndrome) OR (benign fasciculation-cramp syndromes) OR (cramp-fasciculation syndrome) OR (cramp fasciculation syndrome) OR (cramp-fasciculation syndromes) OR (Oppenheim disease) OR (Oppenheim's disease) OR (Oppenheims disease) OR (amyotonia congenita) OR (motor neuron disease) OR

(motor neuron diseases) OR (motor system disease) OR (motor system diseases) OR (familial motor neuron disease) OR (lateral sclerosis) OR (lateral scleroses) OR (primary lateral sclerosis) OR (primary lateral scleroses) OR (upper motor neuron disease) OR (secondary motor neuron disease) OR (anterior horn cell disease) OR (lower motor neuron disease) OR (muscular disease) OR (myopathies OR myopathy OR (muscle disorders) OR (muscle disorder) OR (myopathic conditions) OR (myopathic condition) OR (neuromuscular junction diseases) OR (neuromuscular junction disease) OR (neuromuscular transmission disorders) OR (neuromuscular transmission disorder) OR (neuromuscular junction disorders) OR (neuromuscular junction disorder) OR (neuromuscular junction toxic disorders) OR (chest wall disorders)) AND ((respiratory insufficiency) OR (respiratory failure) OR (respiratory depression) OR (ventilatory depression)) AND (diaphragm OR diaphragms OR (respiratory diaphragm) OR (respiratory diaphragms))

89.2

("acute neuromuscular disease" OR "neuromuscular disease" OR "Foley-Denny-Brown syndrome" OR "Foley Denny Brown syndrome" OR "benign fasciculation-cramp syndrome" OR "benign fasciculation-cramp syndromes" OR "cramp-fasciculation syndrome" OR "cramp fasciculation syndrome" OR "cramp-fasciculation syndromes" OR "Oppenheim disease" OR "Oppenheim's disease" OR "Oppenheims disease" OR "amyotonia congenita" OR "motor neuron disease" OR "motor neuron diseases" OR "motor system disease" OR "motor system diseases" OR "familial motor neuron disease" OR "lateral sclerosis" OR "lateral scleroses" OR "primary lateral sclerosis" OR "primary lateral scleroses" OR "upper motor neuron disease" OR "secondary motor neuron disease" OR "anterior horn cell Disease" OR "lower motor neuron disease" OR "muscular disease" OR myopathies OR myopathy OR "muscle disorders" OR "muscle disorder" OR "myopathic conditions" OR "myopathic condition" OR "neuromuscular junction diseases" OR "neuromuscular junction disease" OR "neuromuscular transmission disorders" OR "neuromuscular transmission disorder" OR "neuromuscular junction disorders" OR "neuromuscular junction disorder" OR "neuromuscular junction toxic disorders" OR "chest wall disorders") AND ("respiratory insufficiency" OR "respiratory failure" OR "respiratory depression" OR "ventilatory depression") AND ("diaphragm OR diaphragms OR "respiratory diaphragm" OR "respiratory diaphragms")

89.3

(acute neuromuscular disease OR neuromuscular disease OR Foley-Denny-Brown syndrome OR Foley Denny Brown syndrome OR benign fasciculation-cramp syndrome OR benign fasciculation-cramp syndromes OR cramp-fasciculation syndrome OR cramp fasciculation syndrome OR cramp-fasciculation syndromes OR Oppenheim disease OR Oppenheim's disease OR Oppenheims disease OR amyotonia congenita OR motor neuron disease OR motor neuron diseases OR motor system disease OR motor system diseases OR familial motor neuron disease OR lateral sclerosis OR lateral scleroses OR primary lateral sclerosis OR primary lateral scleroses OR upper motor neuron disease OR secondary motor neuron disease OR anterior horn cell Disease OR lower motor neuron disease OR muscular disease OR myopathies OR myopathy OR muscle disorders OR muscle disorder OR myopathic conditions OR myopathic condition OR neuromuscular junction diseases OR neuromuscular junction disease OR neuromuscular transmission disorders OR neuromuscular transmission disorder OR neuromuscular junction disorders OR neuromuscular junction disorder OR neuromuscular junction toxic disorders OR chest wall disorders) AND (respiratory insufficiency OR respiratory failure OR respiratory depression OR ventilatory depression) AND (diaphragm OR diaphragms OR respiratory diaphragm OR respiratory diaphragms)

89.4

(acute neuromuscular disease OR neuromuscular disease OR Foley-Denny-Brown syndrome OR Foley Denny Brown syndrome OR benign fasciculation-cramp syndrome* OR cramp-fasciculation syndrome OR cramp fasciculation syndrome OR cramp-fasciculation syndromes OR Oppenheim

disease OR Oppenheim's disease OR Oppenheims disease OR amyotonia congenita OR motor neuron disease* OR motor system disease* OR familial motor neuron disease OR lateral scleros* OR primary lateral scleros* OR upper motor neuron disease OR secondary motor neuron disease OR anterior horn cell Disease OR lower motor neuron disease OR muscular disease OR myopath* OR muscle disorder* OR myopathic condition* OR neuromuscular junction disease* OR neuromuscular transmission disorder* OR neuromuscular junction disorder* OR neuromuscular junction toxic disorders OR chest wall disorders) **AND** (respiratory insufficiency OR respiratory failure OR respiratory depression OR ventilatory depression) **AND** (diaphragm* OR respiratory diaphragm*)

89.5

acute neuromuscular disease OR neuromuscular disease OR Foley-Denny-Brown syndrome OR Foley Denny Brown syndrome OR benign fasciculation-crimp syndrome OR benign fasciculation-crimp syndromes OR cramp-fasciculation syndrome OR cramp fasciculation syndrome OR cramp-fasciculation syndromes OR Oppenheim disease OR Oppenheim's disease OR Oppenheims disease OR amyotonia congenita OR motor neuron disease OR motor neuron diseases OR motor system disease OR motor system diseases OR familial motor neuron disease OR lateral sclerosis OR lateral scleroses OR primary lateral sclerosis OR primary lateral scleroses OR upper motor neuron disease OR secondary motor neuron disease OR anterior horn cell Disease OR lower motor neuron disease OR muscular disease OR myopathies OR myopathy OR muscle disorders OR muscle disorder OR myopathic conditions OR myopathic condition OR neuromuscular junction diseases OR neuromuscular junction disease OR neuromuscular transmission disorders OR neuromuscular transmission disorder OR neuromuscular junction disorders OR neuromuscular junction disorder OR neuromuscular junction toxic disorders OR chest wall disorders **AND** respiratory insufficiency OR respiratory failure OR respiratory depression OR ventilatory depression **AND** diaphragm OR diaphragms OR respiratory diaphragm OR respiratory diaphragms

90.1

(endometriosis OR endometrioses OR endometrioma OR endometriomas OR adenomyosis) **AND** (ovary OR ovariectomy) **AND** ((postoperative period) OR (postoperative care))

90.2

(endometriosis OR endometrioses OR endometrioma OR endometriomas OR adenomyosis) **AND** (ovary OR ovariectomy) **AND** ("postoperative period" OR "postoperative care")

90.3

(endometriosis OR endometrioses OR endometrioma OR endometriomas OR adenomyosis) **AND** (ovary OR ovariectomy) **AND** (postoperative period OR postoperative care)

90.4

(endometriosis* OR endometrioma* OR adenomyosis) **AND** (ovary OR ovariectomy) **AND** (postoperative period OR postoperative care)

90.5

endometriosis OR endometrioses OR endometrioma OR endometriomas OR adenomyosis **AND** ovary OR ovariectomy
AND postoperative period OR postoperative care

91.1

((cystic fibrosis) OR mucoviscidosis) **AND** (triage OR triages OR (neonatal screening) or (neonatal screenings))

91.2

("cystic fibrosis" OR mucoviscidosis) AND (triage OR triages OR "neonatal screening" or "neonatal screenings")

91.3

(cystic fibrosis OR mucoviscidosis) AND (triage OR triages OR neonatal screening or neonatal screenings)

91.4

(cystic fibrosis OR mucoviscidosis) AND (triage* OR neonatal screening*)

91.5

cystic fibrosis OR mucoviscidosis AND triage OR triages OR neonatal screening or neonatal screenings

92.1

((heart failure) OR (cardiac failure) OR (myocardial failure) OR (heart decompensation) OR (congestive heart failure)) AND (therapeutics OR therapeutic OR treatment OR treatments) AND (child or children)

92.2

("heart failure" OR "cardiac failure" OR "myocardial failure" OR "heart decompensation" OR "congestive heart failure") AND (therapeutics OR therapeutic OR treatment OR treatments) AND (child or children)

92.3

(heart failure OR cardiac failure OR myocardial failure OR heart decompensation OR congestive heart failure) AND (therapeutics OR therapeutic OR treatment OR treatments) AND (child or children)

92.4

(heart failure OR cardiac failure OR myocardial failure OR heart decompensation OR congestive heart failure) AND (therapeutic* OR treatment*) AND (child*)

92.5

heart failure OR cardiac failure OR myocardial failure OR heart decompensation OR congestive heart failure AND therapeutics OR therapeutic OR treatment OR treatments AND child or children

93.1

(trauma OR traumas OR wound OR wounds OR injury OR injuries) AND (thorax OR thorace OR chest) AND ((second-look surgery) OR reoperation)

93.2

(trauma OR traumas OR wound OR wounds OR injury OR injuries) AND (thorax OR thorace OR chest) AND ("second-look surgery" OR reoperation)

93.3

(trauma OR traumas OR wound OR wounds OR injury OR injuries) AND (thorax OR thorace OR chest) AND (second-look surgery OR reoperation)

93.4

(trauma* OR wound* OR injur*) AND (thorax OR thorace OR chest) AND (second-look surgery OR reoperation)

93.5

trauma OR traumas OR wound OR wounds OR injury OR injuries AND thorax OR thorace OR chest AND second-look surgery OR reoperation

94.1

((pleural effusion) OR (pleural effusions)) AND (surgery OR (operative surgical procedure) OR (operative surgical procedures) OR (operative procedures) OR (operative procedure) OR (ghost surgery))

94.2

("pleural effusion" OR "pleural effusions") AND (surgery OR "operative surgical procedure" OR "operative surgical procedures" OR "operative procedures" OR "operative procedure" OR "ghost surgery")

94.3

(pleural effusion OR pleural effusions) AND (surgery OR operative surgical procedure OR operative surgical procedures OR operative procedures OR operative procedure OR ghost surgery)

94.4

(pleural effusion*) AND (surgery OR operative surgical procedure*OR operative procedure* OR ghost surgery)

94.5

pleural effusion OR pleural effusions AND surgery OR operative surgical procedure OR operative surgical procedures OR operative procedures OR operative procedure OR ghost surgery

95.1

((varicose ulcer) OR (varicose ulcers) OR (venous hypertension ulcers) OR (venous hypertension ulcer) OR (venous ulcer) OR (venous ulcers) OR (venous stasis ulcers) OR (venous stasis ulcer) OR (stasis ulcer) OR (stasis ulcers)) AND (therapeutics OR therapeutic OR treatment OR treatments)

95.2

("varicose ulcer" OR "varicose ulcers" OR "venous hypertension ulcers" OR "venous hypertension ulcer" OR "venous ulcer" OR "venous ulcers" OR "venous stasis ulcers" OR "venous stasis ulcer" OR "stasis ulcer" OR "stasis ulcers") AND (therapeutics OR therapeutic OR treatment OR treatments)

95.3

(varicose ulcer OR varicose ulcers OR venous hypertension ulcers OR venous hypertension ulcer OR venous ulcer OR venous ulcers OR venous stasis ulcers OR venous stasis ulcer OR stasis ulcer OR stasis ulcers) AND (therapeutics OR therapeutic OR treatment OR treatments)

95.4

(varicose ulcer* OR venous hypertension ulcer* OR venous ulcer* OR venous stasis ulcer* OR stasis ulcer*) AND (therapeutic* OR treatment*)

95.5

varicose ulcer OR varicose ulcers OR venous hypertension ulcers OR venous hypertension ulcer OR venous ulcer OR venous ulcers OR venous stasis ulcers OR venous stasis ulcer OR stasis

ulcer OR stasis ulcers AND therapeutics OR therapeutic OR treatment OR treatments

96.1

(endosonography OR endosonographies OR (echo endoscopies) OR (ultrasonic endoscopy) OR echo-endoscopy) AND ((pancreatic neoplasms) OR (cancer of pancreas) OR (pancreas cancers))

96.2

(endosonography OR endosonographies OR "echo endoscopies" OR "ultrasonic endoscopy" OR echo-endoscopy) AND ("pancreatic neoplasms" OR "cancer of pancreas" OR "pancreas cancers")

96.3

(endosonography OR endosonographies OR echo endoscopies OR ultrasonic endoscopy OR echo-endoscopy) AND (pancreatic neoplasms OR cancer of pancreas OR pancreas cancers)

96.4

(endosonograph* OR echo endoscop* OR echo-endoscopy) AND (pancreatic neoplasms OR cancer of pancreas OR pancreas cancers)

96.5

endosonography OR endosonographies OR echo endoscopies OR ultrasonic endoscopy OR echo-endoscopy AND pancreatic neoplasms OR cancer of pancreas OR pancreas cancers

97.1

(hypertension OR (blood pressure high) OR (blood pressures high) OR (high blood pressure) OR (high blood pressures)) AND (infarction OR infarctions) AND (woman or women) AND (adult or adults)

97.2

(hypertension OR "blood pressure high" OR "blood pressures high" OR "high blood pressure" OR "high blood pressures") AND (infarction OR infarctions) AND (woman or women) AND (adult or adults)

97.3

(hypertension OR blood pressure high OR blood pressures high OR high blood pressure OR high blood pressures) AND (infarction OR infarctions) AND (woman or women) AND (adult or adults)

97.4

(hypertension OR blood pressure* high OR high blood pressure*) AND (infarction*) AND (wom*) AND (adult*)

97.5

hypertension OR blood pressure high OR blood pressures high OR high blood pressure OR high blood pressures AND infarction OR infarctions AND woman or women AND adult or adults

98.1

(pneumonias OR pneumonitis OR (pulmonary inflammation) OR (lung inflammation) OR (lobar pneumonia)) AND (bacterial) AND (children OR child)

98.2

(pneumonias OR pneumonitis OR "pulmonary inflammation" OR "lung inflammation" OR "lobar pneumonia") AND (bacterial) AND (children OR child)

98.3

(pneumonias OR pneumonitis OR pulmonary inflammation OR lung inflammation OR lobar pneumonia) AND (bacterial) AND (children OR child)

98.4

(pneumoni* OR pneumonitis OR pulmonary inflammation OR lung inflammation OR lobar pneumonia) AND (bacterial) AND (children*)

98.5

pneumonias OR pneumonitis OR pulmonary inflammation OR lung inflammation OR lobar pneumonia AND bacterial
AND children OR child

99.1

((intensive care) OR (critical care) OR (surgical intensive care)) AND ((congenital abnormalities) OR (congenital abnormality) OR deformities OR deformity OR (congenital defects) OR (congenital defect) OR (birth defects) OR (birth defect))

99.2

("intensive care" OR "critical care" OR "surgical intensive care") AND ("congenital abnormalities" OR "congenital abnormality" OR deformities OR deformity OR "congenital defects" OR "congenital defect" OR "birth defects" OR "birth defect")

99.3

(intensive care OR critical care OR surgical intensive care) AND (congenital abnormalities OR congenital abnormality OR deformities OR deformity OR congenital defects OR congenital defect OR birth defects OR birth defect)

99.4

(intensive care OR critical care OR surgical intensive care) AND (congenital abnormalit* OR deformit* OR congenital defect* OR birth defect*)

99.5

intensive care OR critical care OR surgical intensive care AND congenital abnormalities OR congenital abnormality OR deformities OR deformity OR congenital defects OR congenital defect OR birth defects OR birth defect

100.1

(epilepsies OR (seizure disorder) OR (seizure disorders) OR (epileptic seizures) OR (epileptic seizure) OR (single seizure) OR (single seizures) OR (cryptogenic epilepsies) OR (cryptogenic epilepsy) OR aura OR auras OR (awakening epilepsy)) AND (depressions OR (depressive symptoms) OR (depressive symptom) OR (emotional depression) OR (emotional depressions))

100.2

(epilepsies OR "seizure disorder" OR "seizure disorders" OR "epileptic seizures" OR "epileptic seizure" OR "single seizure" OR "single seizures" OR "cryptogenic epilepsies" OR "cryptogenic epilepsy" OR aura OR auras OR "awakening epilepsy") AND (depressions OR "depressive symptoms" OR "depressive symptom" OR "emotional depression" OR "emotional depressions")

100.3

(epilepsies OR seizure disorder OR seizure disorders OR epileptic seizures OR epileptic seizure OR single seizure OR single seizures OR cryptogenic epilepsies OR cryptogenic epilepsy OR aura

OR auras OR awakening epilepsy) AND (depressions OR depressive symptoms OR depressive symptom OR emotional depression OR emotional depressions)

100.4

(epilepsies OR seizure disorder* OR epileptic seizure* OR single seizure* OR cryptogenic epilepsies OR cryptogenic epilepsy OR aura* OR awakening epilepsy) AND (depressions OR depressive symptom* OR emotional depression*)

100.5

epilepsies OR seizure disorder OR seizure disorders OR epileptic seizures OR epileptic seizure OR single seizure OR single seizures OR cryptogenic epilepsies OR cryptogenic epilepsy OR aura OR auras OR awakening epilepsy AND depressions OR depressive symptoms OR depressive symptom OR emotional depression OR emotional depressions

101.1

((body dysmorphic disorder) OR (body image dysfunction) OR (body image disfunctions) OR (body image disorders) OR (body image disorder)) AND (plastic surgery)

101.2

("body dysmorphic disorder" OR "body image dysfunction" OR "body image disfunctions" OR "body image disorders" OR "body image disorder") AND ("plastic surgery")

101.3

(body dysmorphic disorder OR body image dysfunction OR body image disfunctions OR body image disorders OR body image disorder) AND plastic surgery

101.4

(body dysmorphic disorder OR body image dysfunction* OR body image disorder*) AND plastic surgery

101.5

body dysmorphic disorder OR body image dysfunction OR body image disfunctions OR body image disorders OR body image disorder AND plastic surgery

102.1

((orbital implants) OR (orbital implant)) AND (blepharoptosis OR blepharoptoses OR (eyelid ptosis) OR (eyelid ptoses))

102.2

("orbital implants" OR "orbital implant") AND (blepharoptosis OR blepharoptoses OR "eyelid ptosis" OR "eyelid ptoses")

102.3

(orbital implants OR orbital implant) AND (blepharoptosis OR blepharoptoses OR eyelid ptosis OR eyelid ptoses)

102.4

(orbital implant*) AND (blepharoptos* OR eyelid ptos*)

102.5

orbital implants OR orbital implant AND blepharoptosis OR blepharoptoses OR eyelid ptosis OR eyelid ptoses

103.1

((biocompatible materials) OR biomaterials OR (hemocompatible materials)) AND (blepharoplasty OR blepharoplasties)

103.2

("biocompatible materials" OR biomaterials OR "hemocompatible materials") AND (blepharoplasty OR blepharoplasties)

103.3

(biocompatible materials OR biomaterials OR hemocompatible materials) AND (blepharoplasty OR blepharoplasties)

103.4

(biocompatible materials OR biomaterials OR hemocompatible materials) AND (blepharoplast*)

103.5

biocompatible materials OR biomaterials OR hemocompatible materials AND blepharoplasty OR blepharoplasties

104.1

((congenital heart defects) OR (congenital heart defect) OR (heart abnormalities) OR (heart abnormality)) AND ((pregnancy complications) OR (pregnancy complication)) AND ((prenatal diagnosis) OR (prenatal diagnoses) OR (intrauterine diagnosis) OR (intrauterine diagnoses) OR (antenatal diagnosis) OR (antenatal diagnoses) OR (prenatal screening) OR (prenatal screenings) OR (antenatal screening) OR (antenatal screenings)) AND ((aortic coarctation) OR (aortic coarctations))

104.2

("congenital heart defects" OR "congenital heart defect" OR "heart abnormalities" OR "heart abnormality") AND ("pregnancy complications" OR "pregnancy complication") AND ("prenatal diagnosis" OR "prenatal diagnoses" OR "intrauterine diagnosis" OR "intrauterine diagnoses" OR "antenatal diagnosis" OR "antenatal diagnoses" OR "prenatal screening" OR "prenatal screenings" OR "antenatal screening" OR "antenatal screenings") AND ("aortic coarctation" OR "aortic coarctations")

104.3

(congenital heart defects OR congenital heart defect OR heart abnormalities OR heart abnormality) AND (pregnancy complications OR pregnancy complication) AND (prenatal diagnosis OR prenatal diagnoses OR intrauterine diagnosis OR intrauterine diagnoses OR antenatal diagnosis OR antenatal diagnoses OR prenatal screening OR prenatal screenings OR antenatal screening OR antenatal screenings) AND (aortic coarctation OR aortic coarctations)

104.4

(congenital heart defect* OR heart abnormalit*) AND (pregnancy complication*) AND (prenatal diagnos* OR intrauterine diagnos* OR antenatal diagnos* OR prenatal screening OR antenatal screening*) AND (aortic coarctation*)

104.5

congenital heart defects OR congenital heart defect OR heart abnormalities OR heart abnormality AND pregnancy complications OR pregnancy complication AND prenatal diagnosis OR prenatal diagnoses OR intrauterine diagnosis OR intrauterine diagnoses OR antenatal diagnosis OR antenatal diagnoses OR prenatal screening OR prenatal screenings OR antenatal screening OR

antenatal screenings AND aortic coarctation OR aortic coarctations

105.1

medline AND pubmed AND ((search strategies) OR (search strategy)) AND ((systematic reviews) OR (systematic review)) AND ((comparative study) OR (comparative studies))

105.2

medline AND pubmed AND ("search strategies" OR "search strategy") AND ""systematic reviews" OR "systematic review") AND ("comparative study" OR "comparative studies")

105.3

medline AND pubmed AND (search strategies OR search strategy) AND (systematic reviews OR systematic review) AND (comparative study OR comparative studies)

105.4

medline AND pubmed AND (search strateg*) AND (systematic review*) AND (comparative stud*)

105.5

Medline AND Pubmed AND search strategies OR search strategy AND systematic reviews OR systematic review AND comparative study OR comparative studies

106.1

((anal canal) OR anus OR (human anal gland) OR (human anal glands) OR (anal gland) OR (anal sphincter) OR (anal sphincters)) AND ((human papillomavirus) OR HPV) AND (prevalence OR incidence) AND ((cytological technique) OR (cytological techniques) OR (cytological technic) OR (cytological technics) OR (cytologic techniques) OR (cytologic technique) OR (cytologic technics) OR (cytologic technic))

106.2

("anal canal" OR anus OR "human anal gland" OR "human anal glands" OR "anal gland" OR "anal sphincter" OR "anal sphincters") AND ("human papillomavirus" OR HPV) AND (prevalence OR incidence) AND ("cytological technique" OR "cytological techniques" OR "cytological technic" OR "cytological technics" OR "cytologic techniques" OR "cytologic technique" OR "cytologic technics" OR "cytologic technic")

106.3

(anal canal OR anus OR human anal gland OR human anal glands OR anal gland OR anal sphincter OR anal sphincters) AND (human papillomavirus OR HPV) AND (prevalence OR incidence) AND (cytological technique OR cytological techniques OR cytological technic OR cytological technics OR cytologic techniques OR cytologic technique OR cytologic technics OR cytologic technic)

106.4

(anal canal OR anus OR human anal gland* OR anal gland OR anal sphincter*) AND (human papillomavirus OR HPV) AND (prevalence OR incidence) AND (cytologic* technique* OR cytologic* technic*)

106.5

anal canal OR anus OR human anal gland OR human anal glands OR anal gland OR anal sphincter OR anal sphincters
AND human papillomavirus OR HPV AND prevalence OR incidence AND cytological technique OR

cytological techniques OR cytological technic OR cytological technics OR cytologic techniques OR cytologic technique OR cytologic technics OR cytologic technic

107.1

Titanium AND (tissue adhesion OR tissue adhesions OR surgical adhesions OR surgical adhesion OR surgery-induced tissue adhesions OR surgery-induced tissue adhesion OR surgery induced tissue adhesions) AND (orbital fracture OR orbital fractures OR blow-out fractures OR blow out fractures OR blow-out fracture)

107.2

Titanium AND ("tissue adhesion" OR "tissue adhesions" OR "surgical adhesions" OR "surgical adhesion" OR "surgery-induced tissue adhesions" OR "surgery-induced tissue adhesion" OR "surgery induced tissue adhesions") AND ("orbital fracture" OR "orbital fractures" OR "blow-out fractures" OR "blow out fractures" OR "blow-out fracture")

107.3

Titanium AND (tissue adhesion OR tissue adhesions OR surgical adhesions OR surgical adhesion OR surgery-induced tissue adhesions OR surgery-induced tissue adhesion OR surgery induced tissue adhesions) AND (orbital fracture OR orbital fractures OR blow-out fractures OR blow out fractures OR blow-out fracture)

107.4

Titanium AND (tissue adhesion* OR surgical adhesion* OR surgery-induced tissue adhesion* OR surgery induced tissue adhesions) AND (orbital fracture* OR blow-out fractures OR blow out fracture*)

107.5

Titanium AND tissue adhesion OR tissue adhesions OR surgical adhesions OR surgical adhesion OR surgery-induced tissue adhesions OR surgery-induced tissue adhesion OR surgery induced tissue adhesions AND orbital fracture OR orbital fractures OR blow-out fractures OR blow out fractures OR blow-out fracture

108.1

(pregnancy OR pregnancies) AND ((inheritance patterns) OR (inheritance pattern)) AND obesity AND reproduction

108.2

(pregnancy OR pregnancies) AND ("inheritance patterns" OR "inheritance pattern") AND obesity AND reproduction

108.3

(pregnancy OR pregnancies) AND (inheritance patterns OR inheritance pattern) AND obesity AND reproduction

108.4

(pregnanc*) AND (inheritance pattern*) AND obesity AND reproduction

108.5

pregnancy OR pregnancies AND inheritance patterns OR inheritance pattern AND obesity AND reproduction

109.1

((postoperative complications) OR (postoperative complication)) AND ((pleural diseases) OR (pleural disease)) AND ((pulmonary aspergillosis) OR (pulmonary aspergilloses) OR (lung aspergillosis) OR (lung aspergilloses) OR (bronchopulmonary aspergillosis) OR (bronchopulmonary aspergilloses))

109.2

("postoperative complications" OR "postoperative complication") AND ("pleural diseases" OR "pleural disease") AND ("pulmonary aspergillosis" OR "pulmonary aspergilloses" OR "lung aspergillosis" OR "lung aspergilloses" OR "bronchopulmonary aspergillosis" OR "bronchopulmonary aspergilloses")

109.3

(postoperative complications OR postoperative complication) AND (pleural diseases OR pleural disease) AND (pulmonary aspergillosis OR pulmonary aspergilloses OR lung aspergillosis OR lung aspergilloses OR bronchopulmonary aspergillosis OR bronchopulmonary aspergilloses)

109.4

postoperative complication* AND pleural disease* AND (pulmonary aspergillos* OR lung aspergillos* OR bronchopulmonary aspergillos*)

109.5

postoperative complications OR postoperative complication AND pleural diseases OR pleural disease AND pulmonary aspergillosis OR pulmonary aspergilloses OR lung aspergillosis OR lung aspergilloses OR bronchopulmonary aspergillosis OR bronchopulmonary aspergilloses

110.1

((reference values) OR (reference value) OR (reference ranges) OR (reference range) OR (normal range) OR (normal ranges) OR (normal values) OR (normal value)) AND ((pulmonary artery) OR (pulmonary arteries)) AND ((nitric oxide) OR (mononitrogen monoxide) OR (nitrogen monoxide) OR (endogenous nitrate vasodilator) OR (endothelium-derived nitric oxide)) AND ((vascular resistance))

110.2

("reference values" OR "reference value" OR "reference ranges" OR "reference range" OR "normal range" OR "normal ranges" OR "normal values" OR "normal value") AND ("pulmonary artery" OR "pulmonary arteries") AND ("nitric oxide" OR "mononitrogen monoxide" OR "nitrogen monoxide" OR "endogenous nitrate vasodilator" OR "endothelium-derived nitric oxide") AND ("vascular resistance")

110.3

(reference values OR reference value OR reference ranges OR reference range OR normal range OR normal ranges OR normal values OR normal value) AND (pulmonary artery OR pulmonary arteries) AND (nitric oxide OR mononitrogen monoxide OR nitrogen monoxide OR endogenous nitrate vasodilator OR endothelium-derived nitric oxide) AND vascular resistance

110.4

(reference value* OR reference range* OR normal range* OR normal value*) AND pulmonary arter* AND (nitric oxide OR mononitrogen monoxide OR nitrogen monoxide OR endogenous nitrate vasodilator OR endothelium-derived nitric oxide) AND vascular resistance

110.5

reference values OR reference value OR reference ranges OR reference range OR normal range OR normal ranges OR normal values OR normal value AND pulmonary artery OR pulmonary arteries AND nitric oxide OR mononitrogen monoxide OR nitrogen monoxide OR endogenous nitrate vasodilator OR endothelium-derived nitric oxide AND vascular resistance

111.1

((electric stimulation therapy) OR (electrical stimulation therapy) OR electrotherapy) AND ((nerve regenerations) OR (nerve regeneration)) AND (axons OR axon)

111.2

("electric stimulation therapy" OR "electrical stimulation therapy" OR electrotherapy) AND ("nerve regenerations" OR "nerve regeneration") AND (axons OR axon)

111.3

(electric stimulation therapy OR electrical stimulation therapy OR electrotherapy) AND (nerve regenerations OR nerve regeneration) AND (axons OR axon)

111.4

(electric* stimulation therapy OR electrotherapy) AND nerve regeneration* AND axon*

111.5

electric stimulation therapy OR electrical stimulation therapy OR electrotherapy AND nerve regenerations OR nerve regeneration AND axons OR axon

112.1

(mesothelioma OR mesotheliomas) AND (molecular targeted therapy) AND ((antineoplastic agents) OR (antitumor drugs) OR (antitumor agents) OR (antineoplastic drugs) OR antineoplastics)

112.2

(mesothelioma OR mesotheliomas) AND "molecular targeted therapy" AND ("antineoplastic agents" OR "antitumor drugs" OR "antitumor agents" OR "antineoplastic drugs" OR antineoplastics)

112.3

(mesothelioma OR mesotheliomas) AND molecular targeted therapy AND (antineoplastic agents OR antitumor drugs OR antitumor agents OR antineoplastic drugs OR antineoplastics)

112.4

mesothelioma* AND molecular targeted therapy AND (antineoplastic agents OR antitumor drugs OR antitumor agents OR antineoplastic drugs OR antineoplastics)

112.5

mesothelioma OR mesotheliomas AND molecular targeted therapy AND antineoplastic agents OR antitumor drugs OR antitumor agents OR antineoplastic drugs OR antineoplastics

113.1

(memory OR learning) AND ((glial cells) OR (glial cell)) AND ((gap junctions) OR (gap junction))

113.2

(memory OR learning) AND ("glial cells" OR "glial cell") AND ("gap junctions" OR "gap junction")

113.3

(memory OR learning) AND (glial cells OR glial cell) AND (gap junctions OR gap junction)

113.4

(memory OR learning) AND glial cell* AND gap junction*

113.5

memory OR learning AND glial cells OR glial cell AND gap junctions OR gap junction

114.1

(synapse OR synapses) AND ((calcium waves) OR (calcium signaling) OR (calcium signaling) OR (calcium wave) OR (calcium oscillations) OR (calcium oscillation) OR (calcium spikes) OR (calcium spike) OR (calcium puffs) OR (calcium puff) OR (calcium sparks) OR (calcium spark)) AND (astrocytes OR astrocyte OR astroglia or astroglia)

114.2

(synapse OR synapses) AND (“calcium waves” OR “calcium signaling” OR “calcium signaling” OR “calcium wave” OR “calcium oscillations” OR “calcium oscillation” OR “calcium spikes” OR “calcium spike” OR “calcium puffs” OR “calcium puff” OR “calcium sparks” OR “calcium spark”) AND (astrocytes OR astrocyte OR astroglia or astroglia)

114.3

(synapse OR synapses) AND (calcium waves OR calcium signalings OR calcium signaling OR calcium wave OR calcium oscillations OR calcium oscillation OR calcium spikes OR calcium spike OR calcium puffs OR calcium puff OR calcium sparks OR calcium spark) AND (astrocytes OR astrocyte OR astroglia or astroglia)

114.4

synapse* AND (calcium wave* OR calcium signaling* OR calcium oscillations OR calcium oscillation OR calcium spike* OR calcium puff* OR calcium spark*) AND (astrocyte* OR astroglia*)

114.5

synapse OR synapses AND calcium waves OR calcium signalings OR calcium signaling OR calcium wave OR calcium oscillations OR calcium oscillation OR calcium spikes OR calcium spike OR calcium puffs OR calcium puff OR calcium sparks OR calcium spark AND astrocytes OR astrocyte OR astroglia or astroglia

115.1

((genetic engineering) OR (genetic intervention) OR (genetic interventios)) AND ((gene targeting) OR (gene targetings)) AND ((transcription factors) OR (transcription factor)) AND ((zinc fingers) OR (zinc finger) OR (zinc finger motifs) OR (zinc finger motif))

115.2

(“genetic engineering” OR “genetic intervention” OR “genetic interventios”) AND (“gene targeting” OR “gene targetings”) AND (“transcription factors” OR “transcription factor”) AND (“zinc fingers” OR “zinc finger” OR “zinc finger motifs” OR “zinc finger motif”)

115.3

(genetic engineering OR genetic intervention OR genetic interventios) AND (gene targeting OR gene targetings) AND (transcription factors OR transcription factor) AND (zinc fingers OR zinc finger OR zinc finger motifs OR zinc finger motif)

115.4

(genetic engineering OR genetic intervention*) AND gene targeting* AND transcription factor*) AND (zinc finger* OR zinc finger motif*)

115.5

genetic engineering OR genetic intervention OR genetic interventios AND gene targeting OR gene targetings AND transcription factors OR transcription factor AND zinc fingers OR zinc finger OR zinc finger motifs OR zinc finger motif

116.1

((physical exertion) OR (physical exertions) OR (physical effort) OR (physical efforts)) AND (obesity) AND ((intellectual disabilities) OR (intellectual disability) OR (mental retardation) OR (mental deficiencies) OR (mental deficiency) OR idiocy)

116.2

("physical exertion" OR "physical exertions" OR "physical effort" OR "physical efforts") AND obesity AND ("intellectual disabilities" OR "intellectual disability" OR "mental retardation" OR "mental deficiencies" OR "mental deficiency" OR idiocy)

116.3

(physical exertion OR physical exertions OR physical effort OR physical efforts) AND (obesity) AND (intellectual disabilities OR intellectual disability OR mental retardation OR mental deficiencies OR mental deficiency OR idiocy)

116.4

(physical exertion* OR physical effort*) AND obesity AND (intellectual disability* OR mental retardation OR mental deficienc* OR idiocy)

116.5

physical exertion OR physical exertions OR physical effort OR physical efforts AND obesity AND intellectual disabilities OR intellectual disability OR mental retardation OR mental deficiencies OR mental deficiency OR idiocy

117.1

((eye diseases) OR (eye disease)) AND cockayne syndrome

117.2

("eye diseases" OR "eye disease") AND cockayne syndrome

117.3

(eye diseases OR eye disease) AND cockayne syndrome

117.4

eye disease* AND cockayne syndrome

117.5

eye diseases OR eye disease AND cockayne syndrome

118.1

(shoe OR shoes) AND (osteoarthritis OR osteoarthritis OR osteoarthrosis OR osteoarthroses OR (degenerative arthritides) OR (degenerative arthritis) OR (osteoarthrosis deformans)) AND

(knee or knees)

118.2

(shoe OR shoes) AND (osteoarthritis OR osteoarthritis OR osteoarthrosis OR osteoarthroses OR “degenerative arthritides” OR “degenerative arthritis” OR “osteoarthrosis deformans”) AND (knee or knees)

118.3

(shoe OR shoes) AND (osteoarthritis OR osteoarthritis OR osteoarthrosis OR osteoarthroses OR degenerative arthritides or degenerative arthritis OR osteoarthrosis deformans) AND (knee or knees)

118.4

shoe* AND (osteoarthriti* OR osteoarthros* OR degenerative arthriti* OR osteoarthrosis deformans) AND knee*

118.5

shoe OR shoes AND osteoarthritis OR osteoarthritis OR osteoarthrosis OR osteoarthroses OR degenerative arthritides or degenerative arthritis OR osteoarthrosis deformans AND knee or knees

119.1

((island flap) OR (island flaps)) AND (fingers OR finger)

119.2

(“island flap” OR “island flaps”) AND (fingers OR finger)

119.3

(island flap OR island flaps) AND (fingers OR finger)

119.4

island flap* AND finger*

119.5

island flap OR island flaps AND fingers OR finger

120.1

((laryngeal cartilages) OR (laryngeal cartilage)) AND ((voice disorders) OR (voice disorder) OR (voice disturbances) OR (voice disturbance))

120.2

(“laryngeal cartilages” OR “laryngeal cartilage”) AND (“voice disorders” OR “voice disorder” OR “voice disturbances” OR “voice disturbance”)

120.3

(laryngeal cartilages OR laryngeal cartilage) AND (voice disorders OR voice disorder OR voice disturbances OR voice disturbance)

120.4

laryngeal cartilage*AND (voice disorder* OR voice disturbance*)

120.5

laryngeal cartilages OR laryngeal cartilage AND voice disorders OR voice disorder OR voice disturbances OR voice disturbance

Apêndice B - Número de registros recuperados de acordo com as estratégias de busca submetidas

(continua)

	Parêntesis ou aspas					Truncagem			Sentenças		
	Com parêntesis	Sem parêntesis	1 = maior 0 = igual -1 = menor	Com aspas	1 = maior 0 = igual -1 = menor	Sem *	C *	1 = maior 0 = igual -1 = menor	uma etapa	varias etapas	1 = maior 0 = igual -1 = menor
1	6515	6515	0	4824	1	6515	6088	1	6515	6515	0
2	19856	19856	0	18556	1	19856	19639	1	19856	19856	0
3	220	220	0	58	1	220	219	1	220	220	0
4	4387	4387	0	3156	1	4387	4332	1	4387	4387	0
5	181	181	0	115	1	181	169	1	181	181	0
6	6670	6670	0	6480	1	6670	6639	1	6670	6670	0
7	2763	2763	0	371	1	2763	13	1	2763	2763	0
8	1970	1970	0	1385	1	1970	1960	1	1970	1970	0
9	27896	27896	0	19921	1	27896	27702	1	27896	27896	0
10	2116	2116	0	1170	1	2116	805	1	2116	2116	0
11	0	0	0	0	0	0	0	0	0	0	0
12	10021	10021	0	685	1	10021	3464	1	10021	10021	0
13	3891	3891	0	3879	1	3891	3901	-1	3891	3891	0
14	1793	1793	0	4342	-1	1793	1738	1	1793	1793	0
15	3188	3188	0	1343	1	3188	438	1	3188	3188	0
16	3308	3308	0	2527	1	3308	2434	1	3308	3308	0
17	3630	3630	0	923	1	3630	923	1	3630	3630	0
18	226	226	0	219	1	226	1	1	226	226	0
19	4742	4742	0	15	1	4742	30	1	4742	4742	0
20	1151	1151	0	1132	1	1151	1120	1	1151	1151	0
21	497	497	0	443	1	497	530	-1	497	497	0
22	63	63	0	31	1	63	31	1	63	63	0
23	750	750	0	651	1	750	750	0	750	750	0
24	28664	28664	0	20638	1	28664	21079	1	28664	28664	0
25	701	701	0	697	1	701	701	0	701	701	0

(continuação)

	Com parêntesis	Sem parêntesis	1 = maior 0 = igual -1 = menor	Com aspas	1 = maior 0 = igual -1 = menor	Sem *	C *	1 = maior 0 = igual -1 = menor	uma etapa	varias etapas	1 = maior 0 = igual -1 = menor
26	1974	1974	0	373	1	1974	575	1	1974	1974	0
27	157	157	0	6	1	157	72	1	157	157	0
28	583	583	0	583	0	583	631	-1	583	583	0
29	4	4	0	4	0	4	0	1	4	4	0
30	330	330	0	16	1	330	16	1	330	330	0
31	121	121	0	67	1	121	71	1	121	121	0
32	492	492	0	69	1	492	69	1	492	492	0
33	607	607	0	183	1	607	351	1	607	607	0
34	373	373	0	34	1	373	46	1	373	373	0
35	138	138	0	68	1	138	68	1	138	138	0
36	947	947	0	885	1	947	816	1	947	947	0
37	48	48	0	23	1	48	24	1	48	48	0
38	2338	2338	0	227	1	2338	116	1	2338	2338	0
39	1639	1639	0	0	1	1639	1349	1	1639	1639	0
40	2913	2913	0	2180	1	2913	1845	1	2913	2913	0
41	1189	1189	0	1151	1	1189	1182	1	1189	1189	0
42	907	907	0	787	1	907	796	1	907	907	0
43	313	313	0	285	1	313	133	1	313	313	0
44	13229	13229	0	2421	1	13229	2824	1	13229	13229	0
45	1581	1581	0	568	1	1581	827	1	1581	1581	0
46	906	906	0	792	1	906	906	0	906	906	0
47	9	9	0	5	1	9	5	1	9	9	0
48	372	372	0	89	1	372	107	1	372	372	0
49	180	180	0	180	0	180	180	0	180	180	0
50	285	285	0	285	0	285	97	1	285	285	0
51	238	238	0	123	1	238	0	1	238	238	0

(continuação)

	Com parêntesis	Sem parêntesis	1 = maior 0 = igual -1 = menor	Com aspas	1 = maior 0 = igual -1 = menor	Sem *	C *	1 = maior 0 = igual -1 = menor	uma etapa	varias etapas	1 = maior 0 = igual -1 = menor
52	33	33	0	31	1	33	31	1	33	33	0
53	1451	1451	0	394	1	1451	1327	1	1451	1451	0
54	1915	1915	0	1578	1	1915	499	1	1915	1915	0
55	266	266	0	7	1	266	117	1	266	266	0
56	640	640	0	634	1	640	635	1	640	640	0
57	2724	2724	0	2175	1	2724	168	1	2724	2724	0
58	2271	2271	0	227	1	2271	105	1	2271	2271	0
59	1738	1738	0	1632	1	1738	1198	1	1738	1738	0
60	299	299	0	36	1	299	60	1	299	299	0
61	65	65	0	46	1	65	55	1	65	65	0
62	1	1	0	1	0	1	1	0	1	1	0
63	126	122	0	34	1	126	36	1	126	126	0
64	947	947	0	112	1	947	923	1	947	947	0
65	15103	15103	0	14978	1	15103	15471	-1	15103	15103	0
66	9039	9039	0	6213	1	9039	8728	1	9039	9039	0
67	9381	9381	0	9023	1	9381	3869	1	9381	9381	0
68	26340	26340	0	17719	1	26340	17725	1	26340	26340	0
69	2941	2941	0	1530	1	2941	2942	-1	2941	2941	0
70	23	23	0	10	1	23	14	1	23	23	0
71	1018	1018	0	809	1	1018	1005	1	1018	1018	0
72	3	3	0	1	1	3	3	0	3	3	0
73	71	71	0	71	0	71	71	0	71	71	0
74	16	16	0	4	1	16	16	0	16	16	0
75	330	330	0	85	1	330	238	1	330	330	0
76	266	266	0	53	1	266	164	1	266	266	0
77	234	234	0	236	-1	234	0	1	234	234	0

(continuação)


	Com parêntesis	Sem parêntesis	1 = maior 0 = igual -1 = menor	Com aspas	1 = maior 0 = igual -1 = menor	Sem *	C *	1 = maior 0 = igual -1 = menor	uma etapa	varias etapas	1 = maior 0 = igual -1 = menor
78	26	26	0	10	1	26	26	0	26	26	0
79	136	136	0	105	1	136	134	1	136	136	0
80	30	30	0	0	1	30	9	1	30	30	0
81	24	24	0	14	1	24	13	1	24	24	0
82	243	243	0	7	1	243	7	1	243	243	0
83	40	40	0	34	1	40	31	1	40	40	0
84	576	576	0	183	1	576	576	0	576	576	0
85	57	57	0	24	1	57	57	0	57	57	0
86	11	11	0	0	1	11	11	0	11	11	0
87	6472	6472	0	92	1	6472	6472	0	6472	6472	0
88	8	8	0	3	1	8	3	1	8	8	0
89	375	375	0	470	-1	375	83	1	375	375	0
90	57	57	0	32	1	57	57	1	57	57	0
91	677	677	0	646	1	677	646	1	677	677	0
92	8850	8850	0	5304	1	8850	5266	1	8850	8850	0
93	666	666	0	664	1	666	611	1	666	666	0
94	8261	8261	0	7917	1	8261	7917	1	8261	8261	0
95	5596	5596	0	3927	1	5596	2456	1	5596	5596	0
96	1590	1590	0	1360	1	1590	1576	1	1590	1590	0
97	2592	2592	0	2402	-1	2592	512	1	2592	2592	0
98	5675	5675	0	5537	1	5675	7051	-1	5675	5675	0
99	8162	8162	0	6965	1	8162	833	1	8162	8162	0
100	4705	4705	0	4357	1	4705	4435	1	4705	4705	0
101	152	152	0	67	1	152	81	1	152	152	0
102	36	36	0	13	1	36	13	1	36	36	0
103	20	20	0	20	0	20	20	0	20	20	0

(conclusão)

	Com parêntesis	Sem parêntesis	1 = maior 0 = igual -1 = menor	Com aspas	1 = maior 0 = igual -1 = menor	Sem *	C *	1 = maior 0 = igual -1 = menor	uma etapa	varias etapas	1 = maior 0 = igual -1 = menor
104	39	39	0	0	1	39	1	1	39	39	0
105	37	37	0	2	1	37	18	1	37	37	0
106	96	96	0	2	1	96	1	1	96	96	0
107	3	3	0	3	0	3	3	0	3	3	0
108	17	17	0	2	1	17	2	1	17	17	0
109	47	47	0	18	1	47	7	1	47	47	0
110	27	27	0	15	1	27	23	1	27	27	0
111	100	100	0	86	1	100	205	-1	100	100	0
112	38	38	0	13	1	38	38	0	38	38	0
113	28	28	0	8	1	28	8	1	28	28	0
114	130	130	0	86	1	130	114	1	130	130	0
115	36	36	0	4	1	36	11	1	36	36	0
116	8	8	0	4	1	8	3	1	8	8	0
117	47	47	0	8	1	47	8	1	47	47	0
118	190	190	0	190	0	190	129	1	190	190	0
119	1994	1994	0	301	1	1994	269	1	1994	1994	0
120	357	357	0	43	1	357	43	1	357	357	0

Apêndice C - Estratégias de busca feitas com e sem uso de truncagem interpretadas pela interface PubMed

1 Para a estratégia: tumor: número de registros recuperados = 2.841.216



How To


PubMed tumor

[RSS](#) [Save search](#) [Advanced](#)

[Display Settings:](#) Summary, 20 per page, Sorted by Recently Added [Send to:](#)

Conteúdo da caixa “search details” para estratégia: tumor

"tumour"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "tumor"[All Fields]



How To

PubMed tumor*

[RSS](#) [Save search](#) [Advanced](#)

[Display Settings:](#) Summary, 20 per page, Sorted by Recently Added [Send to:](#)

Wildcard search for 'tumor*' used only the first 600 variations. Lengthen the root word to search for all endings.

See the search [details](#).

2 Para estratégia: tumor*: número de registros recuperados = 1.101.878

Conteúdo da caixa “search details” para estratégia: tumor*

tumor[All Fields] OR tumor/100[All Fields] OR tumor/2cm[All Fields] OR tumor/36[All Fields] OR tumor/5[All Fields] OR tumor/a[All Fields] OR tumor/abrikossoff[All Fields] OR tumor/abscess[All Fields] OR tumor/ad[All Fields] OR tumor/adc[All Fields] OR tumor/adipose[All Fields] OR tumor/adjacent[All Fields] OR tumor/aerobic[All Fields] OR tumor/aht[All Fields] OR tumor/aldosteronoma[All Fields] OR tumor/aneurysmal[All Fields] OR tumor/angiogenesis[All Fields] OR tumor/animal[All Fields] OR tumor/anirida[All Fields] OR tumor/aniridia[All Fields] OR tumor/aniridia/genitourinary[All Fields] OR tumor/antioxidant[All Fields] OR tumor/aorta[All Fields] OR tumor/arachnoidal[All Fields] OR tumor/area[All Fields] OR tumor/arthritis[All Fields] OR tumor/ascites[All Fields] OR tumor/atypical[All Fields] OR tumor/aucbrain[All Fields] OR tumor/average[All Fields] OR tumor/bacillus[All Fields] OR tumor/background[All Fields] OR tumor/bcg[All Fields] OR tumor/bcnu[All Fields] OR tumor/benign[All Fields] OR tumor/biologic[All Fields] OR tumor/biologically[All Fields] OR tumor/bkg[All Fields] OR tumor/blood[All Fields] OR tumor/bloodmax[All Fields] OR tumor/body[All Fields] OR tumor/bone[All Fields] OR tumor/brain[All Fields] OR tumor/brainstem[All Fields] OR tumor/breast[All Fields] OR tumor/bronchus[All Fields] OR tumor/bs[All Fields] OR tumor/c2146[All Fields] OR tumor/c3h[All Fields] OR tumor/c3h/sed[All Fields] OR tumor/cancer[All Fields] OR tumor/carcass[All Fields] OR tumor/carcinoma[All Fields] OR tumor/cardiac[All Fields] OR tumor/case[All Fields] OR tumor/cell[All Fields] OR tumor/cerebellum[All Fields] OR tumor/cervical[All Fields] OR tumor/chemistry[All Fields] OR tumor/chemotherapy[All Fields] OR tumor/chest[All Fields] OR tumor/chick[All Fields] OR tumor/chondrosarcoma[All Fields] OR tumor/chordoma[All Fields] OR tumor/choriocarcinoma[All Fields] OR tumor/circular[All Fields] OR tumor/cirrhosis[All Fields] OR tumor/clear[All Fields] OR tumor/clinic[All Fields] OR tumor/clinical[All Fields] OR tumor/cn[All Fields] OR tumor/complications[All Fields] OR tumor/connective[All Fields] OR tumor/context[All Fields] OR tumor/contralateral[All Fields] OR tumor/control[All Fields] OR tumor/cord[All Fields] OR tumor/cortex[All Fields] OR tumor/cortical[All Fields] OR tumor/count[All Fields] OR tumor/csf[All Fields] OR tumor/culture[All Fields] OR tumor/cyst[All Fields] OR tumor/cystic[All Fields] OR tumor/cysts[All Fields] OR tumor/cytotoxic[All Fields] OR tumor/day[All Fields] OR tumor/dc[All Fields] OR tumor/deep[All Fields] OR tumor/def[All Fields] OR tumor/dendritic[All Fields] OR tumor/desmoplasia[All Fields] OR tumor/diagnosis[All Fields] OR tumor/differential[All Fields] OR tumor/differentiation[All Fields] OR tumor/disease[All Fields] OR tumor/distal[All Fields] OR tumor/distant[All Fields] OR tumor/dna[All Fields] OR tumor/dotatoc[All Fields] OR tumor/drug[All Fields] OR tumor/duc18[All Fields] OR tumor/duct[All Fields] OR tumor/duodenum[All Fields] OR tumor/ec[All Fields] OR tumor/edema[All Fields] OR tumor/effect[All Fields] OR tumor/effector[All Fields] OR tumor/elliptic[All Fields] OR

tumor/embryonal[All Fields] OR tumor/endothelial[All Fields] OR tumor/endothelium[All Fields] OR tumor/enterocystoma[All Fields] OR tumor/epilepsy[All Fields] OR tumor/epithelial[All Fields] OR tumor/er[All Fields] OR tumor/erythroderma[All Fields] OR tumor/etiology[All Fields] OR tumor/evolving[All Fields] OR tumor/ewing[All Fields] OR tumor/ewing's[All Fields] OR tumor/ewings[All Fields] OR tumor/experimental[All Fields] OR tumor/extracts[All Fields] OR tumor/extraosseous[All Fields] OR tumor/extraosseus[All Fields] OR tumor/extrasketal[All Fields] OR tumor/fa[All Fields] OR tumor/fat[All Fields] OR tumor/fcs[All Fields] OR tumor/female[All Fields] OR tumor/femur[All Fields] OR tumor/fetal[All Fields] OR tumor/fiber[All Fields] OR tumor/fibrous[All Fields] OR tumor/fleck/other[All Fields] OR tumor/g[All Fields] OR tumor/gal[All Fields] OR tumor/ganglioglioma[All Fields] OR tumor/gapdh[All Fields] OR tumor/gastrointestinal[All Fields] OR tumor/genetics[All Fields] OR tumor/genitourinary[All Fields] OR tumor/gland[All Fields] OR tumor/glioma[All Fields] OR tumor/grade[All Fields] OR tumor/graft[All Fields] OR tumor/granulocytic[All Fields] OR tumor/granuloma[All Fields] OR tumor/gray[All Fields] OR tumor/growth[All Fields] OR tumor/hamartoma[All Fields] OR tumor/healthy[All Fields] OR tumor/heart[All Fields] OR tumor/hemangiopericytoma[All Fields] OR tumor/hematologic[All Fields] OR tumor/hemorrhage[All Fields] OR tumor/hilum[All Fields] OR tumor/host[All Fields] OR tumor/hr[All Fields] OR tumor/hyperplasia[All Fields] OR tumor/i[All Fields] OR tumor/immortal[All Fields] OR tumor/immune[All Fields] OR tumor/implant[All Fields] OR tumor/in[All Fields] OR tumor/incision[All Fields] OR tumor/induced[All Fields] OR tumor/induction[All Fields] OR tumor/infection[All Fields] OR tumor/inflammation[All Fields] OR tumor/injected[All Fields] OR tumor/intact[All Fields] OR tumor/intussusception[All Fields] OR tumor/invasion[All Fields] OR tumor/involved[All Fields] OR tumor/iris[All Fields] OR tumor/ivbat[All Fields] OR tumor/jurisprudence[All Fields] OR tumor/kaposi's[All Fields] OR tumor/kidney[All Fields] OR tumor/lak[All Fields] OR tumor/latence[All Fields] OR tumor/left[All Fields] OR tumor/lesion[All Fields] OR tumor/leukaemia[All Fields] OR tumor/leukemia[All Fields] OR tumor/leukocyte[All Fields] OR tumor/limb[All Fields] OR tumor/liver[All Fields] OR tumor/local[All Fields] OR tumor/low[All Fields] OR tumor/lung[All Fields] OR tumor/lvc[All Fields] OR tumor/lymph[All Fields] OR tumor/lymphocyte[All Fields] OR tumor/lymphoma[All Fields] OR tumor/male[All Fields] OR tumor/malignancy[All Fields] OR tumor/manifestations[All Fields] OR tumor/marrow[All Fields] OR tumor/mass[All Fields] OR tumor/maximum[All Fields] OR tumor/mb[All Fields] OR tumor/mean[All Fields] OR tumor/mediastinum[All Fields] OR tumor/medulloblastoma[All Fields] OR tumor/medulloblastora[All Fields] OR tumor/mesenchymal[All Fields] OR tumor/metabolism[All Fields] OR tumor/metalloproteinase[All Fields] OR tumor/metastasis[All Fields] OR tumor/metastatic[All Fields] OR tumor/mice[All Fields] OR tumor/microbe[All Fields] OR tumor/microbial[All Fields] OR tumor/microenvironment[All Fields] OR tumor/min[All Fields] OR tumor/mixed[All Fields] OR tumor/mouse[All Fields] OR

tumor/mouse/week[All Fields] OR tumor/mucinous[All Fields] OR tumor/mucosa[All Fields] OR tumor/multiple[All Fields] OR tumor/muscle[All Fields] OR tumor/myelitis[All Fields] OR tumor/myo[All Fields] OR tumor/myocardium[All Fields] OR tumor/myoepithelioma[All Fields] OR tumor/myoepithelioma/parachordoma[All Fields] OR tumor/myofibromatosis[All Fields] OR tumor/myometrium[All Fields] OR tumor/myxoinflammatory[All Fields] OR tumor/nasopharynx[All Fields] OR tumor/nat[All Fields] OR tumor/nb[All Fields] OR tumor/ncbt[All Fields] OR tumor/necroses[All Fields] OR tumor/necrosis[All Fields] OR tumor/neoplasm[All Fields] OR tumor/nephroblastoma[All Fields] OR tumor/nerve[All Fields] OR tumor/neurogenesis[All Fields] OR tumor/neuron[All Fields] OR tumor/nhl[All Fields] OR tumor/nitrogen[All Fields] OR tumor/nodal[All Fields] OR tumor/nodal/metastasis[All Fields] OR tumor/node[All Fields] OR tumor/node/metastasis[All Fields] OR tumor/nodes[All Fields] OR tumor/nodes/metastases[All Fields] OR tumor/nodes/metastasis[All Fields] OR tumor/nodular[All Fields] OR tumor/nodule[All Fields] OR tumor/noise[All Fields] OR tumor/non[All Fields] OR tumor/nontarget[All Fields] OR tumor/nontrained[All Fields] OR tumor/nontumor[All Fields] OR tumor/norm[All Fields] OR tumor/normal[All Fields] OR tumor/normoxic[All Fields] OR tumor/ns[All Fields] OR tumor/nude[All Fields] OR tumor/number[All Fields] OR tumor/oar[All Fields] OR tumor/obstruction[All Fields] OR tumor/of[All Fields] OR tumor/oil[All Fields] OR tumor/operation[All Fields] OR tumor/organ[All Fields] OR tumor/orofacial[All Fields] OR tumor/osteoclast[All Fields] OR tumor/ovarian[All Fields] OR tumor/p53[All Fields] OR tumor/pancreas[All Fields] OR tumor/papilloma[All Fields] OR tumor/parapaillary[All Fields] OR tumor/parenchyma[All Fields] OR tumor/parkinsonism[All Fields] OR tumor/parotid[All Fields] OR tumor/pathogen[All Fields] OR tumor/pathology[All Fields] OR tumor/pathology/secondary/surgery[All Fields] OR tumor/pathways[All Fields] OR tumor/patient[All Fields] OR tumor/perinephric[All Fields] OR tumor/perineurioma[All Fields] OR tumor/perioperative[All Fields] OR tumor/peripheral[All Fields] OR tumor/peritumoral[All Fields] OR tumor/phantom[All Fields] OR tumor/physiology[All Fields] OR tumor/pigmented[All Fields] OR tumor/plasma[All Fields] OR tumor/plexiform[All Fields] OR tumor/plexus[All Fields] OR tumor/pnet[All Fields] OR tumor/polyp[All Fields] OR tumor/posterior[All Fields] OR tumor/ppar[All Fields] OR tumor/pregnancy[All Fields] OR tumor/primitive[All Fields] OR tumor/progenitor[All Fields] OR tumor/proliferation[All Fields] OR tumor/prostate[All Fields] OR tumor/prs[All Fields] OR tumor/pseudotumor[All Fields] OR tumor/psychology[All Fields] OR tumor/ptbe[All Fields] OR tumor/pyogenic[All Fields] OR tumor/radiography[All Fields] OR tumor/radiotherapy[All Fields] OR tumor/rat[All Fields] OR tumor/reconstructive[All Fields] OR tumor/recurrence[All Fields] OR tumor/red[All Fields] OR tumor/regional[All Fields] OR tumor/regions[All Fields] OR tumor/renal[All Fields] OR tumor/resection[All Fields] OR tumor/residual[All Fields] OR tumor/rhabdoid[All Fields] OR tumor/right[All Fields] OR tumor/s[All Fields] OR tumor/sarcoma[All

Fields] OR tumor/scalp[All Fields] OR tumor/schwannomatosis[All Fields] OR tumor/scid[All Fields] OR tumor/secondary[All Fields] OR tumor/self[All Fields] OR tumor/sem[All Fields] OR tumor/sensitizer[All Fields] OR tumor/serum[All Fields] OR tumor/simulating[All Fields] OR tumor/situs[All Fields] OR tumor/skeletal[All Fields] OR tumor/skin[All Fields] OR tumor/small[All Fields] OR tumor/soft[All Fields] OR tumor/spleen[All Fields] OR tumor/splenic[All Fields] OR tumor/statistics[All Fields] OR tumor/stomach[All Fields] OR tumor/stroke[All Fields] OR tumor/stroma[All Fields] OR tumor/stromal[All Fields] OR tumor/surgery[All Fields] OR tumor/surgical[All Fields] OR tumor/surrounding[All Fields] OR tumor/suvmax[All Fields] OR tumor/syndrome[All Fields] OR tumor/syrinx[All Fields] OR tumor/t[All Fields] OR tumor/target[All Fields] OR tumor/teratoma[All Fields] OR tumor/testis[All Fields] OR tumor/the[All Fields] OR tumor/therapy[All Fields] OR tumor/thorax[All Fields] OR tumor/three[All Fields] OR tumor/thymocyte[All Fields] OR tumor/thyreoiditis[All Fields] OR tumor/thyroid[All Fields] OR tumor/thyroiditis[All Fields] OR tumor/til[All Fields] OR tumor/tissue[All Fields] OR tumor/tissues[All Fields] OR tumor/tongue[All Fields] OR tumor/trained[All Fields] OR tumor/transformation[All Fields] OR tumor/transformed[All Fields] OR tumor/transplantation[All Fields] OR tumor/transurethral[All Fields] OR tumor/treatment[All Fields] OR tumor/trophoblastic[All Fields] OR tumor/tumor[All Fields] OR tumor/tumors[All Fields] OR tumor/tumour[All Fields] OR tumor/uninvolved[All Fields] OR tumor/upper[All Fields] OR tumor/ureter[All Fields] OR tumor/urine[All Fields] OR tumor/urogenital[All Fields] OR tumor/uterine[All Fields] OR tumor/uterus[All Fields] OR tumor/vascular[All Fields] OR tumor/vessel[All Fields] OR tumor/veterinary[All Fields] OR tumor/viral[All Fields] OR tumor/virus[All Fields] OR tumor/well[All Fields] OR tumor/were[All Fields] OR tumor/while[All Fields] OR tumor/white[All Fields] OR tumor/whole[All Fields] OR tumor/window[All Fields] OR tumor'[All Fields] OR tumor''[All Fields] OR tumor'growth[All Fields] OR tumor'ozn'ich[All Fields] OR tumor's[All Fields] OR tumor'u[All Fields] OR tumor,[All Fields] OR tumor0[All Fields] OR tumor1[All Fields] OR tumor2[All Fields] OR tumora[All Fields] OR tumora's[All Fields] OR tumoraal[All Fields] OR tumorabbau[All Fields] OR tumorabbauprodukte[All Fields] OR tumorabgrenzung[All Fields] OR tumorabhangig[All Fields] OR tumorabhangige[All Fields] OR tumorabklarung[All Fields] OR tumorabklatschpreparate[All Fields] OR tumorablatio[All Fields] OR tumorablatiok[All Fields] OR tumorablation[All Fields] OR tumorablations[All Fields] OR tumorablatioval[All Fields] OR tumorable[All Fields] OR tumorabschnitt[All Fields] OR tumorabszess[All Fields] OR tumorabteilung[All Fields] OR tumorabtragung[All Fields] OR tumorabwehr[All Fields] OR tumoracao[All Fields] OR tumoracinoes[All Fields] OR tumoracion[All Fields] OR tumoraciones[All Fields] OR tumoracoes[All Fields] OR tumoractivated[All Fields] OR tumoractivity[All Fields] OR tumoradapted[All Fields] OR tumoradaptierte[All Fields] OR tumoradaptierten[All Fields] OR tumoradjacent[All Fields] OR tumoraes[All Fields] OR tumoraellen[All Fields] OR

tumoraffin[All Fields] OR tumoraffine[All Fields] OR tumoraffinen[All Fields] OR tumoraffiner[All Fields] OR tumoraffines[All Fields] OR tumoraffinitat[All Fields] OR tumoragenecity[All Fields] OR tumoragenic[All Fields] OR tumoraggressivitat[All Fields] OR tumoragtige[All Fields] OR tumoragy[All Fields] OR tumorahnlich[All Fields] OR tumorahnliche[All Fields] OR tumorahnlichen[All Fields] OR tumorahnlicher[All Fields] OR tumorahnliches[All Fields] OR tumorai[All Fields] OR tumoraille[All Fields] OR tumorain[All Fields] OR tumorainak[All Fields] OR tumorairol[All Fields] OR tumorais[All Fields] OR tumoraktivitat[All Fields] OR tumoral[All Fields] OR tumoral/clinical/laboratory[All Fields] OR tumoral/nontumoral[All Fields] OR tumoral/nonvascular[All Fields] OR tumoral/peritumoral[All Fields] OR tumoral/receptores[All Fields] OR tumoral/stromal[All Fields] OR tumoral/tumoral[All Fields] OR tumoral/vascular[All Fields] OR tumoral'[All Fields] OR tumorala[All Fields] OR tumorale[All Fields] OR tumoraler[All Fields] OR tumorales[All Fields] OR tumorales/membranes[All Fields] OR tumorales'[All Fields] OR tumoral[i][All Fields] OR tumoralimmunity[All Fields] OR tumoralis[All Fields] OR tumorallergie[All Fields] OR tumorally[All Fields] OR tumoralp53[All Fields] OR tumoralpathology[All Fields] OR tumors[All Fields] OR tumoralter[All Fields] OR tumoralteration[All Fields] OR tumorambulanz[All Fields] OR tumoramotio[All Fields] OR tumoramyloid[All Fields] OR tumoranamie[All Fields] OR tumoranamien[All Fields] OR tumorand[All Fields] OR tumoranfalligkeit[All Fields] OR tumoranfarbung[All Fields] OR tumorangehrate[All Fields] OR tumorangiogenese[All Fields] OR tumorangiogenesis[All Fields] OR tumorangiognesis[All Fields] OR tumorangiographie[All Fields] OR tumoranorexie[All Fields] OR tumoranreicherung[All Fields] OR tumoransprechens[All Fields] OR tumoransprechverhaltens[All Fields] OR tumoranteile[All Fields] OR tumorantigen[All Fields] OR tumorantigenbeschaffenheit[All Fields] OR tumorantigene[All Fields] OR tumorantigenek[All Fields] OR tumorantigenen[All Fields] OR tumorantigener[All Fields] OR tumorantigenextrakte[All Fields] OR tumorantigens[All Fields] OR tumorantigenspezifischer[All Fields] OR tumorantikorpern[All Fields] OR tumorapa[All Fields] OR tumorar[All Fields] OR tumorarol[All Fields] OR tumorart[All Fields] OR tumorarten[All Fields] OR tumorartige[All Fields] OR tumorartigen[All Fields] OR tumorartiger[All Fields] OR tumorartiges[All Fields] OR tumorascites[All Fields] OR tumorasepsis[All Fields] OR tumoraspect[All Fields] OR tumoraspekt[All Fields] OR tumorassociated[All Fields] OR tumorassociated'[All Fields] OR tumorassocierede[All Fields] OR tumorassozierte[All Fields] OR tumorassozierten[All Fields] OR tumorassoziierter[All Fields] OR tumorassoziertes[All Fields] OR tumoraszites[All Fields] OR tumorasziteskarzinom[All Fields] OR tumorasziteszellen[All Fields] OR tumorat[All Fields] OR tumoratologie[All Fields] OR tumoration[All Fields] OR tumorations[All Fields] OR tumoratiopathogenese[All Fields] OR tumoratrige[All Fields] OR tumoraufnahme[All Fields] OR tumoraugen[All Fields] OR tumorausbreitung[All Fields] OR tumorausbreitungen[All Fields] OR

tumorausbreitungsstadien[All Fields] OR tumorausdehnung[All Fields] OR tumorausdenhnung[All Fields] OR tumorausloeser[All Fields] OR tumorauslosende[All Fields] OR tumorauslosenden[All Fields] OR tumorauslosender[All Fields] OR tumorauslosersubstanzen[All Fields] OR tumorausraumung[All Fields] OR tumoraussaat[All Fields] OR tumorausschluss[All Fields] OR tumoraussparung[All Fields] OR tumoraustauschtransplantationen[All Fields] OR tumoraus[All Fields] OR tumorba[All Fields] OR tumorbaerende[All Fields] OR tumorban[All Fields] OR tumorbank[All Fields] OR tumorbanken[All Fields] OR tumorbearers[All Fields] OR tumorbearing[All Fields] OR tumorbed[All Fields] OR tumorbedinger[All Fields] OR tumorbedingte[All Fields] OR tumorbedingtem[All Fields] OR tumorbedingten[All Fields] OR tumorbedingter[All Fields] OR tumorbeeinflussung[All Fields] OR tumorbefall[All Fields] OR tumorbefallenen[All Fields] OR tumorbefallener[All Fields] OR tumorbefalles[All Fields] OR tumorbefund[All Fields] OR tumorbefunde[All Fields] OR tumorbefundes[All Fields] OR tumorbegleitparameter[All Fields] OR tumorbehandeling[All Fields] OR tumorbehandling[All Fields] OR tumorbehandlung[All Fields] OR tumorbelastung[All Fields] OR tumorbereichen[All Fields] OR tumorbestrahlungen[All Fields] OR tumorbestrahlung[All Fields] OR tumorbestrahlungen[All Fields] OR tumorbetinget[All Fields] OR tumorbettes[All Fields] OR tumorbetts[All Fields] OR tumorbezogene[All Fields]



Anexo

Anexo A – Parecer do Comitê de Ética em Pesquisa

**Universidade Estadual Paulista
Faculdade de Medicina de Botucatu**

Distrito Rubião Junior, s/nº - Botucatu – S.P.
CEP: 18.618-970
Fone/Fax: (0xx14) 3811-6143
e-mail secretaria: capellup@fmb.unesp.br
e-mail coordenadoria: tsarden@fmb.unesp.br



Registrado no Ministério da Saúde
em 30 de abril de 1997

Botucatu, 10 de agosto de 2011.

Of. 350/11-CEP

Ilustríssima Senhora
Prof^a. Dr^a. Regina El Dib
Departamento de Cirurgia e Ortopedia da
Faculdade de Medicina de Botucatu

Prezada Prof^a Regina,

De ordem do Senhor Coordenador deste CEP, informo que o Projeto de Pesquisa **"Subsídios para construção de estratégias de busca para revisões sistemáticas na base de dados Medline via Pubmed, a ser conduzido por Enilze de Souza Nogueira Volpato, orientada por Vossa Senhoria, trata-se de revisão sistemática da literatura, não envolvendo direta ou indiretamente Seres Humanos, portanto está dispensada de obtenção de Parecer Ético.**

Ao final da execução do Projeto, apresentar ao CEP "Relatório Final de Atividades".

Atenciosamente,

Alberto Santos Capelluppi
Secretário do CEP.